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Only of Myself I Knew How to Tell  
Only of myself I knew how to tell. 
My world is as narrow as the ant's, 
Also my burdens I carried like her  
Too many, too heavy for my thin shoulder.  
Also my path - like hers to the treetop -  
path of pain, and path of toil,  
Giants’ hand, malicious and securing,  
teasing hand lay over all.  
All my ways trembled and wept  
constant fright of the giants’ hand.  
Why have you called me, shores of wonder?  
Why disappointed me, distant lights?  
 
 
 
 
 
Rachel the Poetess, 
4.3.1930 
  
יתעדי רפסל ימצע לע קר 
קַר לַע יִמְצַע ר ֵּפַסְל יִתְעַָדי. 
רַצ יִמָלוֹע םַלוֹעְכ הָלְָמנ, 
םַג יִאָשַמ יִתְסַמָע  ָהוֹמָכ 
בַר דֵּבְָכו יִפ ֵּתְכִמ הָלַדַה. 
 
םַג תֶא יִכְרַד – הָּכְרַדְכ לֶא תֶרֶמַצ –  
ךֶרֶד בוֹאְכַמ ךְֶרְֶדו לָמָע, 
ַדי םיִָקנֲע ָהנוְֹדז תַחַטוֹבוּ, 
ַדי תַחַדַבְתִמ הָמָש לאְַל. 
 
לָכ יַתוֹחְראָ זיִלִה עיִמְדְִהו 
דַחַפ ריִמָט דַיִמ םיִָקנֲע. 
הָמָל םֶתאָרְק יִל ,י ֵּפוֹח אֶלֶפַה? 
הָמָל םֶתְבַזְכ ,תוֹרוֹא םיִקוֹחְר? 
 
 
 
 
 
 
,תררושמה לחר 
         ד 'רדא רת".ץ 
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Abstract 
Background Targeted Drug Delivery (TDD) is a therapeutic modality which allows an increase in 
the medication dose at a treatment site, while simultaneously avoiding effects in the rest of 
the human body. This can be achieved via different types of delivery vehicles or carriers which 
encapsulate the free drug and release it only at the needed location. There are various 
methods of drug release, one of which is ultrasound, as in ultrasound-mediated TDD 
(USmTDD). The combination of focused ultrasound (FUS) and magnetic resonance imaging 
(MRI) provides a controllable system of drug release and impact assessment.  
In the work reported here, a novel drug carrier was synthesized and assessed. Ultrasonic drug 
release from the carrier was evaluated in vitro using a clinical MRI-guided Focused Ultrasound 
Surgery (MRgFUS) system. As there was no properly controllable research environment for in-
vitro studies available prior to the investigation of the carriers, such an environment was built 
and characterized.         
Methods MCF7 and A375m human cancer cell lines were subjected to FUS using the ExAblate 
2000 and 2100 systems (InSightec, Haifa, Israel). The experiments were conducted in a 
specially designed research environment, which was comprehensively evaluated to ensure 
both cell sterility and proper FUS propagation. Various sonication parameters were applied, in 
conjunction with a commercially available ultrasound contrast agent (USCA), to achieve 
maximal cellular uptake of Doxorubicin (Dox) with minimal decrease in cell viability. A novel 
cyclodextrin (CD) based drug carrier was synthesized, chemically evaluated, and investigated in 
vitro via two release mechanisms: heating and physical effects.  
Results Two clinical MRgFUS systems were adapted for in-vitro work, showing controllable and 
repeatable results. Both of the assessed release mechanisms showed their competency: the 
application of FUS in the presence of USCA increased the cellular drug uptake of Dox by an 
average factor of 3 ±0.9, and up to a factor of 4 due to heating. The Dox release from the CD-
based carrier was around 100% with both mechanisms.  
Conclusions Adaptation of a clinical MRgFUS system for in-vitro research allows the use of a 
single system starting from in-vitro studies, through the pre-clinical stage to clinical trials. This 
gives physicians the ability to be a part of a wider USmTDD research group, from the beginning 
of the product definition, bringing real meaning to the term “from bench to bedside”. The 
baseline studies reported here have verified that intracellular drug uptake is increased through 
heating and sonoporation processes. The release mechanisms from the carriers were also 
observed, validating the concept of USmTDD from CD-based carriers. 
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 INTRODUCTION CHAPTER 1
 Targeted Drug Delivery and Ultrasound  1.1
Targeted drug delivery (TDD) has been a subject of investigation for many research 
groups worldwide (Barannon-Peppas and Blanchette, 2012). Imaging technologies such as 
magnetic resonance imaging (MRI), ultrasound (US) and computed tomography (CT), gave a 
further drive in this research field, introducing the possibility for real time image guided TDD. 
The potential of targeting drugs to a site-specific location in the body, while maintaining a 
toxin-free environment in the vital organs e.g. heart, lungs, liver etc., has been a possibility 
that is now becoming more likely for millions of patients (Corti et al., 2012; Rösler et al.,2012). 
Still, there are many steps from a promising idea, through a suitable model, to a fully 
functioning and reliable remedy.  
One of the most crucial steps in the development of TDD treatments is the in-vitro 
studies. In the in-vitro stage the core of the principal is investigated in all its aspects, including 
not only the basic questions of cytotoxicity, but also its efficiency in comparison to existing 
treatments and its potential to reach the clinic. Here, one must present an outcome far better 
than the currently used treatments and demonstrate potential to become economically viable. 
An important factor at the in-vitro stage is its possible applicability to the pre-clinical and 
subsequent clinical studies. Therefore, the in-vitro arrangement must be not only accurate in 
terms of statistical significance, but also have a clear affinity to its practical application in the 
clinic.  
There are various methods of TDD, both physical, e.g. focused ultrasound (FUS), laser 
etc., and chemical, e.g. various drug carriers, each of which has its own benefits and 
drawbacks. In the work presented here, a combination of both the physical and the chemical 
methodologies was investigated in order to combine the best features of each approach to 
create a better drug delivery tool (Gao et al., 2004).  
In the medical field, US is divided into two major streams: diagnostic and therapeutic. 
The diagnostic stream mainly refers to imaging, while the therapeutic stream introduces a 
wider spectrum including lithotripsy, phacoemulsification, FUS and assorted TDD. US-mediated 
TDD (USmTDD) can be achieved via two different mechanisms, or their combination, the first 
being generation of local temperature rise (Grüll, and Langereis, 2012) and the second is by 
application of mechanical force, e.g. generation of cavitation and micro streaming. Both of 
these applications can potentially increase cell membrane permeability via different 
mechanisms.  
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Heat treatments are known to increase in-situ drug uptake in cancer cells (Yudina et 
al., 2012) and can be generated in a relatively straightforward way. Cavitation on the other 
hand is a more problematic tool in USmTDD. Acoustic cavitation can be defined as acoustically-
driven bubble oscillations and collapse (Morfey, 2001). In general, natural occurring cavitation 
bubbles and their oscillations and collapse, form a spontaneous and rather unpredictable 
phenomenon which is difficult to control. Nonetheless, it is possible to generate stable and 
controllable cavitation using engineered cavitation nuclei, e.g. microbubbles (MBs). Under 
specific acoustic parameters, MBs are widely utilised for investigation of USmTDD (Yudina et 
al., 2010) for generation of controlled cavitation to increase cell membrane permeability by 
sonoporation (Pitt at al., 2004) and cellular massage (Wu and Nyborg, 2008). One of the 
accelerating research areas is the utilization of FUS to facilitate in-situ drug release from 
various carriers (Kilbanov et al., 2010).  
In the present study, the source of FUS was a clinical MRI guided focused ultrasound 
surgery (MRgFUS) system, CE marked and FDA approved for treatments of uterine fibroids and 
bone metastases. The utilization of such a system is beneficial not only in providing a highly 
monitored research tool, but also in gaining an easier transition platform to pre-clinical in-vivo 
studies (Chen et al., 2010), and potentially up to the clinical stages.  
From the chemical point of view, a novel nanocarrier was synthesized and evaluated 
for the work reported here. The nanocarrier is based on a cyclodextrin (CD) unit, which is 
responsible for complexation with the drug, covalently bonded to an amino-acid-based 
functional group. CDs are natural, water soluble, sugar based, cone structured molecules with 
lipophilic inner cavities (Singh et al., 2010). Their ability to form complexes with a wide variety 
of molecules has been studied for over a century (Schmid, 1989). They have been proven to 
enhance solubility of non-soluble drugs, contribute to the stability of the guest molecules, 
reduce volatility, and even mask odours. Another important feature of CDs, especially in TDD 
applications, is that the created drug-CD complex is in a constant dynamic equilibrium 
(Brewster and Loftsson, 2007). Consequently, it must be properly targeted to reach the 
intended location. Targeting the CD-based formulation is usually achieved by creating a 
chemical derivative, with a functional group as the targeting tool (Van de Manakker et al., 
2009). In this work, a newer approach is shown, in which FUS was introduced to a cell 
monolayer in order to enhance membrane permeability, both through mechanical and thermal 
mechanisms, in conjunction with a chemically modified CD.  
Doxorubicin (Dox) is an antibiotic substance discovered over fifty years ago and is 
currently classified as the most potent treatment for many malignancies and especially for 
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solid tumours (Frederick et al., 1990). The main drawback in treatment with Dox is the high 
cardiotoxicity associated with the cleavage of the Dox molecule and creation of free radicals 
(Šimùnek et al., 2009). Although many efforts have been applied in order to decrease the 
unwanted side effects of Dox, e.g. by encapsulation of the Dox into liposomes (O’Brien et al., 
2004), the challenge of efficient Dox delivery without harming the surrounding tissues, still 
exists. It was recently shown that CDs can potentially aid in the prevention of the Dox cleavage 
and hence decrease their cytotoxicity (Anand et al., 2012; Swiech et al., 2012). In this study, 
the CD-based carrier was chemically modified in a way that resulted in a successful Dox 
delivery vehicle. The CD-Dox complex was tested in vitro, with the application of FUS as the 
drug release mechanism. 
In this work, it is proposed that the combination of FUS from an arrangement based on 
a clinical system with a novel nanocarrier based on the CD technology, not only will allow a 
wide range of possible encapsulated drugs in an in-vitro research environment, but also non-
invasive, site-specific drug delivery with a faster track to reach the patients. 
 Motivation 1.2
Even though USmTDD has been a focus of study for some time, there are still many 
unanswered questions, with the most important being the exact mechanism for increased 
drug uptake. Moreover there is a constant quest for improved drug carriers. For these reasons 
it is very important to start research from the in-vitro stage, since there, under correct 
research environment, fundamental questions will be answered. In the present work, the 
possibility to combine such arrangements with a novel drug carrier presented an opportunity 
to investigate a well-studied field in a new way.  
Using a clinical FUS system gave the work another challenging aspect. While on the 
one side the system led to an easier path to reach potential in-vivo studies, considerable work 
was needed to adapt it to serve as a purely research tool. The quest for an optimal 
arrangement was not the only goal. A crucial part of the research lay in the interaction of the 
novel nanocarriers with FUS, in all its aspects. The possibility to be the first to investigate a CD-
based nanocarrier with a state-of-the-art clinical device in order to improve the delivery of 
drugs was significant.  
The core of the presented work is the investigation of the carriers and FUS in the in-
vitro environment. Due to the fact that in-vitro studies involve fragile yet hazardous research 
materials, they need to be carried out in a biologically strongly controlled setting with specific 
protocols in place, to protect both the high level sterility of the experiments as well as the 
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health and safety of the staff. Therefore, the created arrangement for introducing FUS to cells 
had to utilize standard biological consumables that could then be analysed in common 
biological lab apparatus. This presented a major challenge of this work: the design and 
evaluation of a biologically compatible arrangement for FUS application to cancer cell lines. 
The possibility to establish a bridge between complex biological issues and robust FUS 
mechanisms was the strongest motivation for this work. 
 Contributions to Knowledge 1.3
a. This manuscript presents the successful adaption of a clinical magnetic resonance 
imaging guided FUS surgery (MRgFUS) system to cell culture work. The utilization of a 
clinical system allowed more flexibility as compared to even specially designed 
laboratory sonicators, delivering the possibility to control various parameters, 
including phase manipulations and variable transducer apertures, in addition to 
collecting and recording ultrasonic spectra during sonication. Moreover, the 
establishment and thorough evaluation of the arrangements that were created 
presents the opportunity for effective repetition of the in-vitro experiments by other 
research groups worldwide. 
b. In this study the outcome of the iterative Gerchberg- Saxton (GS) algorithm for 
ultrasound beam design was validated for the first time against acoustic field 
measurements. The novel use of a multi-focal sonication pattern in TDD in-vitro 
experiments was proved to be highly beneficial. A single sonication procedure at 16 
points simultaneously significantly reduced the procedure time, resulting in accurate 
and repeatable results and eliminating the effect of time delay between different 
treatment groups.  
c. In the presented work, the widely used drug Doxorubicin (Dox) was successfully 
encapsulated within a novel CD-based carrier. The carrier was synthesized and 
evaluated by spectroscopic and chemical means including nuclear magnetic resonance 
(NMR), fluorescence measurements and high performance liquid chromatography 
(HPLC). Moreover, the created complex between the carrier and Dox was investigated 
under various NMR methodologies: 1H-NMR, 3D measurements (nuclear Overhauser 
enhancement spectroscopy (NOESY) and correlation spectroscopy (COSY)) and 
diffusion coefficient (D) measurements via diffusion ordered spectroscopy (DOSY).   
d. Hyperthermia was shown to be highly beneficial in the drug release and cellular uptake 
increase of free and encapsulated drug. Although some thermo-sensitive CD-based 
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polymers have been demonstrated in the past, this is the first in-vitro validation of the 
heat sensitivity of a CD-based drug vehicle with FUS as the heating source. 
e. The drug uptake results have confirmed that the use of FUS and microbubbles (MBs) 
enhances the membrane permeability of the cancer cells, as was also confirmed by 
membrane integrity studies. The cell viability results have validated that the 
membrane rupture is a reversible and non-permanent process which does not lead 
directly to cell necrosis. Moreover, the combination of MBs with the CD carrier in the 
presence of FUS has produced significant drug uptake within cancer cells. The 
presented work is the first in-vitro examination of FUS-induced drug delivery from a 
CD-based carrier with the aid of USCA. 
 Outline of the Thesis 1.4
The field of USmTDD is a multidisciplinary biotechnological field, combining topics in 
chemistry, biology, physics and medicine. In order to make this thesis as useful as possible for 
readers with potentially different backgrounds, this manuscript is intended to be thorough and 
informative but also succinct.   
Chapter Two is a literature review on each of the subjects presented in this work. It is 
divided into two parts. The first part describes the field of drug delivery, with different existing 
drug carriers, and then focuses on the chosen delivery vehicle - the CDs. A broad description of 
CDs is presented, including their biocompatibility and physicochemical properties, the 
formation of CD inclusion complexes and their advantages as drug delivery vehicles. TDD is 
introduced next, followed by a more specifically relevant delivery system, FUS. The second 
part of Chapter Two provides a technical background to the technologies in use and focuses on 
the description of the physics behind US, followed by biomedical ultrasound applications. The 
chapter closes with the imaging modality in use in this work, MRI, and an overview of MRgFUS 
is provided, as an introduction to the system used in this work.    
The next three chapters deal with the core of the thesis which is the synthesis and 
chemical evaluation of the novel nanocarriers, the design and calibration of in-vitro 
arrangements for FUS application and the conducted in-vitro research. Each of these chapters 
includes a brief introduction, materials and methods section, the achieved results and their 
discussion, and conclusions. 
Chapter Three is dedicated to the creation of the nanocarriers. This chapter includes a 
focused introduction to the potential modifications of CDs, alongside possible evaluation 
methodologies for the CDs and their complexes. The synthesis of the carrier in use in this work 
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is provided, with a full description of the materials and methods and the analytical 
measurements. Spectroscopic evaluation of the yield, as well as its encapsulation of the guest 
molecule, Dox, is also detailed. 
Chapter Four describes the arrangement for introducing cells to FUS, giving a more 
fundamental introduction to US and MRgFUS, describing the materials and methods in use and 
the logic behind their choice. In the results section, a description of the final arrangement can 
be found, with proper thermal and acoustic evaluations.  
Chapter Five represents the combination of the biological, chemical and physical work 
that has been done. This chapter depicts the in-vitro applications of the apparatus that was 
established for introducing cells to FUS, as presented in Chapter Four. Opening with a preface 
on US application to cell culture, and the possible effects on cells, a description of the 
biological protocols and experimental layout follows.  The outcomes of application of FUS to 
cells in various arrangements and conditions are detailed.  
Chapter Six is assigned to the conclusions and future outcomes of the work presented 
in this manuscript. Here a summarized output is presented of the overall data from the in-vitro 
and ex-vivo experiments conducted as preparation for the in-vivo stage. Furthermore, in 
correspondence with the possible in-vivo studies, the discussion of this chapter presents the 
future work suggested to be performed on this topic.  
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 BACKGROUND CHAPTER 2
 Introduction 2.1
In this chapter a general scientific introduction will be given on each of the research 
fields combined in this work. Because this is a multidisciplinary study that has brought 
together techniques from various fields and backgrounds, the presented scientific overview is 
deliberately broad and deals with various subjects. Thorough description and explanations on 
specific procedures are provided in each following chapter.   
 Drug Delivery Systems 2.2
Administration of drugs in order to heal or prevent illness has been utilised for 
millennia. Humans have always been intrigued by the possible beneficial effects of various 
substances on their bodies and minds, and so the pharmaceutical industry, as we address it 
today, was developed. Substances that used to be labelled as ‘witchcraft’ can be found these 
days in every pharmacy (Saltzman, 2001). Despite the life-changing developments in the 
biological, chemical and medical fields in the past centuries, drug discovery is likely to always 
remain a relevant research topic. While there is still a significant lack in treatment of existing 
diseases, new health hazards constantly arise. Moreover, even if a certain drug is available for 
therapy, there can be various problems with its administration, biocompatibility, formulation 
stability and most importantly, accessibility to the necessary body location (Allen and Cullis, 
2004). Another concerning issue is that, with time, cells and viruses can mutate and become 
immune to established treatments, as often happens in cancer treatments. These reasons 
define the constant quest for innovative, more efficient drug delivery methodologies.   
 Traditional Delivery Systems 2.2.1
A typical cell in the human body consists of about 80% water. It can thus be assumed 
that most of the biological interactions with drugs within the human body occur in water-
based environments, meaning that given drugs should be able to interact in aqueous media. 
Moreover, the delivery of drugs to the cells is mostly done in aqueous media as well, e.g. the 
blood stream. This presents the challenge of introducing hydrophobic drugs into aqueous 
solutions. 
The rather straightforward way to overcome the problem of dissolving hydrophobic 
drugs in aqueous solutions is to have a secondary solvent (co-solvent) present in the solution. 
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A co-solvent can be as simple as another layer of hydrophobic liquid (Liu and Venkatraman, 
2012) or surfactants or emulsions.  
Surfactants can be described as a mixture of amphiphilically-structured molecules in a 
solution or suspension. Amphiphilic molecules have a hydrophilic head and a lipophilic tail. 
They tend to create micelles according to the nature of the surrounding media (Figure 2.1) 
(Torchilin, 2001). Surfactants can be used in drug delivery to enhance solubility of insoluble 
drugs and to stabilize them in aqueous environments. 
 
Figure 2.1 - Amphiphilic molecule and a micelle structure 
Surfactants can be divided into three types according to the electric charge of the 
hydrophilic group: cationic, anionic or amphoteric (Fainerman et al., 2001). Charged 
surfactants can stabilize each other by electric repulsion from the neighbouring molecule 
charge. Moreover, large structured molecules can create a steric interference which can 
stabilize the drug and prevent precipitation. The combination of the mentioned two 
stabilization methods is also known as ‘Electrosteric stabilization’ (Tadros, 2005). Amphiphilic 
molecules are known to reduce surface tension of liquids, which can aid in dissolving bulk 
aggregated drug in aqueous solutions. When constructing a surfactant for drug stabilization, 
special care should be taken to ensure the uniformity of the solution created. Surfactants can 
also be used to decrease the rate of drug clearance from the blood through the phagocytic 
system (Karsa et al., 1996). Since surfactants are basically the building blocks for creating 
micelles, they are also often used in the creation of emulsions. 
Emulsions are the liquid phase of colloids; therefore they can also be described as a 
mixture of two immiscible liquids (e.g. water and oil). Emulsions and micro-emulsions can be 
used to immerse hydrophobic drugs, e.g. Lidocaine, into aqueous solutions. Usually the drug is 
dissolved in an oil-based liquid and then added to the aqueous layer. In this case the oil creates 
droplets of drug in the water (Tadros, 2010). The main cause of unwanted separation of 
Amphiphilic Molecule 
Hydrophilic Head 
Lipophilic Tail 
Micelle in Aqueous Solution 
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emulsions is gravity. Because of the polarity and the surface tension of the droplets and the 
suspension, as well as the earth’s gravity, the droplets may accumulate, causing creaming. To 
avoid this situation, large structured polymers, also known as thickeners, can be added. Gum 
based or high percentage oil in water emulsions are often used for dermal drug delivery. On 
the contrary, for parenteral delivery, the emulsion should have as low viscosity as possible to 
pass through the needle easily (Tadros, 2005).  
The main limitations of emulsions are the cloudiness of the suspensions and their lack 
of stability and tendency to separation. Micro-emulsions on the other hand, do not face these 
difficulties and offer a more stable drug delivery method with a transparent appearance which 
is important for pharmaceutical applications (Lawrence and Rees, 2000).   
 Colloidal Carriers 2.2.2
Drug wrapping within individual carriers (Prodrugs) was developed as a technique for 
drug delivery in order to succeed where general administration failed (Kulkarni, 2010). 
Unfortunately, while solvent-based drug delivery provides a solution to the solubilisation of 
lipophilic drugs, it can assure neither triggered drug release nor targeting to a specific body 
location. Moreover, surfactants might disturb the binding of the drug to the needed receptor 
and alter its metabolic activity and there is also the concerning possibility of interaction 
between the surfactant and the cell membrane (Karsa et al., 1996). Today, there is an 
enormous range of drug carriers designed and manufactured worldwide. Because of the rapid 
development rate of science, particularly nanotechnology (Caruthers et al., 2007), new 
technologies for drug delivery constantly emerge. Most of these new technologies focus on 
the best functionalities of each delivery system. Therefore, it is becoming hard to describe the 
existing drug carriers under individual titles. What follows is a brief introduction to the popular 
types of drug carriers; it should be noted that today’s research usually combines two or more 
of these methods to create the desired drug carrier.    
Polymers The term polymer generally refers to high molecular weight (Mw) 
molecules, e.g. > 5 KDa, consisting of covalently bonded monomers. The size of the polymers 
usually depends on the number of repeated monomers. Polymers were developed early in the 
drug delivery field and can be used in various forms, e.g. to transform from liquid to gels 
(Tadwee et al., 2011). The basic structure of a polymer is a backbone with a drug covalently 
bonded or attached in another form, e.g. absorbed, a solubilizing moiety and a possible 
targeting group (Larson and Ghandehari, 2012). Polymers are considered to be a good drug 
delivery method for anticancer drugs. They can reach specifically into solid tumours due to the 
tumour extended vascular activity and increased endocytosis. Moreover, some polymers have 
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been shown to enhance the paracellular permeability of certain drugs within cancer cells 
(Thanou et al., 2007).  
In drug delivery today, polymeric drug carriers describe a wide spectrum of chemically 
modified molecules containing biodegradable and non-biodegradable structures with an 
average size of 10 - 1000 nm (Torchilin, 2006). Such structures may include purely organic 
molecules or a combination of organic molecules with non-organic elements, e.g.  conjugation 
of gold nanoparticles with polymers (Bergen et al., 2006). Furthermore, unique antibodies can 
be attached to polymers to guide the drugs to a specific location (Pasut and Veronese, 2007).    
A well-known polymer often used in drug delivery is polyethylene glycol (PEG). PEG is a 
FDA-approved substance which can be combined with all types of drug carriers by either 
spherical encapsulation around the carrier or chemical conjugation to it (Greenwald et al., 
2003). The combination of drug carriers with PEG has many benefits which depend on the 
individual needs of the designed carrier; e.g. it could prolong a certain carrier blood circulation 
time. PEG is present in all the commercially available drug carriers. Similarly to any chemical 
substance used in medical applications, there are pros and cons regarding the wide use of PEG 
in drug delivery, but at present it seems that the benefits PEG offers outweigh its 
disadvantages (Knop et al., 2010).  
Micro-emulsions As previously explained, amphiphilic molecules can form micelles, 
Figure 2.1, and potentially carry drugs within them. The size of such micelles varies from 5 to 
100 nm (Schäfer-Korting, 2010). Micelles are the essence of micro emulsions, and although 
they are mainly considered to be spherical in structure, as shown in Figure 2.1, they may have 
various structures such as tubes and hexagonal rods (Lawrence and Rees, 2000). The principle 
of drug delivery via micelles or micro-emulsions is similar to that of emulsions. Surfactants are 
normally used to stabilize micro-emulsions (Aboofazeli et al., 1994).  
Despite the great potential of micro-emulsions to serve as drug carriers, there is a 
potential limitation concerned with their dissolution due to dilution (Owen et al., 2012). When 
introduced into large volumes of aqueous environment, e.g. the blood stream, they tend to 
separate and release the drug rather quickly, in order to maintain the ratio of water to 
surfactant. The dissociation rate depends on the critical micelle concentration (CMC); the point 
from which the surfactants become micelles (Narang et al., 2007). This fact allows optimisation 
of the rate of dissociation by pH, temperature and ionic charge. In general, anionic micro- 
micelles tend to dissolve faster than non-ionic ones, but this depends on the aqueous 
environment and surfactants chemistry.   
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In conclusion, micelles have the capability to serve as successful drug carriers and 
therefore to be of use for certain in-vivo applications (Julianto et al., 2000). Yet various 
parameters should be considered when using micro-emulsions for drug delivery, such as the 
difficulty to control the drug release, their major stability issues, and their cytotoxicity.      
Liposomes Liposomes are spherical organic vesicles composed mostly of amphiphilic 
molecules in a lipid bilayer. The size of liposomes used in drug delivery varies from 
80 - 1000 nm. The liposomes’ lipid bilayer is somewhat similar to the cellular one and so there 
could be an interaction between the two (Mayer et al., 1986). The duality of the liposome 
composed of amphiphilic molecules offers the possibility for delivery of both lipophilic drugs, 
in the lipid layer, and hydrophilic drugs, in the core (Al-Jamal and Kostarelos, 2011). Most 
liposomes are eliminated from the blood by liver cells within 15 - 30 min after administration. 
The procedure of elimination is in correlation with the liposomes’ size; the bigger the 
liposomes, the faster they will be removed (Harashima and Kiwada, 1996). Postponement of 
the liposome elimination from the blood circulation can be achieved by protective coating, e.g.  
PEG coating, as used clinically in Doxil®. Moreover, shell-protected liposomes can also have a 
targeting moiety that can aid in accumulation of the drug in the right location, e.g. the use of 
site-specific antigens integrated within the liposome or its coating (Juergen et al., 2012). The 
drug release from the liposome can be achieved by either a chemical reaction such as in pH 
change sensitive liposomes (Karanth and Murthy, 2007) or a physical method such as triggered 
release by US (Huang, 2006; Schroeder et al., 2009).  
Additional Types of Drug Carrier As mentioned previously, a significant number of 
drug carriers and prodrugs is currently under development. Some of these novel carriers for 
drug transportation include DNA based vehicles (Bagalkot et al., 2006), colloidal gold 
nanoparticles (Paciotti et al., 2006), carbon nanotubes (Elhissi et al., 2012) and dendrimers, i.e. 
highly branched molecules (Gillies and Fréchet, 2005). The drug carriers presented here are 
just a fraction of the drug delivery vehicles investigated at various research levels worldwide 
and although many of them might never reach the market, the list of clinically approved 
prodrugs is constantly growing: a summary of FDA approved nanoparticles for cancer therapy 
can be found in Wang and Thanou (2010). 
 Cyclodextrins  2.2.3
CDs were first discovered in 1891 by the French scientist A. Villiers, who isolated them 
from starch which was digested by bacteria. After classifying the substance as dextrin, Villiers 
named it ‘cellulosine’, which was identified as CD a decade later by the Austrian 
microbiologist, Franz Schardinger (Schmid, 1989). Schardinger distinguished between two 
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types of CD: CD andCD, which he had derived from potato starch using a microbe called 
Bacillus Macerans. In 1935, Freudenberg and Jacobi discovered CD. Together with Carmer and 
their co-workers they established CD physicochemical profiles, structural features and their 
capability to create various complexes with other substances (Brewster and Loftsson, 2007).  
Up until the 1970s, although more types of CDs were discovered, there was an inability 
to manufacture substantial amounts of pure, affordable CDs. It was the advancement in the 
biotechnological field throughout the 1970s that brought a revolution in CD production. The 
ability to (almost) selectively create specific subtypes of CD became possible using CD 
glucosyltransferases (CGTases), starch converting enzymes (Maarel et al., 2002; Schmid, 1989). 
Currently, a purifying process in conjugation with those enzymes can produce significant 
quantities of highly pure (>99%) specific CD subtypes (Manakker et al, 2009). 
 Physicochemical Properties 2.2.3.1
Structural Features CDs, also known as cyclic oligosaccharides, are D-glucopyranose 
units linked by -(1, 4)-glucosidic bonds (Figure 2.2) (Li et al., 2007). The number of the D-
glucopyranose units, n, (Figure 2.2a) may vary from 6 (fewer do not exist because of steric 
interference) to 10 or more, although the latter are problematic to purify. Therefore the main 
CDs utilized are the 6 D-glucose units (CD), 7 D-glucose units (CD) and 8 D-glucose units 
(CD) (Singh et al., 2010).         
 
Figure 2.2- (a) Chair conformation of D-glucopyranose in a CD and (b) a 3D structure of a D-
glucopyranose unit, where the atoms C,O,H marked with grey, red and white, respectively 
The D-glucopyranose units in their chair conformation form a truncated cone. The 
hydroxyl groups are orientated to the outer surface of the cone, with the primary hydroxyls 
located on the narrow edge of the cone and the secondary hydroxyls on the wider edge 
(Tafazzoli and Ghias, 2009), as presented in Figure 2.3.  
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Figure 2.3- (a) Schematic representation of CD 3D conformation and (b) CD 
This arrangement creates an inner cavity with a relatively lipophilic nature and an 
outer hydrophilic surface, which enables the CD to form complexes with hydrophobic drugs 
while simultaneously to be water-soluble (Bibby et al., 2000). A schematic representation of 
the truncated cone shape of CD is presented in Figure 2.3a. The size of the cavity and other 
dimensions of the natural, also referred to as ‘parental’, CDs are presented in Table 2.1. 
Table 2.1- Dimensions of --andCD 
CD Type Number of Glucose 
Units 
Dimensions (nm) 
H OD ID 
α-Cyclodextrin (αCD) 6 0.78 1.37 0.57 
β-Cyclodextrin (βCD) 7 0.78 1.53 0.78 
γ-Cyclodextrin (γCD) 8 0.78 1.69 0.95 
 
As can be seen in Table 2.1, the height of the CD remains the same and only the cavity 
size enlarges with addition of glucose units. 
Solubility & Stability Despite the fact that parental CDs possess hydroxyl groups 
located on the outer surface of the cone, they have relatively poor solubility in water. 
Therefore, introducing a CD with a drug in an aqueous solution may result in a solid 
precipitation of the CD-drug complex (Loftsson and Brewster, 1996).  
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Table 2.2- Water solubility characteristics of --and CD 
Characteristics/ CD   
No. of Glucopyranose Units  6 7 8 
Molecular Weight (Mw) 972 1135 1297 
Water Solubility at 25 °C (g/100 mL) 14.5 1.85 23.2 
 
Table 2.2 shows that CD has a particularly low solubility. A possible explanation is 
that the secondary OH groups form intramolecular hydrogen bonds, reducing their ability to 
react with the water molecules. This phenomenon usually occurs in CDs with non-even 
numbers of D-glucose units (Zhou and Ritte, 2010). A remarkable increase in the solubility can 
be achieved by replacing any of the hydroxyl groups, even with hydrophobic functions, in 
order to reduce the intramolecular hydrogen bonds. Nevertheless, the substitution degree 
should be carefully considered as it may cause a steric hindrance which can subsequently 
prevent the creation of complexes (Frömming and Szejtli, 1993). It can also be noticed 
thatCD, Figure 2.3b, has the highest water solubility factor among the CDs, which makes it 
the most potentially valuable natural CD for drug encapsulation. 
Although, in alkaline solutions, the CDs’ glycosidic bonds are quite stable, strong acids 
will hydrolytically cleave those bonds, resulting in linear oligosaccharides. The ring-opening 
ratio due to such hydrolysis is proportional to the CD’s cavity size, therefore it will increase 
with larger cavity sizes (CD <CD< CD). Various factors can decelerate the ring-opening 
rate; e.g. adding guest molecules to CD inhibits the access of the oxonium ions to the 
glycosidic bonds. Against enzymatic hydrolysis, by substituting the hydroxyl groups in the CD, it 
is possible to slow down the degradation process (Uekama et al., 1998).  
 Biocompatibility 2.2.3.2
The proven high stability of hydroxypropyl-CD (HP-CD) against enzymatic hydrolysis 
indicates that it will not be significantly degraded by the body’s metabolism (Szente and Szejtli, 
1999). The same is true for natural CD and CD. These are not hydrolyzed in the blood flow 
or in the metabolic system of rats, dogs or humans, and are excreted unaltered in the urine 
(Brewster and Loftsson, 2007). Unlike CD and CD, CD is hydrolyzed by the human 
pancreatic and salivary -amylase because of its larger cavity (Uekama et al., 1998).  
From the toxicological point, all of the CD subtypes are generally defined as non-toxic 
and are widely used in pharmaceutical applications by various administration routes, as well as 
in the food and cosmetics industries (Bilensoy, 2011).  
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 Cyclodextrin Inclusion Complexes 2.2.3.3
The CD’s notable ability to form complexes has been widely recognized and 
investigated since 1980 and continues today. In principle, CDs are able to form inclusion 
complexes with practically any type of molecule (Dodziuk, 2006). The possibilities vary from 
natural or ionic organic/inorganic compounds up to noble gases. The only condition for such 
interaction is the guest’s ability to fit inside the CD’s cavity, even just partially (Li and Purdy, 
1992). A 1:1 complex formation is represented in Figure 2.4. 
 
Figure 2.4- Illustration of 1:1 inclusion complex of a guest molecule in a CD 
According to Vyas et al. (2008), there are some suggested parameters that can indicate 
if a certain molecule is suitable for encapsulation within a CD:  
 The backbone of the molecule consists of at least 5 atoms (mostly C, N, S and P). 
 The melting point of the molecule is below 250°C. 
 The molecule should have no more than 5 aromatic rings. 
 The solubility of the guest molecule in H2O is less than 10 mg/ml. 
 The Mw of the guest molecule should be preferably between 100 and 400 g/mol. 
Although these are practical guidelines for choosing a possible guest molecule, these 
conditions often change for specific cases and have many exceptions (Dick et al., 1992).  
The main driving force behind the creation of the CD-based complexes is the 
displacement of the water molecules, with relatively high enthalpy, from the CDs cavity, with a 
more preferable, less polar, guest molecule (Szejtli, 1989). 
Factors Influencing Formation and Stability of Inclusion Complexes There are 
four main factors that can determine the stability of a created complex: 
 The geometric capability: This is by far the most critical influencing factor. 
Although it is possible for a CD to form a complex with a significantly larger guest 
than the cavity size, it will only bind to a certain group or a side chain whilst overly 
small molecules will pass through the cavity, resulting in no bonding at all (Zhou 
and Ritte, 2010).  
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 The polarity of the guest molecule: In order to form a complex with a CD, the 
guest molecule must have a hydrophobic tendency. Moreover, there is a linear 
correlation between the guest’s hydrophobic character and the stability of the 
complex created, resulting in hydrophilic guest molecules creating weak 
complexes or none at all.  
 The medium: Although the formation of these complexes is possible in solution or 
in the crystalline state, it is most commonly carried out in a water solution. 
 The temperature: There is an inverse correlation between temperature and the 
formation of the complex: an increase in temperature will decrease the stability of 
the complex (Liu and Purdy, 1992). 
Determination of Binding Constant When complexation occurs between CDs and 
different guest molecules, many types of complexes can be created. Even if the molecular ratio 
between the CD and the guest is 1:1 (1 molecule of CD: 1 guest molecule), the resulting 
complex can be 1:2; 2:2; 2:1 and even higher (Arun et al., 2008). The variation in the order of 
the complexation is dependent on many features of the guest molecule, such as the structure, 
stereochemistry and polarity, and its interaction with the specific CD in use. The most 
commonly investigated interaction, and the one investigated in the present work, is the 1:1 
inclusion ratio (Szejtli, 1998; Davis and Brewster, 2004). 
The formation of a guest (G) and CD complex (CD·G), in 1:1 binding ratio, can be 
described by the following equilibrium:  
    
 
      
Equation 2.1- Complex equilibrium 
The equilibrium constant (K) is defined by Equation 2.2: 
  
[    ]
[  ][ ]
 
Equation 2.2- Equilibrium constant calculation 
When considering a poorly soluble guest molecule, with intrinsic solubility G0, for 
complexation within the CD, a typical manner of studying the solubility behaviour of the 
created inclusion complexes is by the phase-solubility approach (Kurkov et al., 2011), as 
presented in Figure 2.5. 
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Figure 2.5- Diagram of phase solubility behaviour 
This schematic representation of the guest molecule solubility, free and encapsulated 
guest i.e. G0 + G·CD, as a function of the CD concentration is achieved by introducing increasing 
concentrations of CD to a high excess constant amount of the guest. The solubility of a guest 
molecule as shown can be divided into two types, referred to as ‘Type A’ and ‘Type B’ (Szejtli, 
1989). Type A indicates that the created complex is soluble and Type B clearly represents low 
solubility inclusion complexes.  
The solubility behaviour of ‘Type A’ has three common trends: AL, AP and AN. In the 
case of AL, there is a linear correlation between the amount of CD added and the solubility of 
the guest molecule. This can be represented by: 
 
          
   [       ]
     
 
Equation 2.3- AL solubility equation 
where G0 is the intrinsic solubility of the guest molecule (no CD added), GTotal is the guest total 
solubility, and [CDTotal] is the total concentration of CD added. This equation shows that a rise 
in the CD concentration will result in greater solubilisation of the guest, where the slope of 
such growth is:         
      
   
     
 
Equation 2.4- Slope of AL 
Therefore the influencing factors on the guest solubility are the guest’s intrinsic 
solubility (G0), the equilibrium constant (K) and the concentration of the added CD ([CDTotal]). 
42 
 
 
In the case of AP, at higher concentrations of CD the solubility of the guest will be greater than 
linear, usually as a result of a higher order complex creation such as G·CD2, G·CD3 etc. 
(Brewster and Loftsson, 2007). In the final case, AN, at higher concentrations of CD the 
solubility of the guest will increase in a lower rate. This may occur for various reasons, e.g. 
changes in the characteristics of the solution or the formation of CD-CD complexes (Dell Vale, 
2004; Davis and Brewster, 2004).  
The solubility behaviour of ‘Type B’ has two common trends: BS and BI. In the BS trend, 
the complexes created have limited solubility. At first there is a linear increase in the guest 
solubility (up to point A) at which the guest creates a complex with the CD resulting in a 
solution of both G0 and the created complex CD·G. The complex created with the CD added 
after point A precipitates. Due to equilibrium, while the complex precipitates, free guest 
molecules dissolve (according to their G0). Hence, the concentration of the guest in solution 
remains the same between points A and B. At point B, when there are no free guest molecules 
in the solid state, the remaining complexes precipitate as well. In the BI trend, the complexes 
created are insoluble. Since the complexes create precipitates, the concentration of dissolved 
guest in the solution remains G0 at a plateau phase until there are no free guest molecules left 
in the solid state (Kurkov et al., 2011). 
 Dissociation of Drugs from Inclusion Complexes CD-based complexes are very 
stable in their dried form, with long shelf life. Once the complex is introduced back into water, 
the various activation forces in the CD inclusion formation reappear. In the aqueous solution 
many factors can influence the formation (and hence the dissociation) of complexes, examples 
include hydrogen bonding with the hydroxyl groups and thermodynamic considerations. 
However, the main binding criterion between the CD and its guest is considered to be van der 
Waals/ hydrophobic interactions (Arun et al., 2008). Accordingly, there is no covalent bonding 
between the CD and the guest molecule, meaning that the host-guest complex is in a constant 
dynamic equilibrium state (Rozou et al., 2005). Due to the rapidity of the transit between 
association and dissociation of complexes, this equilibrium is considered to be a ‘rapid 
equilibrium’, with the most significant in-vivo dissociation factor of the CD-guest complex 
being dilution (Stella and Quanren, 2008). 
  Cyclodextrins in Pharmacology and Drug Delivery  2.2.3.4
As previously stated, there are numerous applications for CDs and the inclusion 
complexes they create. Although, in this work, the main focus is on their pharmaceutical 
exploitation, they are currently widely used in the food and beverage, cosmetics and chemical 
industries (Boer et al., 2000). 
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Control of Drugs Solubility The major reason for creating CD-based complexes is 
their ability to increase the solubility of guest molecules.  As demonstrated in Figure 2.5, the 
increase in solubility of a guest molecule can be determined using phase-solubility analysis. 
The mentioned increase in solubility can usually be described as linear. In addition to the 
toxicological benefit, this gives the CDs an advantage over organic solvents. Organic solvents 
often behave in a log-linear way; therefore, the complex might precipitate once introduced 
into an aqueous solution (Brewster and Loftsson, 2007; Davis and Higson, 2011). The increased 
solubility as a result of the complexation can enable a certain drug to become suitable for 
parenteral administration or enhance its oral bioavailability. The latter is specifically applicable 
to class II drugs (insoluble yet permeable through the gastrointestinal tract (GIT)), as defined 
by the Biopharmaceutical Classification System (BCS) (Davis and Brewster, 2004).  
In-Situ Drug Release from CD-Based Complexes As mentioned previously the 
main dissociation factor of the CD-drug complex is dilution. This factor is extremely important 
when discussing the stability of encapsulated drugs in vivo. Relatively small amounts of drugs 
encapsulated in CDs, with K < 1 x 105 M-1, will be completely dissolved in the human body, e.g. 
1 ml injected in a 70 kg subject will result in about a 1: 4,200 dilution factor considering only 
the extracellular water, being about 30% of the body weight (Stella and Rajewski, 1997).  
After administration other factors can contribute to the drug release. Such factors 
include binding of the drug to various proteins, competitive displacement of the drug, and 
drug uptake into the tissues. These processes can all result in an equilibrium shift towards the 
dissociation of the complex, according to Equation 2.1. However, in certain circumstances one 
may desire to keep the drug encapsulated. A good example is in application of encapsulated 
drugs in muscle (IM) or subcutaneously (SC) when an unwanted precipitation of the drug can 
result in tissue damage. A possible solution is the utilization of chemically modified CDs, such 
as sulphobutyl ether βCD (SBE-CD) (Stella and Quanren, 2008). Through chemical 
modifications it is possible to control the time and location of the drug release from 
encapsulation. A description of the modifications needed as a function of the time and release 
location can be found in Uekama et al. (2006). 
Stabilization of Drugs CDs may greatly improve the stability of various molecules via 
the complexation process. It has been proven that CDs not only stabilize a lipophilic drug in an 
aqueous environment, but can also stabilize it in the solid state and hence create a complex 
that can be orally administered (Terao et al., 2006). CDs are not only able to physically stabilize 
the guests by inhibition of crystal growth, but also to suppress the guest’s chemical reactivity 
(Davis and Higson, 2011). 
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Directing of Physical and Chemical Reactions The complexation ability of CDs can 
be utilized in directing chemical reactions. One example is selectively protecting functional 
groups on molecules in order to perform regioselective reactions (Breslow, 1980). Inclusion 
complexes are also able to translate liquid or oily compounds into a crystalline form. For 
example, the combination of CDs with greasy coffee aroma concentrates creates a stable 
complex in the microcrystalline form, which can be then be added to instant coffee products 
(Cabral Marques, 2010). Another controllable parameter available to manoeuvre chemical 
reactions is the ability of the CD to accelerate or decelerate the reactivity of a guest molecule, 
as a result of the complex creation. Usually, in complexes where the functional group of the 
guest molecule is located inside the CD’s cavity, it will result in an inhibition effect. However, if 
the active moiety is partially or fully outside the cavity, acceleration may occur. 
Reduction of Volatility An important application of CD-based complexes is the 
reduction of volatility of different compounds. The formed inclusion complex can stabilize 
highly volatile substances, and increase their boiling point in a solution (sublimation point in 
the solid state). Moreover complexation with CD can transform volatile liquids into stable solid 
crystals (Szejtli, 1985). This function is especially useful in the food and cosmetic industries, 
where it is used to preserve flavours, colours, aromas and vitamins during storage periods, 
which later can be released upon contact with water (Astray et al., 2009).  
Masking of Organoleptic Properties of Drugs A further application of the CD 
inclusion complexes is the ability to mask odours and tastes of different substances. The 
modification or elimination of certain tastes and odours can be achieved at low temperatures 
and at high concentrations of CD. The possibility to mask drug odour or bitterness without 
altering its functionality is of great interest, especially in orally administered drugs. Recent 
clinical studies proved reduction in the bitterness of antihistaminic drugs using CDs (Ono et 
al., 2011). 
 Targeted Drug Delivery  2.3
The delivery of drugs into a specific location within the body refers not only to the 
arrival of the drug close to a certain organ, but also to its penetration into the cells or even into 
their nuclei. In order to design a drug delivery vehicle, the mechanisms of drug absorption in 
situ must be thoroughly understood.  
Drug penetration within cells usually occurs through binding receptors on the surface 
of the cell. Hence the amount of absorbed drug is proportional to the amount of drug bound 
to receptors (Golan et al., 2008). Once the drug has entered the cell, it can alter various 
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processes to cause cell destruction. Such processes include changes related to mRNA creation 
and degradation or/and alteration of various enzymatic behaviours. More on cell structure and 
behaviour in the presence of various substances can be found in Lu and Øie (2004).  
 Targeting Principles 2.3.1
The methodology of targeting drugs within the human body can be divided into three 
main pathways as follows: directing of the drug via chemical modification, e.g. encapsulation 
within a drug carrier with a targeting function; application of an external stimulus, e.g. 
hyperthermia, magnetophoresis, in-situ injection etc.; and the combination of the two 
methods, e.g. US triggered drug release from liposomes, thermal application to heat-sensitive 
nanocarriers etc. (Tadwee et al., 2011). While this chapter mainly focuses on the chemical 
approach of TDD as a general background for the chemical and biological work, the 
mechanisms of TDD via US and the effects of US on cell membrane, together with current 
research in USmTDD, are reported in Chapter 5. 
 Targeting Moieties 2.3.2
Drug targeting with pharmaceutical carriers which can survive long enough in the 
blood circulation to reach the target region, can be achieved via the following mechanisms 
(Schäfer-Korting, 2010): 
 Passive diffusion by spontaneous penetration into the cells 
 In-situ drug release due to environmental changes (pH, temperature etc.) 
 Targeting ligands (antigens, proteins) 
When designing drug carriers, there are various targeting possibilities to choose from. 
The decisive parameters for the delivery method are determined by the nature of the targeted 
region. 
 Cyclodextrins in Targeted Drug Delivery 2.3.3
The proven advantage of CDs over traditional drug systems such as co-solvents and 
surfactants is that the pharmacokinetics (PK) and pharmacodynamics (PD) of the encapsulated 
drug generally remain unaltered due to complexation (Stellla et al., 1999).  
 CDs, in their nature, are not capable of crossing cell membranes easily and their effect 
on membrane permeability highly depends on the composition of the membrane barrier and 
the properties of the encapsulated drug (Loftsson et al., 2007). This must be taken into 
consideration when designing a CD-based drug vehicle as the complex formation can 
potentially aid in delivery of drugs to the cells by manipulation of the aqueous diffusion 
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barriers or obstruct the absorption of drugs through lipophilic membrane barriers (Rasheed et 
al., 2008). In addition, CD complexes can enhance drug availability in specific locations by re-
complexation with competing agents from the cell components and so releasing high doses of 
drugs only in situ, which results in a promising TDD vehicle (Uekama, 2006).  
 Routes of Administration 2.3.3.1
CDs can be administered into the body by most of the conventional drug delivery 
routes. Full explanations on drug absorption mechanisms and in-situ drug activation within 
each organ, via all administration routes presented here can be found in Jain (2008).  
Oral Drug Delivery The utilization of CDs in oral drug delivery has dual benefits: the 
improvements of the drug characteristics due to complexation, e.g. bioavailability, solubility, 
stability etc. and the possibility of taste/ odour masking (Brouwers et al., 2008; Terao et al., 
2006). The complex created with CDs often acts like a shield with the purpose of carrying the 
drug to the target location. Once the target is reached, the released drug penetrates the 
biomembranes. Moreover, CDs can aid in the creation of stable tablets for oral administration 
of oily drugs (Motoyama et al., 2009). The CD is considered to be non-toxic for oral 
administration; especially due to the CD’s low penetration ability through the GIT (Moses et 
al., 1999). CDs can be used not only to deliver therapeutic drugs orally but also lipophilic 
vitamins with relatively low bioavailability, as was shown for vitamin E in vivo by Miyoshi et al. 
(2011). 
Parenteral Drug Delivery The major release mechanism in parenteral 
administration of drugs encapsulated by CD is dilution. As previously discussed, when 
introducing the complex into the blood stream, it is likely to dissociate due to the high dilution 
factor. In addition, the drug can also dissociate from the CD due to the CD encapsulation of 
competing agents and covalent binding to proteins or functional groups (Stella et al., 1999). 
The most commonly used CDs in parenteral drug delivery are HP-CD and SBE-CD, which are 
considered non-toxic with high aqueous solubility.   
The main benefits from the usage of CDs in parenteral drug delivery are solubilisation 
and stabilization of drugs in an aqueous environment. Moreover, they can be used to minimize 
irritation that may be caused by the drug at the administration location (Challa et al., 2005).  
Ocular Delivery Similar to the parenteral administration, the HP-CD and SBE-CD 
show great potential in ocular drug delivery. The main reason is that they are well tolerated in 
aqueous eye drop solutions. Beyond the usual utilization of CDs in enhancement of drug 
solubility and stability, in ocular administration they are used to reduce the drug irritation and 
to enhance its permeability.  
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In ocular drug delivery, it is crucial for both the drug and the potential delivery vehicle 
to be non-irritating to the ocular surface. This will avoid rapid washout of the drug due to 
tearing and blinking reflexes (Davies, 2000). The key difficulty in ocular drug administration is 
the maintenance of large drug amounts. A possible solution was suggested through gel 
administration but was rejected in the clinical phase due to patient dissatisfaction. 
Consequently, eye drops remain the most acceptable form of ocular drug delivery. CDs do not 
penetrate the ocular biological membranes; therefore they can enhance the uptake of 
ophthalmic drugs by keeping them in solution on the eye surface. As dilution usually does not 
occur in the precorneal area, the dissociation factors are the displacement of the drug by the 
precorneal liquids and the binding and absorption of the drug by the ocular tissues (Stella and 
Rajewski, 1997). 
Nasal Drug Delivery Regarding nasal drug delivery, one should always assess the 
possible impacts of the drugs on the mucociliary system. CDs are proven to be clinically non-
toxic in nasal drug formulation, making them useful drug carriers in nasal delivery. The 
absorption of the drug is improved by the CD’s ability to open tight junctions and enhance the 
cell membrane permeability (Pires et al., 2009). CDs can also be used in conjunction with other 
drug enhancers or can be coupled with other polymers. A recent in-vivo study presented a 
novel delivery method for insulin via nasal administration using a HPG-conjugated CD (Zhang 
et al., 2011). 
Rectal Drug Delivery The main benefit from CD-based rectal drug delivery is the 
enhancement of drug release from the suppository base. This enhancement occurs because 
the complex created between a lipophilic drug and the hydrophilic CD is not soluble in the 
suppository base. This leads not only to enhancement of drug uptake from the melted vehicle, 
but also to inhibition of the reverse diffusion into the base. The influencing factors on CD-
enhanced rectal drug diffusion are mainly the partition coefficient of the drug and the 
complexes’ stability constant. Accordingly, three important facts must be noted: firstly, there 
might be no effect on the drug release if the complex dissociates in the suppository base; 
secondly, the partition coefficient of the CD-drug complex is highly significant as part of the 
drug might be absorbed while still in complex; and thirdly, once the CD-drug complex is 
released from the suppository base, it usually dissociates leaving a free drug for absorption 
(Matsuda and Arima, 1999; Challa et al., 2005).  
Rectal drug delivery based on CD complexes has been studied for its promising ability 
to enhance morphine drug uptake from the suppository base, an extremely important clinical 
need in advanced cancer patients. While the release rate of the drug from the suppository 
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base was not greatly influenced, the CD increased the morphine permeability into the mucosal 
membrane (Rajewski and Stella, 1996; Uekama et al., 1998). 
Dermal Drug Delivery In dermal drug delivery, CD-based complexes can sustain the 
drug release from solution; improve the drug stability/solubility; increase the absorbance in 
situ due to enhancement of membrane permeability of the skin cells, e.g. increase in the 
diffusion into the stratum corneum; and lower the side effects such as irritation. By enhancing 
the thermodynamic activity of drugs within the vehicle, the CD can increase the drug release 
rate. A dual advantage of CD-based dermal drug delivery can be achieved by enhancement of 
drug uptake in situ, e.g. drug release due to displacement of the drug by components of an 
ointment-based vehicle, while decreasing irritation effects caused by application of the free 
drug (Matsuda and Arima, 1999). Although, typically, CDs cannot penetrate biological 
membranes, in their free form they may interact with some compounds of the skin (Loftsson 
et al., 2007). This intriguing feature allows the CDs to remove some parts of the membrane 
and thereby to increase the local absorption of drugs, especially hydrophilic ones.  
Currently CDs are used for dermal administration of anti-aging and anti-wrinkle 
substances. The complexation of CDs in anti-aging creams is done in order to protect the active 
substances from oxidation and for controlled release (Buschmann and Schollmeyer, 2002). 
Colon Specific Drug Delivery  In the case of colon-specific drug delivery, the 
equilibrium of the CD-drug complex is regarded as a disadvantage. The nominal dissociation 
rate of drugs from CDs is not compatible with the extended time it takes a drug to reach the 
colon by oral administration, i.e. about 8 h in humans, which indicates a different approach 
should be adopted. The suggested solution is to bind the CD covalently to the drug, rather than 
creating an inclusion complex (Hirayama and Uekama, 1999). It is well known that CDs are 
rarely affected by hydrolysis in the stomach and the small intestine, meaning they will be 
enzymatically degraded specifically in the colon (Uekama, 2004). A prodrug for colon-specific 
drug delivery is based on the conjugation between a drug and a CD by an ester or amide 
linkage on one of the CDs’ primary hydroxyl groups.  
Protein & Gene Delivery Absorption difficulties through the biological membranes, 
unstable chemical structures and fast disposal by the plasma are just some of the reasons that 
make peptide and protein drug delivery extremely difficult. CDs are able to enhance 
intracellular absorption of peptides and protein by lowering the cells’ barrier function (Vyas, et 
al., 2008). In addition, their relatively non-toxic nature offers a potential approach for peptide, 
protein and gene delivery (Kihara, 2003). Although CDs are able to identify the structural 
features of amino acids, proteins may be too big to be included in the CD’s cavity, meaning 
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only parts or side-chains will be encapsulated. Nonetheless, this is enough to stabilize and 
solubilize certain peptides and proteins, e.g. growth hormones. An additional option for 
protein and gene delivery via CD-based complexes is with CD-conjugated supramolecular 
hydrogels (Li and Loh, 2008). Other applications of CDs involve triggering folding and re-folding 
of proteins, inhibition of efflux pumps, and interactions with the membranes in the nasal 
epithelium in order to enhance drug absorbance (Huang et al., 2010).  
The many difficulties in chronic therapy with peptide and protein-based drugs can 
cause major discomfort to the patients, e.g. daily injections. Controlled release of drugs over a 
certain time period offers a possible solution. One example is the combination of CDs with 
injectable oil-based suspensions. CDs offer an alternative to limited cell membrane 
penetration of viral based gene and oligonucleotides (ONs). Moreover, the CD is also able to 
inhibit the ON’s degradation by endonucleases. Both neutral and charged CDs are used in 
development of novel gene delivery mechanisms (Davis, 2009). 
Brain Drug Delivery Because of the blood brain barrier (BBB), it is hard to deliver 
drugs to the brain. One of the methods to overcome this is by conjugating the active drugs 
with highly lipophilic prodrugs. CDs are used in this situation as a solubilizing agent for the 
lipophilic prodrugs. Moreover, when utilising CDs for solubilisation of lipophilic prodrugs, it 
allows the possibility of combining two or more types of drug in one treatment (Hirayama and 
Uekama, 1999). 
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 Ultrasound  2.4
 Principles of Ultrasound  2.4.1
Although ultrasound (US) has been in practical use only over the past century, its 
theoretical principles can be traced to the 6th century BC. The first practical application for US 
is known as SONAR (SOund Navigation And Ranging) and its idea emerged a hundred years ago 
with the sinking of Titanic in 1912 (Szabo, 2004). The possibility of knowing the location of 
underwater icebergs, and later on submarines, was so stimulating that by the end of WWI the 
first hydrophone was created. The technology in use was mainly based on the ‘The Theory of 
Sound’ by Lord Rayleigh (1877) and the discovery of piezoelectric materials to generate and 
detect US waves by the Curie brothers in 1880. Within a few decades US had found various 
additional applications, such as sonochemistry and medicine (Luque de Castro and Capote, 
2007) and by the nineteen forties the commonly used ultrasonic device was invented - the 
diagnostic US imaging system. Since then, US has been broadly in use in medical environments 
for both diagnosis and therapy (National Academy of Sciences, 2003).  
US can be defined as a pressure wave propagating through a medium. These waves 
create what is referred to as an ‘acoustic field’ (Azhari, 2010). The ‘ultra’ prefix in US refers to 
the frequency of the wave, which in this case is above the human hearing threshold (>20 kHz). 
The frequency of an ultrasonic wave can be defined as the velocity of the sound divided by the 
wavelength, which is temperature dependent. The effect of US waves on the surrounding 
environment, i.e. the propagation of US, results in compression at the high pressure points and 
rarefaction at low pressure points (Seegenschmiedt et al, 1995). This occurs due to shifting of 
the particles under the application of US from their equilibrium positions. Therefore, the 
propagation of the acoustic field depends on the elasticity of the medium it is propagating 
through. Full equations for homogenous and inhomogeneous environments are given in 
Section 2.4.2. 
US can be generated and detected by a piezoelectric material, most commonly crystal 
or ceramic. The deformation of the material due to an electric field produces pressure waves 
that are distributed in the surrounding media and, vice versa, where under a mechanical force 
the piezoelectric material produces electrical voltage (Jaffe and Berlincourt, 1965). The 
piezoelectric principle lies in the presence of dipoles. The net dipole moment of a specific non-
conductive material is altered due to applied mechanical force. This change results in a charge 
density difference that can then be measured.  
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Ultrasonic waves can be directed in order to create a focused beam (Zanelli et al., 
1993). Focused ultrasonic fields are implemented in various devices, partially in diagnostic US 
but mainly in therapeutic applications (see Section 2.4.4.2). The most common methods to 
create focused beams are either via a bowl-shaped transducer or with a phased array. The 
principle of focusing acoustic waves is similar to optical focusing by lenses. The spherical shell 
resembles the optical lens when a ray of light is passing through it (Mueller and Adam, 2012). 
Due to lens geometry, at a specific distance a focus will occur. The same is true for an acoustic 
field created by a curved piezoelectric bowl (Huo and Chen, 2001). The shape of the focus is an 
ellipsoid structure, usually described as a ‘cigar shape’. 
 
Figure 2.6- Focusing of acoustic waves 
The intensity at the focal point can be represented by 
      (
      
    
)
 
 
Equation 2.5- Intensity at focal point 
where I0 represents the transducer’s surface average intensity, r is the flat radius of the 
transducer and Dn is the natural focal distance (Figure 2.6). According to Equation 2.5 the 
intensity at the focal point is in inverse correlation to the wavelength (), and therefore it is 
also dependent on the frequency (Duck et al., 1998).   
A phased array transducer is a more complicated device which consists of many small 
ultrasonic elements that need to be coherently driven in order to create a focus (Bai et-al., 
2009). Such a transducer can be spherically shaped similar to a single element bowl 
transducer; this way, it will have a natural focus, but the multiple transmitting elements also 
allow flat surface geometry. The great benefits of using a relatively high number of focusing 
elements are the variability in the focal distance and the possibility of creating multi-focal 
patterns (Hertzberg et al., 2010). Both of these benefits are important in the present work.   
 
 
2r 
Dn 
Transducer 
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 Ultrasound in Materials: Properties of Ultrasound Propagation 2.4.2
 Acoustic Fields in Homogenous Environments 2.4.2.1
As mentioned previously there is a correlation between the type of the medium and 
the velocity of the sound wave propagation (c [m/s]). Moreover, c is also dependent on the 
state of matter and the temperature. In gas, the velocity of sound increases as a function of 
temperature; in ideal gases, the rise is approximately 60 cm/(sec·°C). On the other hand, in 
liquids, there is an inverse correlation between the temperature and c, with a decrease of 
about 2 - 6 m/s·°C. It should be noticed that c in gas is about one order of magnitude lower 
than in liquids, e.g. cNitrogen in its gas form (20°C) ≈ 351 m/s while in the liquid form (-197°C) 
cNitrogen ≈ 869 m/s. In other words, there is an increase in c according to cgas < cliquid < csolid 
(Shutilov, 1988).  
The dependence on temperature as described previously is true for most liquids, 
except water and some liquid metals. H2O is well known for its anomaly, and in this case it is 
expressed by a nonlinear relation between temperature and the sound velocity. This behaviour 
is presented in Figure 2.7, in comparison with standard behaviour of liquids.  
 
Figure 2.7- Schematic representation of sound velocity in different liquids 
As presented in Figure 2.7 there is a rise in c of about 2.5 m/(sec·°C) up until the 
maximum at 67 °C at which c = 1550 m/s. After reaching the maximum, the dependence on 
the temperature reverses and decreases as in the rest of the liquids.   
The Acoustic Wave Equation The general acoustic wave equation can be 
represented by  
   (
 
  
)  (
   
   
) 
Equation 2.6- General acoustic wave equation 
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where Δ is the Laplace operator (second order differential operator), is the wave function 
and t is the time (Azhari, 2010).  
In homogenous environments the wave function can be described as a harmonic sinusoidal 
wave:  
 (   )          (     ) 
Equation 2.7- Sinusoidal wave equation 
where       is the amplitude of the wave,  2f is the angular frequency, where f is the 
oscillation frequency, k = c is the wave number, and x is the distance the wave has travelled. 
Most of the theoretical and mathematical models describing waves, e.g. Equation 2.6 and 
Equation 2.7 refer to a one dimensional planar propagating wave. In practice, this is only 
partially correct for gas and liquid and especially solids, where shear waves may occur (Szabo, 
2004). 
Acoustic Field of a Phased Array Focused Beam As previously mentioned, a 
phased array transducer consists of many elements that, by manipulation of their transmission 
phase, can create a focused acoustic beam (Yu et-al., 2011). The acoustic beam created equals 
the superposition of the acoustic wave created from each element, eikx or sin(kx), where x is 
the distance from the element to the focal point. This can be calculated by the Rayleigh-
Sommerfeld integral (Ebbini and Cain, 1989). Exact calculations for the phased array 
transducers in use in the present work can be found in Hertzberg et al. (2010). 
 Acoustic Fields in Inhomogeneous Environments 2.4.2.2
Although the model of an homogenous environment represents well the physical 
principles of US, many materials, including the human body, are inhomogeneous; therefore 
the mathematical and physical assumptions must be adjusted. While in an acoustically 
transparent medium, such as water, there is almost no attenuation of the acoustic field, in a 
body, not only is the energy partially absorbed, but it is also scattered and reflected (Laugier 
and Haiat, 2011). There is a wide range of scattering surfaces in the body, from as small as the 
nucleus within an individual cell up to the margins of the organs (Webb, 1988). The interface of 
ultrasonic waves with boundaries, i.e. sudden changes in the medium, is governed by acoustic 
impedance, Z, whose principles can be derived from Snell’s law. According to Snell’s law, when 
a wave is incident on a surface, it is partially transmitted and partially reflected, as illustrated 
in Figure 2.8. 
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Figure 2.8- Snell's law 
This reflection may occur even within the same tissue due to inhomogeneity on a 
microscale. The reflection, mostly known as scatter reflection, may contribute to measurable 
amplitudes of acoustic wave, causing interference (Suetens, 2002). Z can also be derived from 
the density of the medium, , and c according to  
Z=·c 
Equation 2.8- Acoustic impedance 
Once Z is known, it is possible to calculate the ratio between the transmitted, Ti, and 
reflected, Ri, wave’s intensity travelling between different media (Seegenschmiedt et al, 1995). 
R is defined by  
   (
                 
                 
)
 
      
Equation 2.9- Reflection coefficient 
where the various symbols are defined in Figure 2.8. The described reflection of the acoustic 
waves from boundaries can also create standing waves. Standing waves occur in a specific case 
where the reflected waves are exactly in the same phase as the incident wave, resulting in an 
increase in the amplitude of the acoustic wave (Crocker, 1998). 
 Cavitation 2.4.3
Cavitation is “the growth and collapse of gas bubbles in a liquid in response to 
pressure fluctuations in the liquid” (Morfey, 2001). These bubbles usually consist of gas, such 
as air, or vapour and form under very low pressure, which can be explained by classical 
thermodynamics (Feng et al., 2010). There are various reasons for their creation, and a broad 
investigation of their behaviour has been on-going since 1950 (Noltingk and Neppiras, 1950).  
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Although there are several conditions under which cavitation may be generated, such 
as acceleration of a solid surface in a liquid environment and hydrodynamic flow in a narrow 
passage (Jean-Pierre and Jean-Marie, 2004), the focus in this work is on the oscillation of air 
bubbles as a result of an applied acoustic field, which is referred to as ‘acoustic cavitation’ or 
‘ultrasonic cavitation’ (Duck et al., 1998). While there are several detailed categories of 
cavitation, they can be generally divided into the oscillation of bubbles without bursting, i.e. 
stable cavitation, and the collapse of gas bubbles due to applied pressure, i.e. inertial 
cavitation (Leighton, 1994).  
Inertial Cavitation Inertial cavitation was first described at the beginning of the 20th 
century by Lord Rayleigh and was suggested as an explanation for damage that occurred to 
ship propellers. It was considered that air bubbles surrounding the propellers were 
isothermally enlarged, and then rapidly collapsed. This is still considered to be the mechanism 
of intertial cavitation (Lecoffre, 1997). Moreover, the bursting of bubbles not only generates 
high temperature gas but may also create free radicals (Birkin et al., 2001), which can generate 
light (Luque de Castro and Capote, 2007). This procedure is called ‘sonoluminescence’ and it is 
of great experimental interest as it could indicate the presence of inertial cavitation 
(Taleyarkhan et al., 2002). The use of sonoluminescence as a cavitation indicator has been 
shown in various studies (Taleyarkhan et al., 2004).  
Inertial cavitation is threshold dependent, as is the creation of stable cavitation, 
meaning that a bubble needs to be a certain size under the influence of an acoustic field with 
specific amplitude and frequency in order to collapse. The threshold for occurrence of 
cavitation can be predicted via the mechanical index (MI). MI is based on the calculations of 
Apfel and Holland (1991), and is in wide use in all aspects of ultrasonic applications (Jong, 
2002). 
   
   
√ 
 
Equation 2.10- Mechanical index  
where PNP is the peak negative pressure (MPa) and f is the acoustic frequency (MHz). The MI 
itself is referred to without units (Duck et al., 1998). MI is a useful tool for assessment of 
cavitation occurrence and needs to be taken into account while working with US signals.  
The inertial collapse of the bubble, also called Rayleigh collapse, depends on the pressure of 
the surrounding liquid and the geometry of the collapse (Ashokkumar, 2011). There are 
various mechanisms of bubble implosion, e.g. continuous eruptions and regeneration cycles or 
a jetting effect near a boundary (Leighton, 1994) or even a single cell (Prentice et al., 2005).  
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Stable Cavitation Although, even in a perfectly homogenous medium, the pressure 
applied by an acoustic field may create cavitation bubbles, the pressure required for such a 
process is substantial (1000 - 10,000 atm). Pressures of such magnitudes are far higher than 
the ones created in normal experimental arrangements, yet cavitation occurs regularly in 
various lab conditions. This can be explained by the fact that liquids are imperfect. Most 
laboratory liquids, especially water, are saturated with air, gases, and various dissolved 
substances, which act as cavitation nuclei (Shah et al., 1999).  
After the creation of a bubble, a new question arises regarding its stability. The answer 
is driven from the same source as the previous one, the saturation of the medium with various 
impurities. One hypothesis claims that ions created by dissolved salts may stabilize the bubble 
structure and prevent its implosion, and another that a collection of molecules which are 
absorbed from the medium into the bubble’s surface will create a monolayer and decrease the 
surface tension (Shutilov, 1988).  
The stable bubble state can be described by the following equation: 
      
   
 
 
Equation 2.11- Stability of a cavitation bubble 
where PO is the outer static pressure; PT is the sum of saturated vapour pressure in the 
medium, PS, and the pressure of the diffused gas within the bubble, PB;  is the surface 
tension; and r is the radius of the bubble (Neppiras, 1980). Equation 2.11 shows an inverse 
correlation between the radius of the bubble and the pressure. The lower the pressure, the 
bigger the bubble and vice versa. In other words an applied pressure can expand and contract 
the bubbles (Crocker, 1998). In the stable state, the gas cavities oscillate in a linear manner at 
the acoustic field frequency, its harmonics and its sub-harmonics. This movement is also 
referred to as ‘resonant oscillations’. Groups of oscillating bubbles can also create coherent 
‘bubble clouds’ (Gerold, 2011) and micro-streaming. 
Enhancement of stable cavitation can be achieved by introducing microbubbles (MBs) 
into a specific US field. The use of MBs with US beams has been found useful, in slightly 
different ways, in diagnostic and therapeutic fields (Dijkmans et-al., 2004). In US imaging for 
diagnostic purposes MBs, also referred to as USCAs, are used to enhance image resolution and 
contrast and to assess the rate of blood flow (Schropet et-al., 1992; Nicolau et-al., 2004). The 
behaviour of MB’s depends on the MI (Duck et al., 1998).  
Nowadays, studies have combined both the visual enhancement by the MBs with their 
ability to maintain stable cavitation. MBs are under investigation in the drug delivery field 
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(Hernot and Klibanov, 2008; Hu et al., 2009), as it is known that stable cavitation can be used 
to stimulate membrane permeability (Dino et al., 1989). A full explanation of the effects of 
stable and unstable cavitation on cells, with and without MBs, is given in Section 5.1.1.2.    
 Biomedical Ultrasound Applications 2.4.4
 Diagnostic Ultrasound 2.4.4.1
Diagnostic US refers to the imaging method called ultrasonography that utilizes 
transmitting and receiving US transducers. This imaging method is very straightforward and 
considered to be safe (Merritt, 1989). Hence it is widely used for imaging various organs and 
especially during pregnancy (Bricker, 2000). The principle of ultrasonic imaging is, in some 
ways similar to that of a bat’s navigation system, where the return of a transmitted US wave is 
interpreted as an echo image of a surface. The typical frequencies for creation of the 
diagnostic images are around 2 - 20 MHz (Bluth et al, 2000). USCAs are sometimes used to 
enhance the quality of US imaging, mainly in echocardiography scans because blood and highly 
perfused tissue are highly anechogenic (Main, 2009). 
 Therapeutic Ultrasound 2.4.4.2
There are several ways to utilise US systems for therapeutic purposes. Some of the 
common therapeutic ultrasonic applications include: phacoemulsification, a method for 
removal of cataract using an ultrasonic tip (Packer, 2005); various dental treatments (Ustun et 
al., 2008; Ang et al., 2010); ultrasonic physical therapy (Roebroeck et al., 1998); lithotripsy, i.e. 
the destruction of liver/ gallbladder/ kidney stones using a focused acoustic beam (Pengfei et 
al., 2011); and high intensity focused ultrasound (HIFU) surgery.   
High Intensity Focused Ultrasound (HIFU) The ability of US to create focused 
beams, as explained in Section 2.4.1, is not only beneficial in the diagnostic field, but also the 
reason for the interest in HIFU for non-invasive surgery. Using a focused beam at a certain 
frequency, usually between 0.25 - 10 MHz, it is possible to create a sharp and accurate focus at 
varying distances up to many centimeters within the human body (Zhou, 2011). The acoustic 
beam does not harm the propagating tissues on the way to the focus nor the cells surrounding 
the focus, and the margins of the focus can be as little as six cells wide (Duck, 1998). In 
opposition to conventional surgery, where the physician needs to cut the patient’s body and 
precisely remove tissue using a scalpel, HIFU offers the potential of a safer, more accurate, 
non-invasive method for the same or better outcome.  
The methodology in HIFU is to heat the selected tissues to the level of necrosis 
(Overgaard and Suit, 1979), also known as ‘ablation’ (Habash et al., 2006). The thermal dose in 
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situ can be calculated through the time (t) /temperature (T) equation by Sapareto and Dewey 
(1984). 
       
   
Equation 2.12- Thermal dose 
In Equation 2.12, R is a constant that can be derived from the enthalpy of the process. 
For tissues above 43°C, R is considered to equal approximately 0.5 (Halperin et al., 2008). 
According to this equation, given the temperature in situ one can know whether cell necrosis is 
achieved after a certain exposure time to US.  
The effect of HIFU in tissues is not purely thermal, due to the possibility of cavitation. 
As mentioned previously, cavitation is a threshold-dependent, spontaneous and apparently 
random phenomenon which is very hard to control. The appearance of cavitation in tissue 
ablation procedure might have damaging effects and is usually avoided, yet some indicate that 
cavitation is essential for tissue ablation (Wu and Nyborg, 2006).  
 
Figure 2.9- In-vivo liver ablation through the ribcage (InSightec, Ltd.) 
Figure 2.9 depicts an ablated area in a liver. The sonications were performed in a 
sedated pig under MRI guidance. The main challenge was to avoid damage to the ribcage 
when focusing the beam. 19 sonications were performed by an ExAblate 2000 system 
(InSightec Ltd., Haifa, Israel) with a total energy of about 116 kJ for 377 s at f = 1.15 MHz. As 
can be seen, the ablated area appears in the image as brighter spots with an average size of a 
few mm. Although the first in-vivo application of HIFU was in the 1950s by the Fry Brothers, 
HIFU was not in clinical use until the 1990s due to lack of means to visualise the targeted tissue 
and thus target and monitor treatment. Recent developments in imaging, such as CT, MRI and 
US moved HIFU from the research stage into a clinical therapeutic device.  
The leading imaging modalities in use for FUS surgery are US (Wu et al., 2005) and MRI 
(Jolesz, 2009). HIFU surgery has many therapeutic applications, especially in oncology, 
including: prostate cancer (Rewcastle, 2006), bone metastases (Liberman, 2008), breast cancer 
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(Huber et al., 2001), pancreatic cancer (Wu et al., 2005), liver and kidney tumours (Illing, 2005). 
Non-oncological utilization of FUS surgery includes, for example, the ablation of uterine 
fibroids (UFs), a process that can dramatically increase the quality of life without the removal 
of the uterus (Zowall et al., 2008). 
 Magnetic Resonance guided Focused Ultrasound Surgery 2.4.5
The mathematical principles of MRI are complex and mainly rely on quantum 
mechanics. Nevertheless, those principles can be formulated using ‘quasi-classical’ techniques, 
which are more intuitive. Initially named ‘nuclear magnetic resonance imaging’ (NMRI) 
(Lauterbur, 1973), the physics behind it lies in the nucleus of the atoms, more precisely in the 
hydrogen atom (Purcell et al., 1945).  
The nucleus of a hydrogen atom consists of a positive charge created by a single 
proton in a constant spinning motion. By electromagnetism, this motion creates a magnetic 
field which has a ‘magnetic moment’ (Bloch et al., 1946). When discussing a human body, 
which is filled with myriad protons spinning in different directions, the average magnetic 
moment without application of external magnetic field equals zero (Abragam, 1961). Under 
the influence of a strong external magnetic field, B0, the protons should theoretically align with 
the direction of this field (Pykett et al., 1982). In practice, this does not happen: the protons  
rotate around the axis of the applied external magnetic field, precessing, instead. The 
precessional frequency, 0, of the spin is constant and depends solely on the magnitude of B0, 
as defined by the Larmor equation (Epstein, 2008). 
        
Equation 2.13- Larmor equation 
where 2.7·108 rad/s·T also known as the gyromagnetic ratio and B0 is the strength of the 
magnetic field. The protons’ rotation direction can be parallel or anti-parallel to B0 (Wolbarst, 
1999). The ratio between the parallel and anti-parallel spins depends on the strength of B0 and 
temperature. The sum of the spins is the net magnetization, M0, which is aligned with B0 in the 
equilibrium state and can be measured in units of Tesla. In practice, the value of M0 is 
considerably lower than B0, e.g. by 10
6, hence it is practically immeasurable (Brown et al., 
2010). For that reason a secondary pulse, B1, is generated transverse to B0, which tilts M0 in the 
direction of the diagonal axis, as illustrated in Figure 2.10. This way the signal generated by M0 
can be translated into voltage and recorded (McRobbie et al., 2003). 
60 
 
 
 
Figure 2.10- A schematic representation of M0 under the influence of B1 
B1 is a radio frequency (RF) wave at the Larmor frequency. M0 will stay tilted until the 
end of the RF pulse. In Figure 2.10, the RF pulse presented is a 90° pulse, which tilts M0 into the 
transverse axis (Bernstein et al. 2004). This is not always the case, and in order to define the 
wanted tilt degree () the following equation is needed: 
          
Equation 2.14- Angle of M0 tilt 
where TP is the RF pulse duration time and B1 is the strength of RF pulse. Since  depends both 
on the strength of the pulse and its length, it is recommended that only the strength will be 
changed while the time stays constant (Brant and De Lange, 2012). The RF pulse not only tilts 
M0 but also creates phase coherence between the spins; this is the principle behind spin echo 
(SE) imaging, allowing increases in the level of the signal, the M0 recordable level (Suetens, 
2002). Unfortunately, the spins re-phase rapidly and as a result their signal decays to zero, in a 
process known as Free Induction Decay (FID); therefore some additional modulations need to 
be performed in order to overcome this problem. 
There are two types of echoes with different  values, the gradient echo (GE) and the 
SE (Westbrook et al., 2011). GE is usually applied with a RF pulse in which ° while, in SE, 
the RF pulse is transverse to Z (°). In GE, a negative gradient lobe is applied straight after 
the initial RF pulse, which causes a fast dephasing of M0, e.g. much quicker the FID. An 
application of a positive gradient not long after the negative one, rephases the precessing 
spins around the Y axis, and in that way forming the GE (Webb, 2003). In SE, the spins are left 
to dephase for a specific time, and a 180° (Y axis) pulse is applied. As a result, the spins flip and 
eventually rephase at the Y axis, creating the SE (Hashemi et al., 2010).  
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The spins’ relaxation time highly depends on two things: the spin interaction with 
other spins, known as spin-spin relaxation or T2 relaxation time, and the interaction of the spin 
with its environment, the spin-lattice relaxation or T1 relaxation time. In T2, the spins dephase 
due to a small variation in the precessional frequencies of the spins they interact with. This 
variation occurs as a result of the accumulating effect of each spins’ magnetic moment 
(Poustchi-Amin, 2001). When the interaction is over, they return to the Larmor frequency but 
with different phase angles they have attained from the interaction. There is no energy loss in 
T2 relaxation and it is independent of the magnitude of B0. T1, on the contrary, is considered to 
be the energy the spin loses to its environment, blood flow etc., and it is dependent on the 
strength of the magnetic field (B0) (McRobbie et al., 2003).   
While T2 is the de-phasing on the Y-X plane of the rotating frame of reference, T1 is the 
dephasing of M0 back to the Z axis. Since the de-phasing of the spin is much quicker, by several 
orders of magnitude, in the transversal plane than the dephasing in the Z axis, in a given tissue, 
T1 will always be greater than T2 (Webb, 2003).  
From this it is clear that timing plays an important role in MRI. The two important 
features that define the desired timing in regular MRI are the echo time (TE) and repetition 
time (TR). TE refers to the length of the echo pulse (GE/ SE) and TR to the RF and gradient 
pulse recurrence time (Brant and De Lange, 2012).  In SE, the images acquired rely solely on TE 
and TR, so that short TR and TE will result in T1 imaging and long TR and TE in T2 imaging, while 
in GE the angle of RF () is an important factor. If > 50° a T1 weighted image will be 
generated, whereas if < 40° a T2* image will be generated.  
It is necessary at this point, to explain about T2* weighted images (Weishuapt et al., 
2006). While in SE there is a correction of the inhomogeneities of the magnetic field, in GE 
there is no consideration of that factor. Moreover, since the positive pulse only compensates 
for the negative one, it results in no consideration of the spin-spin relaxation as well (Suetens, 
2002). The compensation of both of the things mentioned above in GE images is referred to as 
the ‘apparent’ relaxation (T2*) (Kuperman, 2000).  
There is another optional image contrast approach named proton density (PD) 
weighted images. This type of imaging is rarely used, since most of the soft tissues have similar 
proton densities, but can be achieved via long TR and short TE in SE, or a small angle,  < 40°, 
and a short TE in GE (McRobbie et al., 2003).  
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 Existing Methods of Magnetic Resonance-guided Focused Ultrasound 2.4.5.1
Surgery 
MRgFUS is presently considered to be the ultimate combination of non-invasive 
surgery and accurate real time monitoring. The main benefits of using MRI as a guiding tool for 
FUS surgery are the possibility for real-time thermometry and relatively high resolution 3D 
imaging (Wu and Nyborg, 2006).  
MR-guidance has clear advantages over US guidance in treatment location planning, 
treatment monitoring, focal point location and thermometry (Jolesz and Hynynen, 2008). In 
each of these fields, US imaging lags the equivalent MR capability. For example, US lacks 
accuracy in margin detection of tumours in US imaging, increases uncertainty regarding the 
location of nerves within the treatment area, and, most importantly, lacks temperature 
measurement capability (Jolesz, 2009).  
As previously described, FUS has many clinical applications and the mechanism of 
tissue ablation as a surgical tool is in use worldwide (Peters and Cleary, 2008). Further 
explanation on MRI thermometry and a full description of the systems in use in this work are 
given in Section 4.1. 
 Limitations 2.4.5.2
The main drawback in MRgFUS is in obtaining access to an MRI scanner. Because of 
the large He capacity needed to maintain the temperature of the superconducting coil that 
generates the magnetic field, the costs of MRI suites can go up to a few million dollars. 
Moreover, these highly complicated and expensive systems require frequent maintenance and 
servicing, which can add up to a significant sum per annum, e.g. 10% of the machine cost. 
Furthermore, MRI is not suitable for all patients, e.g. those who are obese and patients with 
implants.  
From the technical point, one of the current limitations of FUS surgery is the 
penetration of the acoustic beam past energy absorbing features, such as bones. Bones reflect 
and absorb the acoustic beam much more than other tissues, which results in heating and 
disturbance or prevention of the focus formation. Due to the importance of these issues, there 
is a significant research effort to overcome this problem, focusing mainly on manipulation of 
the transmitting elements (Bobkova et al., 2010; Liu et al., 2010). Overcoming the challenge of 
focusing beyond bone also opens up the possibility for neurological treatments through the 
skull (Clement et al., 2000; Hynynen et al., 2004). Additional problems in the application of FUS 
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include the motion of the body due to breathing, and the need to ablate large volumes of 
tissue, e.g. large UFs, which results in long treatment times (Jolesz, 2009).  
 Magnetic Resonance guided Focused Ultrasound Surgery Systems 2.4.6
in Drug Delivery 
In recent years MRgFUS has been investigated as a guiding and localizing tool for TDD 
(Vaezy and Zderic, 2009). MRI guidance in USmTDD can be used to monitor the distribution of 
drugs and their accumulation in the target regions, by conjugation of drug carriers and MRI 
contrast agents, and/ or to measure temperature in situ for targeted drug release from 
thermo-sensitive carriers (Deckers et al., 2008). 
MRI contrast agents are complexes that usually consist of a paramagnetic element, 
such as Co2+/3+, Fe2+/3+ or Gd3+ and a polymeric shell in order to reduce toxicity (Weishuapt et 
al., 2006). Such complexes are commercially available and are widely used in order to gain 
clearer MR images. The interaction of these paramagnetic materials with the protons in the 
body results in shorter T1 and T2. MRI contrast agents are used to enhance site-specific imaging 
according to the organ in question. Currently, there is a great interest in the utilization of MRI 
contrast agents to enhance visualization and TDD (Veiseh et al., 2010; Sun et al., 2008). Recent 
in-vivo studies proved the feasibility of utilization of MRgFUS with targeted drug release from 
Gd-conjugated thermo-sensitive liposomes (Smet et al., 2011). Another possible 
implementation of such an idea is the conjugation of Gd with CD-based carriers (Battistini et 
al., 2008; Banerjee and Chen, 2009).  
 Summary 2.5
This chapter aimed to provide the necessary background for the work presented in this 
thesis. The broad introduction to TDD included the various existing chemical methods and 
mechanisms for targeting drugs in the body. CD technology was presented, with the 
fundamental chemical background as well as the pharmaceutical applications in TDD and the 
possible routes of administration. The design, characterization and chemical evaluation of CD-
based drug carriers is discussed in Chapter 3. To provide background on the MRgFUS system 
that was utilized in this study, the basic physics and applications of both US and MRI were 
reviewed.  
As a part of the introduction to US, the following points were discussed: acoustic fields 
and the general wave equation, types of cavitation and its formation, and biomedical US 
applications. Although the working principles of MRI involve highly complicated physics, a 
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general description of the mechanisms involved was included to provide basic understanding 
and to introduce the reader to the terminology in use. More information on the evaluation of 
acoustic fields and MRI thermometry is provided in Chapter 4.           
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 DEVELOPMENT AND CHAPTER 3
CHARACTERIZATION OF A CYCLODEXTRIN- BASED 
DRUG CARRIER  
 Introduction  3.1
This chapter will discuss possible methods for synthesis of CD derivatives alongside 
evaluation techniques for the yield. In addition, the complexation process as well as the 
investigation of the guest, host and the created complex structures and reactivity via different 
methodologies, will be presented.    
 Chemical Modification and Cyclodextrin Derivatives 3.1.1
The motivation for chemical modification of CDs varies and may include improvement 
of their solubility in certain solvents, increase in their stereo-selectivity for specific guest 
molecules in host-guest complexes and the possibility to explore enzyme-catalyzed reaction 
mechanisms (Uekama, 2004).  
When modifying CDs, two important factors must be taken into account. Firstly, one 
must consider the hydroxyl groups’ nucleophilicity, as the initial reaction of modification will 
be an electrophilic attack on these groups, and secondly it is important to acknowledge the 
CD’s ability to form complexes with the reagents in use. If a strong complex is formed, the 
product will be defined by the reagent, whereas in a weak complex, the product is guided by 
the hydroxyl group nucleophilicity. Additional important considerations in the chemical 
modification process are the cavity size of the CD and the solvent used for the reaction, e.g. in 
DMF a sulphonation reaction occurs non-selectively on all of the hydroxyl groups, whereas the 
same reaction in pyridine will be directed to the hydroxyl groups on the 6th position (Khan et 
al., 1998; Szejtli, 2004).  
As previously presented in Figure 2.3, the CD’s glucopyranose ring has primary 
hydroxyl groups on the 6th position and secondary hydroxyl groups on the 2nd and 3rd positions, 
wherein the hydroxyl groups on the 2nd position are the most acidic ones, and the ones on the 
3rd position are the most difficult to access. The hydroxyl groups on the 6th position are the 
most nucleophilic and will react selectively with less reactive reagents. The intramolecular 
hydrogen bonds created between the hydroxyl groups on the 2nd and 3rd positions restricts 
their rotation while the hydroxyl groups on the 6th position rotation are free, which reduces 
the accessibility to the cavity from the primary face (Khan et al., 1998).  
76 
 
 
Sole substitution of the CD’s hydroxyl groups (either on the second, third or sixth 
position) also known as monosubstitution, usually increases the CD’s aqueous solubility 
comparing to that of the natural one and hence is used, along with other materials, to enhance 
drug delivery to specific sites (Tang et al, 2007). It is a challenge to synthesize such molecules, 
due to difficulties in selectively modifying the three different hydroxyl groups on the outer 
surface of the CD (Muderawan et al., 2005). Therefore, the higher the number and variety of 
groups to be substituted on the CD, the harder it will be to synthesize (Himeno et al, 2009). A 
proposed way to avoid a mixture of unwanted products is by protection of certain hydroxyl 
groups and thereby directing of the reaction to the desired yield (Badi et al., 2006). A newly 
proposed, unconventional method for selective substitution on CDs suggested utilization of 
power US with microwaves, which is suggested not only to yield higher amounts of a specific 
product, but also to dramatically shorten the reaction time (Trotta et al., 2007).  
When discussing chemically modified CDs, the following two commonly used CD 
derivatives should be mentioned: HP-CD and SBE-CD. Both of these have higher water-
solubility values than the naturel CD and good complexing properties. Various studies were 
conducted on the safety profile and toxicological effects of HP-CD and SBE-CD which defined 
them as essentially non-toxic to humans and so, at present, they are used in several Food and 
Drug Administration (FDA) approved products (Loftsson and Duchene, 2007). Furthermore, 
investigation of HP-CD abilities in complex formation with various anti-cancer agents has 
shown high encapsulation levels of various drugs, especially of highly hydrophobic ones such 
as Taxol (Cserhfiti and Hollo, 1994). Other modifications can create charged CDs which provide 
additional ionic interactions for diverse applications, e.g. electrophoresis (de Boer et al., 2000).  
 Cyclodextrin-Based Polymers 3.1.1.1
The initial step in creation of CD-based polymers and larger scale carriers is to link CDs 
to one another. The basic method to create linked CDs is by substitution of the hydroxyl 
groups with a functional group, which due to certain chemical reactions, will become the 
linkage to another CD molecule, creating a dimer (Liu et al., 2002; Pham et al., 2010). The 
dimer can be further polymerized to create branched CDs and even CD-based polymeric 
networks (Auzely-Velty, 2011; Van de Manakker et al., 2009). Additionally, CD-based polymers 
can be achieved by coupling of the CD to an existing polymer network, copolymerizing it 
chemically, by radiation, or even radical reactions (Balta et al., 2008).  
Unfortunately the methods discussed above usually involve toxic reagents which have 
limited the medical applications of the created linked CDs. Therefore, an additional method for 
synthesis of such molecules was developed. This method is based on utilization of the CD’s 
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inclusion ability in order to design a specific polymer. A good example is the use of adamantine 
in conjunction with CD to form CD-modified hydrogels (Deng, 2007). Furthermore, it is 
possible to modify this inclusion-motivated polymerization process to be selectively sensitive 
to ultraviolet (UV) / visible light, a specific pH level, or a certain temperature. With further 
modifications, macro- and nanoscale self-assembled particles have been created that have 
shown the ability to remain a relatively long time in the blood stream and are therefore  
potential drug delivery vehicles (Challa et al., 2005). 
Conjugation of micelles and other CD-based polymers with magnetic particles was 
suggested for magnetically-guided TDD (Battistini et al., 2008; Banerjee and Chen, 2009). An 
additional possibility is the combination of CDs, on their own or in a complex, with liposomes. 
The conjugation is usually made to exploit the best properties of both drug carriers, in order to 
create a better drug delivery vehicle, e.g. through improvement of drug solubility by CD 
complex while targeting via a specially designed liposome (Maestrelli et al., 2005; Maestrelli et 
al., 2006; Hagiwara et al., 2006).  
 Peptidic Cyclodextrin Polymers  3.1.1.2
Since the 1920’s, when insulin was first introduced to the market, it has changed the 
lives of millions. Moreover, it has shown the great potential behind peptidic drug delivery (van 
der Walle, 2011). The research field of peptide and protein drug delivery has developed greatly 
since then, yet challenges to their practical use are still to be overcome. Peptides and proteins 
suffer from poor absorption through the biological barriers as well as rapid clearance from the 
blood circulation by the plasma, which complicates their cellular delivery (Irie and Uekama, 
1999).  
Conjugation of CDs with various peptidic structures can offer a new platform of 
selective tumour therapy. The peptidic-CD type of drug carriers can exploit the ability of CDs to 
encapsulate anti-cancer drugs, even highly lipophilic ones, and to solubilize them in aqueous 
solutions while obtaining site-specific delivery via the peptidic conjugate (Schaschke et al., 
2000). Moreover, the CDs are able to stabilize (Haeberlin et al., 1996) and increase the water 
solubility of high molecular weight peptides, even without covalently bonding to them, which 
can provide a larger therapeutic window with higher selectivity (Arnusch et al., 2012). In 
addition to cancer research, at present CD-based dimers are being studied for their ability to 
interrupt the peptide aggregation leading to Alzheimer’s disease ( ahlstr m et al., 2012). 
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 Production Methods of Complexes 3.1.2
Complexation of lipophilic guest molecules with CDs in aqueous solutions is usually a 
spontaneous interaction in which the guest escapes the surrounding media into the cavity of 
the CD.   
 Doxorubicin as Guest Molecule in a Cyclodextrin-based Complex 3.1.2.1
Doxorubicin (Dox), Figure 3.1, also known as Adriamycin, belongs to the anthracycline 
family, a well-known antibiotic drug that is widely used in anti-cancer treatments. The 
anthracycline type drugs are ranked among the most effective oncological treatments 
discovered so far. The cytotoxicity mechanism of Dox is via interaction and modification of the 
DNA structure by disturbance of various DNA-related processes such as replication, 
transcription, and repair mechanisms (Frederick et al., 1990).  
 
Figure 3.1- Doxorubicin (Dox) 
The anthracycline type drugs are known to create reactive oxygen species (ROS) 
(Šimùnek et al., 2009) which have a highly cytotoxic effect that can result in various adverse 
side effects such as major cardiac damage (Green and Leeuwenburgh, 2002). To overcome 
extravasation of Dox during administration and to partially scavenge the created radicals, a 
delivery mechanism by DMSO was clinically tested (Lopez et al., 1999). DMSO is known to pass 
the dermal barrier and penetrate easily within tissues without causing irreversible damage. 
Due to its unique biological features, DMSO has been used in medicine since the 1960s as an 
analgesic, an anti-oxidant and a drug delivery vehicle (Tucker and Carrizo, 1968). Addition of 
DMSO to the administration of Dox can aid in rapid transfer of Dox through the tissues and 
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promote the drug into the blood circulation and can also reduce Dox-induced skin ulcers 
(Hajarizadeh et al., 1994).   
Another way of preventing the creation of the ROS is through protection of the 
quinone group by complexation with a CD (Swiech et al., 2012). A significant drawback in the 
clinical efficiency of the anthracyclines is their tendency to self-aggregate (Evstigneev et al., 
2006; Barthwal et al., 2008). Self-association of these drugs influences greatly their anticancer 
action in several ways such as causing difficulties in crossing the cell’s lipid bilayer and the 
ability to interact with the DNA helix (Agrawal et al., 2009). It was discovered that when Dox in 
its monomer and dimer structures was conjugated with micelle-based carriers, the Dox 
monomer showed significant antitumor activity while the dimer showed no antitumor activity 
by itself (Nakanishi et al., 2001).  
Dox has also been shown to interact with other widely consumed aromatic molecules, 
such as caffeine, which lowers its pharmacological activities (Piosik et al., 2002). Consequently, 
encapsulation of Dox inside a CD can significantly increase its medico-biological activity within 
the body by prevention of unwanted encapsulation to various molecules, yet maintenance of 
its cytotoxicity, while simultaneously lowering the potential creation of free radicals by 
maintaining the minimal needed dose and the protection of the quinine group from hydrolysis 
(Anand et al., 2012; Swiech et al., 2012).   
 Characterization of Cyclodextrins and Their Complexes 3.1.3
The high density of electrons located inside the CD’s cavity can change the local 
environmental polarity affecting the electronic transitions and hence the optical behaviour of 
both the guest and the CD. Accordingly, inclusion complexes are widely studied by various 
analysis methods, such as UV-visible spectrophotometry, fluorescence, IR, and various NMR 
(Singh et al., 2010). 
 High-Performance Liquid Chromatography  3.1.3.1
Liquid chromatography (LC) is a well-established method for separation of chemical 
mixtures in the liquid phase by an absorbent material (McMaster, 2007). All the existing 
variations of this method consist of a stationary phase and a mobile phase which moves over 
the immobilized one (Weston and Brown, 1997; Dong, 2005). The working principle behind this 
technique lies in the interactions of a sample with both of the stationary and the mobile 
phases. In high-performance liquid chromatography (HPLC) the liquid mobile phase is pumped 
through the stationary phase located in a column.  
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The main parts of any HPLC system are a sample injector, a pump, a stationary phase 
column and a detector, such as an UV sensor (Dong, 2006). The initial HPLC measurements, 
nowadays referred to as ‘normal HPLC’, were performed on a hydrophilic stationary column 
(such as unmodified alumina or silica), allowing the hydrophobic samples to be eluted first 
(Jiskoot and Crommelin, 2005). Currently, it is more common to use reversed phase HPLC (RP-
HPLC), which utilizes an hydrophobic stationary phase (such as octadecyl carbon chain bonded 
silica (C18)) with a more polar mobile phase (H2O and methanol/ acetonitrile), this is usefull 
especially when working with peptides (Synder et al., 2010).  
 Thin-Layer Chromatography  3.1.3.2
The working principle of thin-layer chromatography (TLC) also known as ‘planar 
chromatography’ is identical to that of HPLC described above. The only variation between 
HPLC and TLC is in the method of the sample transportation. Where, in HPLC, the sample is 
pressed out by a high pressure pump, in TLC the movement of the sample on the stationary 
phase is due to capillary forces (Kazakevich and LoBrutto, 2007). In the current work, TLC was 
used as a monitoring tool to follow the formation of the carrier and to distinguish it from any 
unwanted by-products (Caliceti et al., 2003).  
 Ultraviolet – Visible and Fluorescence Spectrometry 3.1.3.3
The principle of UV - visible light spectrometry is based on the interactions of photons 
with an electron cloud in a material. This interaction promotes the electron to a higher energy 
level that corresponds to a specific wavelength. Recording of the degree of absorption by the 
sample at different wavelengths will produce a nominal UV spectrum, being the plot of the 
absorbance (A) versus the wavelength (λ [nm]) (Thomas and Burgess, 2007). The energy 
needed to excite an electron depends on its orbital location, as presented in Figure 3.2. 
 
Figure 3.2- Transition between orbitals 
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According to the energy levels shown in Figure 3.2, mostly the n-electrons (non-
bonding) and π-electrons will be excited by ultraviolet and visible light. Hence, the wavelength 
of absorption can indicate the character of the sample molecule (Krupadanam et al., 2001).   
Since the beginning of the 1950’s, CDs were discovered to be quite useful in 
determining the spectrophotometric properties of many compounds and materials. When the 
CDs form complexes with a substance and/or a colouring agent, they can modify the 
properties of the reagent. Examples of such changes are increased solubility and / or stability 
of the reagents in different solution environments, increased sensitivity of colour reactions and 
even improvement in their selectivity (Liu and Purdy, 1992). Various groups worldwide that 
have studied the interactions of and CD and their conjugates in host-guest complexes by 
spectrographic means have demonstrated the inclusion complexation formation through UV-
spectroscopy. The results have shown that CDs have the ability to increase (Li et al., 2010) as 
well as decrease (Swiech et al., 2012) the absorption of the guest molecules.  
In addition to studying various chemical changes occurring due to complexation by UV 
measurements, the binding constant (Kbinding) of the created complex can be established (Wang 
and Eaton, 1985). Kbinding represents the level of interaction that occurs between the guest 
molecule and the carrier. The widely used method for calculation of the Kbinding is the Benesi-
Hildebrand method (Benesi and Hildebrand, 1949), as described in Equation 3.1: 
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Equation 3.1- Kbinding calculation via Benesi-Hildebrand method 
where ∆A is the difference between the absorption of the complex and that of the free guest, 
∆ϵ is the difference in the absorption constants, [G] the concentration of the guest (Dox), [H] 
the concentration of the host (carrier) and Kbinding is the binding constant. Following the 
assumption of 1:1 complex formation, one can calculate Kbinding by plotting 1/∆A vs. 1/[H]: the 
ratio of the intercept to the slope will provide the value of Kbinding. The same calculation 
method could also be applied in fluorescence studies of CD inclusion complexes (Park and 
Song, 1989; Mukhopadhyay et al., 2005; Lu et al., 2009). 
Fluorescence can be defined as the spontaneous emission of light from an 
electronically excited molecule. As previously described, photons have the ability to excite the 
electrons of substances to higher energy levels (Figure 3.2). In specific molecules, the de-
excitation process results in spontaneous light emission (Valeur and Berberan-Santos, 2012).    
Fluorescence spectrometry in many cases can provide more specified data than can be 
achieved by a UV spectrum due to its higher detection limit. The parental CDs are 
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spectroscopically inert, meaning that typically they will not interfere with the guest 
fluorescence signal. Similarly to UV spectroscopy, the CDs are able to enhance (Frankewich et 
al., 1991; Liu et al, 2002; Lu Z. et al., 2009) or quench (Mukhopadhyay et al., 2005) the emitted 
fluorescence signal of the guest molecule. In addition to tracing the fluorescent signals of the 
guest, the CDs can be substituted with fluorescent markers that can aid in molecular 
recognition of various substances (Ueno, 1996). Moreover, the formation of inclusion 
complexes can also provide information on the reaction of different molecules with each 
other, e.g. by 3D fluorescence scanning (Zhang and Xiong, 2012). 
 Nuclear Magnetic Resonance  3.1.3.4
The principles of nuclear magnetic resonance (NMR) were previously explained in 
Section 2.4.5 as the basis for MR imaging. In chemical analysis, tracking of the slight changes in 
the resonance frequency of certain atoms can provide insight into the structure and 
consistency of the investigated substance. The difference between the resonance frequency of 
the atom and the reference sample (usually tetramethylsilane (TMS) for 1H and 13C-NMR), 
divided by the precessional frequency (0) (Equation 2.13) of the operating magnet is referred 
to as the chemical shift () of the element (Balcı, 2005). As the change in frequency between 
the sample and the reference is very small (measured in Hz) and the operating frequency of 
the magnet is given in MHz, the chemical shift is presented in ppm.   
An important phenomenon present in NMR spectra of molecules is a split in the 
recorded peaks of a single atom in a molecule. This phenomenon is attributed to the spin-spin 
splitting that occurs as a result of atoms neighbouring the measured one. The positive and 
negative contributions of the neighbouring atoms contribute to the overall alteration of the 
applied magnetic field sensed by the measured atom and, as a result, cause a split in its NMR 
signal. The size of the spilt (in Hz) is referred to as the coupling constant (J) (Jacobsen, 2007). 
The intensity and type of split are defined by Pascal’s triangle and dependent on the number 
and nature of the neighbouring spin active atoms.  
NMR spectroscopy can be used not only to identify the consistency of a substance, but 
also to gain information on its 3D structure. Possible techniques to achieve such information 
are via NOESY or COSY measurements. These methods are based on tracking of changes 
occurring in different atoms due to irradiation at the resonance frequency of a certain atom in 
the molecule. Due to irradiation in COSY measurements, only the influence of covalently 
bonded atoms will be reordered, whereas in NOESY any atom in the spatial area of less than 5 
Å will produce a signal, regardless of covalent bonding. Subtraction between the achieved 
readings of the two methods will yield the sole 3D interactions of unbonded atoms, which, 
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with proper attribution of the atoms, can indicate the 3D structure of the molecule (Holzgrabe 
et al., 1999).  
CDs probed by NMR NMR is considered to be the most powerful and conclusive tool 
in identifying CD-based inclusion complexes (Fernandes, 2003). In the early 1970s, the 
milestones were established for the use of NMR as a complexation monitoring method. 
Throughout this period, it was observed by 1H-NMR that, due to shielding of the inner cavity 
protons (3H, 5H) by the guest molecule, a significant upfield shift occurs. On the other hand, 
the hydrogen atoms located on the exterior of the cavity (2H, 4H, 6H) are generally not 
affected (Singh et al., 2010). Although it was initially discovered in 1H-NMR, nowadays 13C-
NMR, 15N-NMR, 31P-NMR and 19F-NMR are also in use for studies of inclusion complexes, even 
with solid samples (Cabral Marques, 2010). 
 Diffusion Ordered Spectroscopy  3.1.3.5
DOSY is an NMR-based method for discovery of the diffusion coefficient (D) of 
molecules in solution. The diffusion rate of molecules can indicate the dynamics of a molecule 
in solution and provide information on its molecular structure and organization within the 
medium. The working principle behind this method is in observation of the NMR signals 
attenuation during an applied pulsed field gradient. The recorded decay in signal corresponds 
to the diffusion rate of the molecule (Loening et al., 2001). In complex formations, the 
measurement of D can indicate the percentage of the guest encapsulation within a host 
molecule (Calderini et al., 2012). Equations for calculation of D, the percentage of 
complexation and the relation between D and Mw of the molecule can be found in Appendix i. 
 Aims and Objectives 3.1.4
This chapter will mainly focus on the synthesis of the novel nanocarrier utilized for in-
vitro and possible in-vivo delivery of anticancer agents. The full synthesis of the 
monosubstituted CD will be presented together with the chemical analysis of the yield. 
Moreover, the investigation of the carrier - Dox complex will be discussed and examined by 
various methodologies.   
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 Materials and Methods 3.2
 Materials 3.2.1
Table 3.1- Equipment and chemicals 
Material Manufacturer  Place of 
Origin 
Notes 
Equipment    
400 MHz NMR spectrometer  Bruker USA Model: Advance III 
500 MHz NMR spectrometer  Bruker USA Model: Advance III 
HPLC  Sedere France Model: SEDEX 75 
UV Reader Anthos USA Model: Multiread 400 
Fluorescence spectrophotometer Agilent 
Technologies 
USA Model: Varian Cary Eclipse 
ELISA reader Tecan  UK Tecan infinite M200 
Freeze-dryer Labconco USA Model: Freezone 2.5 Plus 
Reversed-phased column  Merck Israel Model: LiChroprep 
Arguslab 4.0.1  Mark Thompson USA  Version: v.2.1.10 
Chemicals    
P2O5  Sigma Aldrich  Israel  
CD  Sigma Aldrich  Israel  
Amino acid derivatives Sigma Aldrich  Israel  
Doxorubicin (Dox) Sigma Aldrich  Israel  
Dimethylformamide (DMF) Sigma Aldrich  Israel  
Dimethyl Sulphoxide (DMSO) Sigma Aldrich  Israel  
Trifluoroacetic Acid (TFA) Sigma Aldrich  Israel  
4,4-Dimethylaminopyridine (DMAP) Sigma Aldrich  Israel  
N,N-Dicyclohexylcarbodiimide 
(DCC) 
Fluka Israel  
1-Hydroxybenzotriazole (HOBT) Sigma Aldrich  Israel  
N-Boc-3-(2-naphthyl)-L-alanine Sigma Aldrich  Israel  
Dichloromethane (CH2Cl2) Sigma Aldrich  Israel  
Sulphuric Acid  Sigma Aldrich  Israel  
Ninhydrine  Sigma Aldrich  Israel  
Acetone Sigma Aldrich  Israel  
Methanol  Sigma Aldrich  Israel  
Phosphate Buffered Saline (PBS)  Sigma Aldrich  Israel  
Dimethyl Sulphoxided6 (DMSOd6) Sigma Aldrich  Israel  
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D2O Sigma Aldrich  Israel  
Acetonitrile (AcN)  Sigma Aldrich  Israel  
Consumables    
96-well plates  Greiner Austria Polystyrene cell culture 
microplates with μClear® 
bottom 
UV Cuvettes Yavin-Yeda Israel 4 ml volume 
TLC plates  Yavin-Yeda Israel Silica gel 60 
PLC plates Yavin-Yeda Israel Silica gel 60 F254 
 Methods 3.2.2
 Synthesis  3.2.2.1
Two isomers of the carrier were produced via the synthesis specified below, with 
dependence on the stereochemistry of the added amino acid derivative. The D isomer was 
named Ca-1688 and the L isomer Ca-1709. In this chapter the term ‘carrier’ refers solely to the 
D isomer.  
 
Figure 3.3- Synthesis of carriers Ca-1688 and Ca-1709 
Prior to the synthesis, CD was dried at 110°C /0.1 mmHg in the presence of P2O5 for 
24 h. Amino acid derivatives, DMF, DMSO, TFA, DMAP, DCC, and HOBT were used without 
further purification. The synthesis of the carrier in use was achieved via a two-step reaction as 
described in Figure 3.3. The first step was the coupling of CD with the N-Boc-3-(2-naphthyl)-
L/D-alanine, using DDC, DMAP and HOBT in DMF and the second step was the removal of the 
N-protecting Boc group from the compound using CF3COOH in CH2Cl2. To couple the CD with 
the amino acid derivative, 12.97 g (10 mmol) of CD, 1.22 g (10 mmol) DMAP, 1.35 g (10 mmol) 
HOBT, 3.15 g (10 mmol) N-Boc-3-(2-naphthyl)-L/D-alanine and 4.12 g (20 mmol) DCC, were 
dissolved in 50 ml DMF and stirred at 25°C for 24 h.  
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The white precipitate was removed by filtration and the filtrate solution was added 
dropwise with stirring into 500 ml of hot acetone. The white solid product was then filtered 
and dried under vacuum. The purification of the compound was done by reversed phase 
column chromatography. The crude product was dissolved in 500 ml of hot water (60 - 90°C) 
and the resulting solution was applied to a reversed-phase column (300 g of LiChroprep RP-18, 
40 - 63 m; 50 mm x 260 mm). The column was eluted with water (500 ml), methanol: water 
20:80 (1000 ml), 40:60 (1000 ml), 60:40 (1000 ml) and 100% methanol (500 ml) at flow rate of 
20 ml per min and detected by TLC. Fractions of 80 ml volume were collected. The desired 
yield was eluted with the mixture of methanol: water 30:70.  
The removal of the protective Boc group (step 2 in Figure 3.3) was done by dissolving 
the yield in 20 ml TFA and 20 ml CH2Cl2, and the mixture was stirred at 25°C for 3 h following 
which the solvent was removed by evaporation under reduced pressure (<25°C).  
The residue was dissolved in 5 ml H2O and poured into 200 ml methanol. The reason 
for using methanol is that, while the carrier does not dissolve in it, some impurities do, and 
more importantly, it can remove any traces of TFA. The white precipitate was washed three 
times with 100 ml acetone and then dried under vacuum at 70°C overnight. The solid product 
was dissolved in 20 ml of DDH2O, until complete dissolution. The solution was freeze-dried for 
3 days, finally affording small white crystals.     
 Dox Encapsulation within the Carrier  3.2.2.2
The complexation between the carrier and the guest molecule, Dox, is a spontaneous 
process which occurs in aqueous solutions without any external aid. Hence, the encapsulation 
of Dox was performed in aqueous solutions by addition of the carrier into the final Dox 
solution. Normally, the Dox was kept at high concentrations of 100 mM, dissolved in DMSO as 
a stock solution in the dark at 4°C1. For complexation purposes the Dox was diluted at least by 
a factor of 1000 (maximal final concentration of DMSO in the final Dox solutions was 0.1%) in 
an aqueous medium (H2O/ Culture Medium) in the dark at RT.  
The main reason for the utilization of DMSO as the stock solution medium is it being a 
well-known method for dissolving Dox (Panta e al., 2004; Lu, F. et al., 2009). In addition, in the 
presence of CDs it can possibly aid in the prevention of the Dox cleavage and generation of 
ROS (Swiech et al., 2012), and, although not very likely in the concentration used, it can 
potentially promote the process of drug penetration within the cells (Tucker, E.J. and Carrizo 
A., 1968).   
                                                           
1
 full description can be found in 5.2.2.6. 
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 Chemical and Structural Analyses of the Carrier and the Created 3.2.2.3
Complex 
TLC The synthesis was monitored by TLC. The TLC analyses were performed on silica 
gel 60 TLC plates and silica gel 60 F254 PLC plates (Caliceti et al., 2003) with 1-butanol: ethanol: 
NH4OHconc.(32% w/v aq.) [4:5:6 (v/v/v)] eluents. Spot detection was carried out by UV light and 
by spraying with 5% v/v concentrated sulphuric acid in ethanol, for detection of all the 
materials, or ninhydrine solution (0.3 g ninhydrine, 97 ml 1-butanol and 3 ml acetic acid), for 
detection of the free amino groups, and heating at 150°C for 5 min. 
HPLC HPLC analysis was performed on a Thermo Electron instrument equipped with UV/Vis & 
ELSD (Sedex 75) detectors. The column in use was a Gemini 5m octadecyl carbon chain 
bonded silica (C18)  (110 Å, 250-4.6 mm) mobile phase: Acetonitrile (AcN) / H2O, with a 
gradient elution from 98% H2O / 2% AcN to 10% H2O / 90% AcN within 30 min at a constant 
flow rate of 1.2 ml / min (Table 3.2).  
Table 3.2- HPLC elution solvents 
Time (min) H2O (%) AcN (%) 
0 98 2 
10 50 50 
15 10 90 
20 98 2 
25 98 2 
 
The UV signal was measured at = 254 nm.   
Fluorescence Spectrometry For fluorescence spectrometry studies, a solution of 
4 M Dox was prepared by dilution2 of the Dox in DMSO stock solution into PBS, with the final 
concentration of DMSO being 0.04%. To 8 ml of the final 4 M Dox solution, 3.8 mg1 of carrier 
was added to obtain the concentration of 320 M (1:80 Dox: carrier ratio). Double dilutions of 
the carrier in constant 4 M Dox were performed to obtain the following Dox: carrier ratios: 
1:40; 1:20; 1:10; 1:5; 1:2.5; 1:1.25. Each solution was transferred into a 4 ml cuvette and the 
fluorescence was measured at excitation = 480 nm, emission = 500 - 800 nm (max chosen to be 
592 nm), with excitation and emission slits of 10 nm. 
NMR 1H-NMR and 13C-NMR spectra of Dox, carrier and the complex at various 
concentrations were recorded on a 500 and 400 MHz Advance III spectrometer with 
                                                           
2
 Full equations can be found in 5.2.2.6.  
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deuterated DMSO (DMSOd6) or deuterated water (D2O) as a solvent. All the chemical shifts are 
expressed as units (ppm). 
DOSY DOSY measurements were conducted to establish the change in D of the Dox 
and the carrier as a result of the complexation. For this purpose, each of the free substances 
and their complex were dissolved in D2O and transferred to dedicated tubes. A series of 
longitudinal eddy-current delay (LED) sequences (Cohen et al., 2005; Evan-Salem et al., 2007) 
were applied, and the signal decays of the tested substances at 500 and 400 MHz were 
recorded. 
 Results 3.3
 Synthesis  3.3.1
Following the purification process as described in Section 3.2.2.1, the obtained yield 
was 7.61 g (51%). The 49% unwanted yield consisted of about 40% starting materials and 
about 9% di-substituted and tri-substituted products.  
 Chemical and Structural Analyses of the Carrier and the 3.3.2
Complexation with Dox  
 Thin-Layer and High-Performance Liquid Chromatography  3.3.2.1
To analyse the conjugated product of the carrier synthesis, TLC and HPLC were 
conducted. The TLC Rf value of the carrier was 0.5 relative to the solution described in Section 
3.2.2, whereas the Rf of unsubstituted CD was 0.3 and the di- and tri-substituted CDs were 
0.65 and 0.75, respectively. Figure 3.4 depicts the HPLC graph as detected by a UV detector, 
corresponding to the carrier in the stationary and mobile phases as described in Section 
3.2.2.3. 
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Figure 3.4- HPLC measurement of the carrier 
 Fluorescence Spectroscopy 3.3.2.2
The fluorescence spectrum of Dox at constant concentration with increasing 
concentrations of carrier was recorded and Kbinding was calculated from the changes in the peak 
at 592 nm. 
 
 
Figure 3.5- (a) Fluorescence spectrum of Dox with increasing carrier concentrations and (b) 
Dox fluorescence at 592 nm as a function of carrier concentration 
The left side of Figure 3.5 represents the recorded fluorescence spectrum of Dox at 
increasing concentrations of carrier (0 - 320 M), the right side of the figure depicts the 
fluorescence at the peak, 592 nm, of Dox with increasing carrier concentrations. 
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Figure 3.6- Benesi-Hildebrand plot of Dox fluorescence 
In Figure 3.6, the change in the fluorescence of Dox is presented in a Benesi-
Hildebrand plot, where the ratio of the intercept and the slope (equation presented top right) 
gives Kbinding for the complex. 
 Nuclear Magnetic Resonance  3.3.2.3
1H-NMR 1H-NMR measurements were conducted in different solvents for an 
unmodified CD, the synthesized carrier, Dox and the complex solution of carrier and Dox. The 
measured spectra and the chemical shift attribution are presented in Figure 3.7- 21 and Table 
3.3- 4.  
 
Figure 3.7- 1H-NMR spectrum of CD in D2O 
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Figure 3.8- 1H-NMR spectrum of CD in DMSO 
Figure 3.7 and Figure 3.8 present the measured 1H-NMR spectra of 20 mM CD 
performed at 400 and 500 MHz in DMSOd6 and D2O, respectively. 
 
Figure 3.9- 1H-NMR spectrum of the carrier in D2O 
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Figure 3.10- 1H-NMR spectrum of the carrier in DMSO 
Figure 3.9 and Figure 3.10 present the measured spectrum of 1H-NMR of 20 mM 
carrier performed at 400 and 500 MHz in DMSOd6 and D2O, respectively. 
 
Figure 3.11- 1H-NMR spectrum of CD (top) and carrier (bottom) in D2O 
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Figure 3.12- 1H-NMR spectra of the carrier  in D2O (top) and DMSO (bottom) 
For comparison, Figure 3.11 depicts both of the 1H-NMR spectra of 20 mM CD (top) 
and 20 mM carrier (bottom) performed at 400 MHz in D2O, while Figure 3.12 depicts the 
1H-
NMR spectra of 20 mM carrier in D2O (top) and DMSO (bottom).  
Table 3.3 summarizes all the observed chemical shifts of the CD and the carrier in 
different solvents and concentrations (hydrogen numbering as presented in Figure 3.3).  
Table 3.3- 1H-NMR chemical shifts of CD and the carrier 
Concentration 20mM 20mM 10mM 20mM 20mM 
Solvent D2O DMSO D2O D2O DMSO 
Hydrogen/  (ppm) CD  Carrier  
4H (dd) 3.02 3.32 3.26 3.20 3.47 
2H (dd) 3.61 3.52 3.53 3.52 3.47 
6H (d) 3.68 3.62 3.70 3.68 3.47 
5H (td) 3.88 4.52 3.84 3.79 3.47 
3H (dd) 3.95 4.88 4.01 3.97 3.47 
9H (d)     4.40 4.41 4.46 
8H (dd)     4.54 4.50 4.91 
1H (d) 5.13 5.76 5.13 5.10 5.78 
19H (m)     7.45 7.39 7.39 
15H (m)     7.67 7.57 7.51 
14H (m)     7.67 7.57 7.51 
11H (m)     7.73 7.65 7.73 
18H (m)     7.89 7.81 7.87 
16H (m)     7.91 7.83 7.87 
13H (m)     7.94 7.85 7.87 
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In addition to the 1H-NMR measurements of CD and the carrier, 1H-NMR evaluation of 
Dox at different concentrations and solvents was performed. The obtained spectra and 
chemical shifts are presented below. 
 
Figure 3.13- 1H-NMR spectrum of Dox in D2O 
 
Figure 3.14- 1H-NMR spectrum of Dox in DMSO 
Figure 3.13 and Figure 3.14 present the measured spectrum of 1H-NMR of 2 mM Dox 
performed at 400 MHz and 500 MHz in DMSOd6 and D2O, respectively. 
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Figure 3.15- Comparison between 1H-NMR spectra of 2 mM Dox  in D2O (top) and DMSO 
(bottom) 
As mentioned previously, Dox has a tendency to self-aggregate above certain 
concentrations. This phenomenon was observed by 1H-NMR measurements at different 
concentrations of Dox. Figure 3.16 compares 1H-NMR spectra of 2 and 10 mM Dox in D2O.  
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Figure 3.16- 1H-NMR spectra of Dox  in D2O at 2 mM (top) and 10 mM (bottom) 
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Table 3.4- 1H-NMR chemical shifts of Dox 
  Measurement Literature 
Hydrogen/ 
(ppm) 
      Agrawal et 
al. (2009) 
Barthwal 
et al. 
(1994) 
Mondelli and 
Ragg (1987) 
Concentration 10 mM 2 mM DCon
.*
2 mM  DCon. 8 
mM-0.01 
mM *
11.5 mM  5.8 
mM  
(1 mg/ 
ml) 
 17.4 
mM (30 
mg/ ml) 
Solvent D2O D2O, 
0.01% 
DMSO 
D2O DMSO D2O D2O D2O DMSO 
5' CH3 (d) 1.37 1.33 0.03 1.15 0.02 1.34 1.29 1.16 
2' Heq (ddd) 2.07 2.05 0.02 1.65 -0.01 2.04 1.98 1.90 
2' Hax (ddd) 2.07 2.05 0.02 1.88 -0.01 2.04 2.03 1.71 
8 Hax (dd) 2.30 2.14 0.17 1.88 -0.24 2.04 2.06 2.11 
8 Heq (dd) 2.30 2.14 0.17 2.15 -0.28 2.28 2.28 2.18 
10 Hax (d) 2.64 2.68 -0.04 2.97 -0.68 2.60 2.68 2.87 
10 Heq (d) 2.96 2.99 -0.04 2.97 -0.49 2.93 2.95 2.97 
3' H (td) 3.75 3.66 0.08 3.33 0.10 3.76 3.68 3.32 
4' H (dd) 3.89 3.84 0.05 3.52 0.04 3.88 3.83 3.61 
4 OCH3 (s) 3.89 3.94 -0.05 4.01 -0.30 3.88 3.90 3.97 
5' H (qd) 4.29 4.47 -0.18 4.16 -0.17 4.27 4.21 4.21 
7 H (dd) 4.87** 4.84 ** 0.02 4.97 0.01 4.80 4.79 4.90 
9 COCH2OH (s) 4.87** 4.84 ** 0.02 4.57 - 4.80 4.82 4.63 
1' H (t) 5.50 5.49 0.02 5.28 -0.12 5.48 5.43 5.28 
3 H (d) 7.37 7.43 -0.05 7.94 -0.28 7.34 7.37 7.60 
1 H (d) 7.37 7.50 -0.12 7.93 -0.52 7.34 7.45 7.84 
2 H (dd) 7.65 7.71 -0.06 7.68 -0.37 7.61 7.66 7.86 
* Downfield shift is +ve; upfield shift is –ve. ** under the HOD peak 
Table 3.4 summarizes all the observed chemical shifts of Dox in different solvents and 
concentrations alongside the values found in the literature. (The numbering is consistent with 
Figure 3.1.)  
The 1H-NMR measurements of the complex solution were performed at 1:10, i.e. 
2 mM Dox and 20 mM carrier, and 1:1 Dox:carrier, i.e. 10 mM Dox and 10 mM carrier, ratios in 
D2O and DMSOd6. The obtained spectra are presented in Figure 3.17 to Figure 3.20. 
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Figure 3.17-1H-NMR spectrum 1:10 Dox:carrier complex in D2O 
 
Figure 3.18- 1H-NMR spectra of Dox (top), carrier (middle) and 1:1 Dox:carrier complex 
(bottom) in D2O 
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Figure 3.19- 1H-NMR spectra of 1:10 Dox:carrier complex (in red) and 1:1 Dox:carrier complex 
(in blue) in D2O 
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Figure 3.20- 1H-NMR Spectra of Dox (top), carrier (middle) and 1:1 Dox:carrier complex 
(bottom) in DMSO 
13C-NMR To validate the structure of the designed carrier, 13C-NMR measurements 
were performed. 
 
Figure 3.21- 13C-NMR spectrum of the carrier 
Figure 3.21 presents the measured spectrum of 13C-NMR of 20 mM carrier performed 
at 500 MHz in D2O. The chemical shifts of attributed carbons (numbered corresponding to 
Figure 3.3) in the carrier as measured by 13C-NMR are summarized in Table 3.5.  
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Table 3.5- 13C-NMR chemical shifts of the carrier 
Carbon num. (ppm) 
C9 36.53 
C8 53.87 
C6 59.63-60.15 
C6* 65.84 
C5* 69.52 
C5 71.56-71.82 
C2 72.01-72.38 
C3 72.64-73.06 
C4 79.83-80.9 
C1 100.97-102.17 
C15 126.59 
C14 126.73 
C18 126.81 
C13 127.31 
C16 127.53 
C19 127.94 
C11 128.35 
C17 131.69 
C12 132.23 
C10 132.92 
C7 169.68 
* Carbon of the substituted ring 
sel-NOEY, NOESY and COSY To evaluate the 3D conformation of the created 
complex sel-NOEY, NOESY and COSY measurements were conducted. Figure 3.22- 3.26 depict 
the acheived spectra. 
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Figure 3.22- 1H-NMR sel-NOE of 1:10 Dox:carrier in D2O 
Figure 3.22 depicts the 1H-NMR spectra of 2 mM Dox (top), 1:10 (2 mM Dox, 20 mM 
carrier) Dox:carrier complex (middle) and the sel-NOE spectrum of the complex, following 
irradiation of the peak at 5.8 ppm (marked by black arrow).  
 
Figure 3.23- 1H-NMR (a) COSY and (b) NOESY spectra of 1:1 Dox:carrier complex in D2O 
 
COSY NOESY 
  a 
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Figure 3.24- Subtraction of the COSY and NOESY spectra presented in Figure 3.23 
Figure 3.23 depicts the 1H-NMR spectra of COSY and NOESY measurements of 1:1, 10 
mM Dox, 10 mM carrier, Dox:carrier complex, and Figure 3.24 depicts their subtraction. The 
expansion of the spectra at 5-6 and 6.8-8 ppm are presented in Figure 3.25 and Figure 3.26. 
 
Figure 3.25- 5-6 ppm 1H-NMR (a) COSY and (b) NOESY spectra and (c) their subtraction of 1:1 
Dox:carrier complex in D2O 
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Figure 3.26- 6.8-8ppm 1H-NMR (a) COSY and (b) NOESY spectra and (c) their subtraction of 
1:1 Dox:carrier complex in D2O 
 Diffusion Coefficient Measurements 3.3.2.4
D measurements of Dox, carrier and the complex Dox - carrier were conducted at 
different concentrations in aqueous solutions.  
 
Figure 3.27- Signal decay in diffusion measurements of Dox, carrier and the complex 
Figure 3.27 presents the decay in signal corresponding to the rate of diffusion for the 
Dox, carrier and Dox - carrier complex, and Table 3.6 summarizes the recorded D values of 
Dox, carrier and the Dox-carrier complex, on both the 400 and 500 MHz spectrometers, in 
comparison to the values found in the literature. 
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Table 3.6- Diffusion coefficients 
 Measurement Literature 
 D [m
2
/s] 
*10
-10
 
1:1 Complexation 
Ratio 
1:10 Complexation Ratio A
graw
al et al. 
V
iel et al. 
P
essin
e et al. 
 Dox 
[10mM] 
Carrier 
[10mM] 
Dox 
[2mM] 
Carrier 
[20mM] 
Dox 
[2mM] 
Carrier 
[20mM] 
Dox
+
 Carr-
ier* 
CD CD 
Solvent D2O D2O D2O, 
0.01% 
DMSO 
D2O D2O, 
0.01% 
DMSO 
D2O 
Operating 
Frequency 
400MHz 500MHz     
CD - - - - - - - - 2.445* 3.15 
±0.012 
Dox  1.58 
±0.01 
- 1.84 
±0.04 
- 1.81 
±0.03 
- 1.63 
±0.21 
- - - 
carrier - 2 ±0.02 - 1.9 
±0.02 
- 1.95 
±0.03 
- 2.28* - - 
Dox+ 
carrier 
1.85 
±0.01 
1.88 
±0.01 
1.86 
±0.06 
1.92 
±0.01 
- - - - - - 
* According to D= 8.2*10
-9
*Mw
-0.49
 [m
2
s
-1
] (Viel et al., 2003) ** in "aggregation concentration" (Agrawal et al., 2009) 
 Discussion 3.4
To validate the chemical structure of the synthesized carrier, 1H and 13C NMR and HPLC 
measurements were performed. The 1H-NMR and in particular 13C-NMR spectra suggest that 
the chemical structure of the carrier is consistent with the desired yield being the mono-
substituted CD with an amino-acid-naphthalene moiety on a primary hydroxyl group. 
According to the HPLC measurement presented in Figure 3.4, the retention time of the mono-
substituted carrier (83% of the product) is 12.07 min. The unwanted di-substituted and tri-
substituted (14.1% in total) retention times are 17.15 min to 18.9 min, depending on the 
relative position of the substituents to each other. As this is a non-specific reaction, it was 
stopped on purpose after 50% of the reagents had reacted and carefully purified. This was 
done to avoid the creation of unwanted di- and tri-substitution on the CD.  
Alongside the chemical investigation of the carrier, i.e. the ‘host’, the guest molecule, 
Dox, was studied by 1H-NMR for its chemical behaviour under various conditions, Figure 3.13 
to Figure 3.16. Table 3.4 presents the chemical shifts of Dox at different concentrations in 
water and DMSO in comparison with the literature. All the obtained figures for the current 
measurements presented in Table 3.4 are in good agreement with the values found in the 
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literature (Mondelli and Ragg, 1987; Barthwal et al., 1994). In the 1H-NMR data as well as D, as 
will be further discussed below, Dox is shown to self-aggregate, to some extent, at both the 
tested concentrations, i.e. 2 mM and 10 mM. Nonetheless, it can be noticed that there are 
changes in the chemical shifts of the Dox protons with higher concentration, i.e. 10 mM, which 
are consistent with the ones presented by Agrawal et al. (2009) when examining the self-
aggregation of Dox as a function of varying concentrations from 0.01 mM to 8 mM.  
To investigate the behaviour of Dox as a guest molecule in the host-guest complex 
with the carrier, various fluorescence and NMR measurements were conducted. It has been 
shown in the literature that addition of natural CD to Dox at a ratio of up to 5000:1 can 
significantly stabilize Dox in aqueous solution via complex formation  (Emara et al., 2000). The 
complex created in our study between the CD-based carrier and Dox was monitored through 
fluorescence measurements based on the Dox fluorescence signal at 592 nm. This signal 
decays with the addition of the carrier, suggesting that, due to encapsulation, good coupling 
between the Dox and the CD-naphthalene derivative is formed, allowing energy transfer 
between them. Therefore, the Dox excited state decays non-radiatively leading to lower 
fluorescence signals. According to the fluorescence studies presented in section 3.3.2.2, the 
main Dox fluorescence peak at 592 nm is decreased by a factor of eight as a result of the 
carrier addition at the maximal concentration of 320 M. Significant encapsulation of Dox 
within the carrier was observed already at ratios as low as 1:1. Satisfying encapsulation was 
observed at 20:1 carrier:Dox ratio which therefore was applied in vitro (Chapter 5).   
The described decrease in the intensity of Dox fluorescence peaks is in good 
correspondence with the literature, where it has been shown that encapsulation within a CD 
can significantly lower the fluorescence and absorbance signals of the guest molecule 
(Mukhopadhyay et al., 2005; Swiech et al, 2012). In addition, it has been shown that for these 
changes, the Benesi-Hildebrand method (Benesi and Hildebrand, 1949) for calculation of the 
binding constant, Kbinding,, can be applied (Dang et al., 1997, Mukhopadhyay et al., 2005; Swiech 
et al, 2012). According to these calculations, Kbinding as indicated by the fluorescence 
measurements is 61944 ±5592.2 M-1. This value is a factor of 310 higher than the fluorescence 
established Kbinding reported by Anand et al. (2009) for the parental CD with Dox in 1:1 
complex formation. The higher value of Kbinding can be attributed to the modification of the CD 
with the naphthalene group, that potentially exhibits -* interactions with the Dox’s 
aromatic rings.  
 As part of the complex structure investigation, various 1H-NMR measurements were 
conducted in different solvents. It is known that generally Dox should not exhibit 
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encapsulation within CDs in pure DMSO (Swiech et al, 2012). Therefore, for comparison, the 
complex solution 1H-NMR spectra were recorded in both aqueous and DMSO solvents. 
Although an unavoidable amount of water was present in the DMSO solution during the 1H-
NMR measurements of the complex (HOD peak at 4.88 ppm in Figure 3.20), a significant 
difference was observed between the two solvents. In the 1H-NMR spectrum of the complex 
dissolved in DMSOd6, Figure 3.20, the superposition, although not total, of the guest and the 
host can be seen. The same measurement performed in an aqueous solution resulted in 
significant changes in the majority of the protons in both the Dox and the carrier, Figure 3.18. 
The variance in the movement of the peaks indicates that a different type of interaction occurs 
between the Dox and the carrier in the different solvents, which is consistent with assumption 
that water must be present for encapsulation to occur (Swiech et al, 2012).  
Moreover, as can be seen in Figure 3.18, in D2O the complex spectrum is not a 
superposition of the Dox and the carrier spectra, indicating that there is indeed an interaction 
between the two molecules. Closer evaluation of the significant amount and manner of Dox 
and carrier’s chemical shifts in aqueous solution suggests encapsulation of Dox within the CDs 
cavity. 
Indications for the encapsulation might be found in the upfield chemical shifts of the 
protons in the 3rd and 5th positions in the CD ring, 3H and 5H - Figure 3.3, which are facing the 
inner space of the cone and are affected by the removal of D2O and Dox entrance (Singh et al., 
2010). Additional information obtained from the 1H-NMR spectrum of the complex can 
indicate the orientation of the Dox within the carrier. As can be seen in Figure 3.18, the OCH3 
moiety on the 4th position of the amino sugar ring of the Dox, 4OCH3- Figure 3.1, is not 
influenced by the presence of the carrier, suggesting it is located outside the CD cavity.  
An additional important factor in the complex formation is the concentrations of the 
reagents and their molar ratio in solution. As can be observed in the 1:1 and 1:10 1H-NMR 
spectra, Figure 3.19, the latter has broader, more widely distributed peaks. This variation 
between the spectra suggests that, in the 1:1 solution, the created complex has a more rigid 
structure than with excess of the carrier. In the latter case, several carrier molecules can 
encapsulate a certain Dox encouraging the Dox to exhibit a faster dynamic equilibrium 
between the free and encapsulated forms. Additionally, the comparison of the two spectra can 
aid in the attribution of the peaks to the appropriate molecules. The appearance of a certain 
peak only in the 1:1 complex spectrum provides a strong indication that the peak belongs to 
Dox rather than the carrier. A good example is the peak at 6.9 ppm which appears only in the 
1:1 spectrum and corresponds to Dox 3H in Figure 3.1.  
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Additional information on the 3D structure of the complex was achieved by sel-NOEY, 
NOESY and COSY measurements. In the sel-NOEY measurements, a single chosen peak was 
irradiated and the 1H-NMR spectrum of the 1:10 Dox:carrier complex was recorded, where 
only the protons in the appropriate spatial distance produced a signal. From Figure 3.22, it can 
be seen that the irradiated peak at 5.76 nm, that presumably corresponds to Dox 1’H (Figure 
3.1), has a spatial interaction with a peak at 5.19 nm. According to thorough examination of 
the whole 3D spectra of Dox and the carrier, the peak at 5.19 nm can be attributed to Dox 7H, 
Figure 3.1, meaning that this interaction is not an indication of complexation with the carrier, 
but rather an intramolecular interaction of the Dox.  
The same interaction of Dox 1’H and 7H, was also observed at 1:1 ratio in the NOESY 
and COSY measurements, presented in Figure 3.25. Subtraction of the COSY and NOESY full 
spectra provided the information on the non-covalently bonded protons present in proximity 
to each other in the 3D structure of the molecule. In the subtraction image, i.e. Figure 3.24, it 
can be noticed that a number of peaks that appear in the NOESY spectrum are absent in the 
COSY spectra, marked by purely pink colour without blue/green. The presence of these peaks 
does not necessarily indicate the complexation reaction, since these peaks could represent the 
3D structure of the Dox / carrier on their own, Figure 3.25, but their amplitude and nature 
strengthen the assumption that some interactions do occur. According to the close up on the 
subtraction of the COSY spectrum from the NOESY one at 6 - 8 ppm, Figure 3.26, it can be seen 
that there is a clear spatial correlation between the peak at 6.9 ppm and the peak at 7.6 ppm. 
As the peak at 6.9 ppm most likely belongs to Dox 3H, Figure 3.1, which is located on the first 
phenyl ring next to the methyl group, marked by green arrow in Figure 3.26, and the peak at 
7.6 ppm can be attributed to the carrier’s naphthalene protons, this is a strong indication of -
* interaction between the Dox aromatic rings and the naphthalene conjugate on the carrier.  
According to the overall 1H-NMR data, it can be suggested that the encapsulation of 
Dox occurs in the following manner:  
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Figure 3.28- Carrier and Dox prior to encapsulation (a) ball shaped and (b) space filling style 
 
Figure 3.29- Carrier and Dox in a suggested encapsulated form (a) ball shaped primary face 
view, (b) space filling style primary face view, (c) ball shaped primary side view, (d) space 
filling style side view, (e) ball shaped secondary face view and (f) space filling style secondary 
face view 
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A suggested mechanism of encapsulation is, as can be seen from the above figures, 
where the Dox enters the CD from the secondary face with the aromatic rings forward, rings 
D, C and B (Figure 3.1) and forms -* interactions with the naphthalene group. The D 
measurements of the free Dox point out the occurrence of the self-aggregation of Dox. 
According to Mw of Dox, 580 g/mol, and the carrier, 1494 g/mol, D of Dox should be a factor 
between 1.37 and 1.6 different to that of the carrier (see equations in Appendix i). Hence if the 
D measured for the free carrier is about 2, the corresponding value for free Dox should be 
around 3, and D of the 1:1 complex for both the carrier and the Dox should be around 1.78 
each. In this case, the observed D value of the complex being 1.85 theoretically indicates 94% 
encapsulation of the Dox within the carrier, according to Appendix i.  
Nevertheless, the measured value of D for free Dox was significantly lower than 
expected and closer to that of the carrier. This data suggests the appearance of Dox in dimer 
form at the measured concentration of 2 mM, which is consistent with the studies performed 
previously by Agrawal et al. (2009). Moreover, when a higher concentration, i.e. 10 mM, was 
measured an additional drop in the value of D was recorded, indicating dependence on the 
concentration of the solution. This is in good agreement with the suggestions of Barthelemy-
Clavey et-al. (1974) that further aggregation occurs beyond the dimer form at concentrations 
higher than 5mM.  
From Table 3.6 it can be noticed that D for both Dox and carrier in the complex 
solution are different from their measured values in the separate solutions. This may indicate 
that there is indeed a complexation between the Dox and the carrier: not only do the values 
differ from those of the free drug and carrier but they are also very similar to each other, 
1.85 ±0.01 and 1.88 ±0.01, in the combined solution which suggests they are conjugated in 
some way. The fact that D for Dox at the higher concentration of 10 mM is higher than that of 
2 mM in the presence of the carrier may also suggest that the carrier aids in dissociation of the 
di/n-mers present at that concentration. According to these results it seems that the carrier- 
Dox interaction is stronger than the Dox - Dox interaction and therefore, through equilibrium, 
the complex is formed even at ‘stacking concentrations’ of Dox.  
 Conclusions 3.5
In conclusion, the overall data presented in this chapter suggest that there is an 
interaction between the created carrier and the chosen drug, Dox, as well as providing an 
indication of complex formation. Moreover, the presented data, such as the DOSY 
measurements, suggest that the designed carrier can potentially lower the self-aggregation of 
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Dox. In addition, the utilization of the carrier in combination with DMSO at physical 
concentrations can potentially aid in prevention of the Dox cleavage and the generation of 
dangerous ROS, and thus lower the harmful side-effects of Dox. The inclusive studies of the 
drug and the carrier structures on their own, as well as in a complex, provided strong insights 
into the mechanisms of interaction between them. The in-vitro investigation of the drug and 
carrier, on their own and in a complex, are presented in Chapter 5.  
 References 3.6
Agrawal, P. et al. (2009) Studies on self-aggregation of anthracycline drugs by restrained 
molecular dynamics approach using nuclear magnetic resonance spectroscopy supported by 
absorption, fluorescence, diffusion ordered spectroscopy and mass spectrometry. Eur J Med 
Chem, 44, pp.1437- 51. 
Anand, R. et al. (2012) A close-up on doxorubicin binding to c-cyclodextrin: an elucidating 
spectroscopic, photophysical and conformational study. RSC Advances, 2, pp. 2346- 57. 
Arnusch, C.J. et al. (2012) Ultrashort peptide bioconjugates are exclusively antifungal agents 
and synergize with cyclodextrin and amphotericin B. Antimicrob Agents Chemother, 56 (1), 
pp.1-9. 
Auzely-Velty, R. (2011) Self-assembling polysaccharide systems based on cyclodextrin 
complexation: Synthesis, properties and potential applications in the biomaterials field. C R 
Chimie, 14, pp.167- 7. 
Badi, N. et al. (2006) Synthesis of per-2,3-di-O-heptyl-b and c-cyclodextrins: a new kind of 
amphiphilic molecules bearing hydrophobic parts. Tetrahedron Letters, 47, pp.8925- 27. 
Balcı, M. (2005) Basic 1h- and 13c-NMR spectroscopy. The Nederlands: Elsevier B.V. 
Balta, D.K. et al. (2008) Chemical incorporation of thioxanthone into -cyclodextrin and its use 
in aqueous photopolymerization of methyl methacrylate. J Photoch Photobio A, 196, pp.33- 7. 
Banerjee, S.S. and Chen, D-H. (2009) Cyclodextrin-conjugated nanocarrier for magnetically 
guided delivery of hydrophobic drugs. J Nanopart Res, 11, pp.2071- 78. 
Barthelemy-Clavey, V. et al. (1974) Self-association of daunorubicin. FEBS Letters, 46 (1), pp.5-
10. 
Barthwal, R. et al. (1994) A 500 MHz proton NMR study of the conformation of adriamycin. J 
Mol Struct, 327, pp.201- 20. 
Barthwal, R. et al. (2008) Structural elucidation of 40-epiadriamycin by nuclear magnetic 
resonance spectroscopy and comparison with adriamycin and daunomycin using quantum 
112 
 
 
mechanical and restrained molecular dynamics approach. Arch Biochem Biophys, 474, pp.48- 
64. 
Battistini, E. et al. (2008) High-Relaxivity Magnetic resonance imaging (MRI) contrast agent 
based on supramolecular assembly between a gadolinium chelate, a modified dextran, and 
poly-b-cyclodextrin. Chem Eur J, 14, pp.4551- 61. 
Benesi, H.A. and Hildebrand, J.H. (1949) A spectrophotometric investigation of the interaction 
of iodine with aromatic ydrocarbons. J Am Chem Soc, 71, pp. 2703- 7. 
Boer, T. et al. (2000) Recent innovations in the use of charged cyclodextrins in capillary 
electrophoresis for chiral separation in pharmaceutical analysis. Electrophoresis, 21, pp.3220-
39. 
Cabral Marques, H.M. (2010) A review on cyclodextrin encapsulation of essential oils and 
volatiles. Flavour Fragr J, 25, pp.313- 26. 
Calderini, A. et al. (2012) Host–guest interactions between dapsone and b-cyclodextrin (part 
I): study of the inclusion compound by nuclear magnetic resonance techniques. J Incl Phenom 
Macrocycl Chem, pp.1-10. 
Caliceti, P. et al. (2003) Synthesis and physicochemical characterization of folate-cyclodextrin 
bioconjugate for active drug delivery. Bioconjugate Chem, 14, pp. 899-908.  
Challa, R. et al. (2005) Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech, 
6(2) Article 43, pp.E329-57. 
Cohen, Y. et al. (2005) Diffusion NMR spectroscopy in supramolecular and combinatorial 
chemistry: an old parameter- new insights. Angew Chem Int Ed, 44, pp.520- 54. 
Cserhfiti, T.  and Hollo, J. (1994) Interaction of taxol and other anticancer drugs with 
hydroxypropyl--cyclodextrin. Int J Pharm, 108, pp.69-75. 
Dang, X-J et al. (1997) Inclusion of 10-methylphenothiazine and its electrochemically 
generated cation radical by -cyclodextrin in water + methanol solvent mixtures. J Electroanaly 
Chem, 437, pp.53- 9. 
Deng, W. et al. (2007) A chemical-responsive supramolecular hydrogel from modified 
cyclodextrins. Angew Chem Int Ed, 46, pp.5144- 7. 
Dong, M.W. (2005) Handbook of pharmaceutical analysis by HPLC. USA: Elsevier. 
Dong, M.W. (2006) Modern HPLC for practicing scientists. USA: John-Wiley&Sons, Inc. 
Emara, S. et al. (2000) Effect of cyclodextrins on the stability of adriamycin, adriamycinol, 
adriamycinone and daunomycin. Talanta, 51, pp.359- 64 
113 
 
 
Evan-Salem, T. et al. (2007) Self-assembled ionophores from isoguanosine: diffusion NMR 
spectroscopy clarifies cationios and anionios influence on supramolecular structure. Chem Eur 
J, 13, pp.1969- 77. 
Evstigneev, M.P. et al. (2006) Complexation of norfloxacin with DNA in the presence of 
caffeine. Biophys Chem, 121, pp.84-95. 
Fernandes, C.M. et al. (2003) Multimodal molecular encapsulation of nicardipine 
hydrochloride by b-cyclodextrin, hydroxypropyl-b-cyclodextrin and triacetyl-b-cyclodextrin in 
solution. structural studies by H NMR and ROESY experiments. Eur J Pharm Sci, 18, pp.285- 96.  
Frankewich, R.P. et al. (1991) Evaluation of the relative effectiveness of different water-
soluble b-cyclodextrin media to function as fluorescence enhancement agents. Anal Chem, 63, 
pp.2924-33. 
Frederick, C.A. et al. (1990) Structural comparison of anticancer drug-DNA complexes: 
adriamycin and daunomycin. Biochemistry, 29, pp.2538- 49. 
Green, P.S. and Leeuwenburgh, C. (2002) Mitochondrial dysfunction is an early indicator of 
doxorubicin-induced apoptosis. Biochimica et Biophysica Acta, 1588, pp.94-101. 
Haeberlin, B. et al (1996) Cyclodextrins useful excipients for oral peptide administration? Int J 
Pharm, 137, pp.103-10. 
Hagiwara, Y. et al. (2006) Preparation and pharmaceutical evaluation of liposomes entrapping 
salicylic acid/g -cyclodextrin conjugate. Chem Pharm Bull, 54(1), pp.26-32. 
Hajarizadeh, H. et al. (1994) Protective effect dimethyl sulfoxide of doxorubicin in vitamin C or 
against skin ulceration in the pig. Ann Surg Oncol, 1(5), pp.411-4.  
Himeno, Y. et al. (2009) -Cyclodextrins possessing an azido group and a 
triisopropylbenzenesulfonyl group as useful synthetic and authentic intermediates for 
unsymmetrically functionalized derivatives. Tetrahedron, 65, pp.9474-80. 
Holzgrabe, U. et al. (1999) NMR spectroscopy in drug development and analysis. Germany: 
WILEY-VCH Verlag.  
Irie, V. and  Uekama, K. (1999) Cyclodextrins in peptide and protein delivery. Adv Drug Deliver 
Rev, 36, pp.101-23. 
Jacobsen, N.E. (2007) NMR spectroscopy explained: simplified theory, applications and 
examples for organic chemistry and structural biology. USA: John Wiley & Sons, Inc. 
Jiskoot, W. and Crommelin, D. (2005) Methods for structural analysis of protein 
pharmaceuticals. USA: American Association of Pharmaceutical Scientists. 
Kazakevich, Y.V. and LoBrutto, R. (2007) HPLC for pharmaceutical scientists. USA: John Wiley 
& Sons, Inc. 
114 
 
 
Khan, A.R. et al. (1998) Methods for selective modifications of cyclodextrins. Chem Rev, 98, 
pp.1977-96. 
Krupadanam, G.L.D et al. (2001) Analytical chemistry. India: University Press. 
Li, H. et al. (2010) Microcalorimetric and spectrographic studies on host–guest interactions of 
-, -, - and M-cyclodextrin with resveratrol. Thermochimica Acta, 510, pp.168–172. 
Li, S. and Purdy, W.C. (1992) Cyclodextrins and their applications in analytical chemistry. Chem 
Rev, 92, pp.1457- 70. 
Liu, Y. et al. (2002) Selective binding of steroids by 2,2’-biquinoline-4,4’-dicarboxamide-
bridged bis(b-cyclodextrin): fluorescence enhancement by guest inclusion. J Org Chem, 68, 
pp.3687- 90. 
Loening, N.M. et al. (2001) One-dimensional DOSY. J Magn Reson, 153 (1), pp.103-112. 
Loftsson, T. and Duchene, D. (2007) Cyclodextrins and their pharmaceutical applications. Int J 
Pharm, 329, p.1-11. 
Lopez, A.M. et al. (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-
induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol, 44, pp.303-306. 
Lu, F. et al. (2009) Aqueous compatible fullerene-doxorubicin conjugates. J Phys Chem C 
Nanomater Interfaces, 113(41), pp.17768- 85. 
Lu, Z. et al. (2009) Study of the complexation of resveratrol with cyclodextrins by spectroscopy 
and molecular modeling. Incl Phenom Macrocycl Chem., 63, pp.295-300. 
Maestrelli, F. et al. (2005) Preparation and characterisation of liposomes encapsulating 
ketoprofen–cyclodextrin complexes for transdermal drug delivery. Intl J Pharm, 298, pp.55- 67. 
Maestrelli, F. et al. (2006) Effect of preparation technique on the properties of liposomes 
encapsulating ketoprofen–cyclodextrin complexes aimed for transdermal delivery. Int J Pharm, 
312, pp.53-60. 
McMaster, M. (2007) HPLC: a practical user's guide. USA: John Wiley & Sons, Inc. 
Mondelli, R. and Ragg, E. (1987) Nuclear magnetic resonance conformational study of 
daunomycin and related antiturnour antibiotics in solution. The conformation of ring A. J Chem 
Soc Perkin Trans, II, pp.15-26. 
Muderawan, I.W. et al. (2005) A reliable synthesis of 2- and 6-amino-- cyclodextrin and 
permethylated- -cyclodextrin. Tetrahedron Letters, 46, pp.7905- 7. 
Mukhopadhyay, M. et al. (2005) Excited state intermolecular proton transfer and caging of 
salicylidine-3,4,7-methyl amine in cyclodextrins. J Photoch Photobio A, 175, pp.94-9. 
Nakanishi, T. et al. (2001) Development of the polymer micelle carrier system for doxorubicin. 
J Control Release, 74, pp.295-302. 
115 
 
 
Panta, G.R. et al. (2004) ATM and the catalytic subunit of DNA-dependent protein kinase 
activate NF-kB through a common MEK/extracellular signal-regulated kinase/p90rsk signaling 
pathway in response to distinct forms of DNA damage. Mol Cell Biol, 24(5), pp.1823-35. 
Park, J.W. and Song, H.J. (1989) Association of anionic surfactants with 6-cyclodextrin. 
fluorescence-probed studies on the 1:1 and 1:2 complexation. J Phys Chem, 93, p.6454-58. 
Pessine, F.B.T. et al. (2012) Review: cyclodextrin inclusion complexes probed by NMR 
techniques. Magn Res Spec, pp.237-64. 
Pham, D-T. et al. (2010) synthesis of C6A-to-C6 A and C3 A-to-C3 A diamide linked -
cyclodextrin dimers. Tetrahedron, 66, pp.2895- 8. 
Piosik, J. et al. (2002) The modulation of xanthines of the DNA-damaging effect of polycyclic 
aromatic agents Part II. The stacking complexes of caffeine with doxorubicin and 
mitoxantrone. Biochemi Pharmacol, 63, pp.635- 46. 
Schaschke, N. et al. (2000) b-Cyclodextrin/epoxysuccinyl peptide conjugates: a new drug 
targeting system for tumor cells. Bioorg Med Chem Lett, 10, pp.677- 80. 
Šimùnek, T. et al. (2009) Anthracycline-induced cardiotoxicity: overview of studies examining 
the roles of oxidative stress and free cellular iron. Pharmacol Rep, 61, p.154- 71. 
Singh, R. et al. (2010) Characterization of cyclodextrin inclusion complexes – a review. J Pharm 
Sci Tech, 2 (3), pp.171- 83. 
Snyder, L.R. et al. (2010) Introduction to modern liquid chromatography. USA: John Wiley & 
Sons, Inc. 
Swiech, O. et al. (2012) Intermolecular interactions between doxorubicin and β-cyclodextrin 4-
methoxyphenol conjugates. J Phys Chem B, 116, pp.1765- 71. 
Szejtli, J. (2004) Past, present, and future of cyclodextrin research. Pure Appl Chem, 76(10), 
pp.1825- 45.  
Tang, W. et al. (2007) Facile synthesis of positively charged monosubtituted - and-
cyclodextrins for chiral resolution of anionic racemates. Tetrahedron:  Asymmetry, 18, 
pp.1548- 53. 
Thomas, O. and Burgess, C. (2007) UV-Visible spectrophotometry of water and wastewater. 
The Netherlands: Elsevier. 
Trotta, F. et al. (2007) Recent advances in synthesis of cyclodextrin derivatives under 
microwaves and power ultrasound. J Incl Phenom Macrocycl Chem, 57, pp.3-7. 
Tucker, E.J. and Carrizo A. (1968) Haematoxylon dissolved in dimethylsulfoxide used in 
recurrent neoplasms. Int Surg, 49(6), pp.516-27.   
116 
 
 
Uekama, K. (2004) Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm 
Bull, 52 (8), p.900- 15. 
Ueno, A. (1996) Review: fluorescent cyclodextrins for molecule sensing. Supramol Sci, 3, pp.31- 
6. 
Valeur, B. and Berberan-Santos, M.N. (2012) Molecular fluorescence. Germany: Wiley-VCH. 
Van de Manakker, F. et al. (2009) Cyclodextrin-based polymeric materials: synthesis, 
properties, and pharmaceutical/biomedical applications. Biomacromolecules, 10(12) pp.3157-
75. 
Van der Walle, C.F. (2011) Peptide and protein delivery. China: Elsevier Inc. 
Viel, S. et al. (2003) Diffusion-ordered NMR spectroscopy: a versatile tool for the molecular 
weight determination of uncharged polysaccharides. Biomacromolecules, 4, pp.1843- 47. 
 a l tr m,  . et al. (2012) Specific binding of a β-Cyclodextrin dimer to the amyloid β peptide 
modulates the peptide aggregation process. Biochemistry, 51, pp. 4280- 9. 
Wang, Y. and Eaton, D.F. (1985) Optically non-linear organic molecules cyclodextrin inclusion 
complexes. Chem Phys Lett, 120 (43), pp.441- 4.   
Weston, A. and Brown, P.R. (1997) HPLC and CE: principles and practice. USA: W.B. Saunders 
Company. 
Zhang, H-X. and Xiong, Z-Y. (2012) Spectroscopic study of the interactions of buflomedil to 
serum albumin and b-Cyclodextrin. J Solution Chem,41, pp.1254- 64.  
117 
 
 
 ADAPTATION OF CLINICAL MRgFUS CHAPTER 4
SYSTEM FOR IN-VITRO APPLICATION OF FUS: 
DESIGN AND EVALUATION  
 Introduction  4.1
The main focus of this chapter is to describe the design and calibration of tailor made 
arrangements for application of USmTDD in vitro. The arrangements to be discussed aim to 
distinguish between different US-induced physical mechanisms acting on cells. The following 
mechanisms must be isolated in order to explore their contribution to cellular drug uptake: 
stable cavitation, transient cavitation and thermal effects, including hyperthermia. According 
to the literature, these are the major contributors for the enhanced drug uptake in USmTDD.  
Although USmTDD is a widely investigated research field, there is still a major concern 
regarding the repeatability and reproducibility of the results generated by the different 
research groups. The lack in standardization of the FUS application techniques as well as the 
existence of properly detailed biological protocols makes it difficult for researchers to compare 
their achieved data. For that purpose, three types of arrangements dealing with the heating 
and mechanical effects correlated to FUS application, were constructed and presented in this 
chapter. All the arrangements described in this work are based on clinical MRgFUS systems. 
This presents the possibility for researchers with accessibility to a clinical MRgFUS system to 
potentially exploit the presented arrangements for various USmTDD related studies. This could 
then create a needed standardization in the research of USmTDD that will ease the 
understanding and communication between researchers worldwide. Furthermore, research 
groups deprived of access to an MRgFUS system could still benefit from the currently 
presented arrangements, and especially the biological protocols described in 5.2.2, since that 
with proper adjustments this can still be applicable in various research environments, e.g. as 
shown in 5.1.1.3.     
The first part of this chapter provides a concise introduction to acoustic effects that 
may occur in the in-vitro application of FUS, such as standing waves, and a description of the 
MRgFUS system in use, as well as the methodologies to evaluate the experimental 
arrangements acoustically and thermally. The second part of the chapter focuses on the 
materials and methods utilised to create and evaluate the arrangements; it also explains the 
rationale behind the design and the evolution of the arrangements to their finalised form. The 
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third part presents the results of the acoustic and thermal evaluation of the various 
arrangements and provides the discussion in the achieved data.     
 Ultrasound  4.1.1
 Transverse Acoustic Waves Propagation 4.1.1.1
In the case studied in the present work, a cell culture growth environment in the form 
of a solid plastic 96-well plate was filled with various solutions in specific patterns (as 
described in 4.2.2) and exposed to different FUS parameters. Because of the plastic boundaries 
between the different wells a concern raised regarding transverse propagation of acoustic 
waves that may occur at the boundaries between liquid-solid or solid-solid media (Shutilov, 
1988), and might influence the cells in the neighbouring wells. 
Consequently, acoustic measurements were conducted to assess the acoustic power 
loss. According to the acoustic measurements there was only a minor loss of power caused by 
the presence of the plate. This may be attributed to various reasons including heating and 
reflection. Hence it is assumed that the appearance of transverse waves in the tested plate 
was negligible. 
 Standing Waves 4.1.1.2
As previously mentioned, standing waves can occur due to coherence of applied and 
reflected acoustic waves within certain structures and media (Repacholi and Benwell, 1982). 
Because the cell culture growth environment of relevance here is the bottom part of a 
perfectly shaped cylinder, a concern raised regarding the possibly of secondary focuses 
creation due to the well’s behaviour as an acoustic wave guide (Redwood, 1960). 
Due to the symmetry of the cylinder, application of certain acoustical parameters – 
which clearly were not utilised for in–vitro work - can create a secondary focus not far from 
the end of the wells in the plate by the reflected waves from the walls of the well. This is 
especially dangerous when working with an inverted plate where the acoustic beam is 
travelling through the well before reaching the cells. A schematic example of such a case is 
presented in Figure 4.1.  
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Figure 4.1- Schematic representation of a secondary focus in a well 
 An example of this was observed when an absorbing material was placed on top of a 
regularly placed plate (not inverted) to absorb the continuation of the acoustic wave after 
passage through the cells. For high intensities, the presence of the secondary focus in 
absorbing material creates bubbles on its surface. These bubbles reflect the US back into the 
well resulting in an additional ultrasonic beam impacting the cell monolayer and potentially 
creating standing waves. Even though high intensities were not used during the in-vitro study, 
to reduce the risk of standing waves in possible future studies the absorbing material was 
moved upwards, 10 cm over the sonicated plate. 
 Prediction and Evaluation of Acoustic Fields 4.1.1.3
Acoustic evaluation of the arrangement was performed to make an accurate 
assessment of the ultrasonic field behaviour in the different arrangements. 
Hydrophones, i.e. specialised receiving transducers, are commonly used in 
measurements of acoustic fields. The principles of hydrophone measurements are explained in 
Section 2.4.1 as an explanation of generation and behaviour of an acoustic field. A hydrophone 
acts like an underwater microphone to record US. Its operation is similar to that of US 
transmitting devices, except that it is a receiver producing a voltage equivalent to the acoustic 
signal. Hydrophones can be made from different materials; the main two are piezoelectric and 
fibre-optic (Chester, 1987). Several hydrophones can be aligned together to create a multi-
hydrophone (Zimmer, 2011).  
The sensitivity of hydrophones depends on the frequency applied, the geometry and 
material of the hydrophone and the direction of the acoustic wave (Sherman and Butler, 
2007). There are various shapes of hydrophones, utilized for many purposes. In this work, a 
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needle-shaped hydrophone (Precision Acoustics, UK) was used to perform accurate 
measurement inside wells of 7 mm diameter (Platte, 1985) and above the 96-well plate.  
 Monitoring of Cavitation 4.1.1.4
As described in Chapter 2, cavitation denotes the generation, oscillation and implosion 
of gas / vapour bubbles in liquid under an applied US field (Leighton, 1994). The minimal 
intensity of the US field that will create cavitation, also known as the cavitation threshold, 
depends mainly on the property of the liquid and especially its impurity.  In order to assess the 
creation of cavitation bubbles and their behaviour, three topics must be considered:  
1. The media the acoustic wave is propagating through. 
2. The applied acoustic field. 
3. A cavitation observation tool. 
While the first two topics are rather straightforward, knowing the characteristics of 
the liquid and the acoustic field applied, the third is referred to as a monitoring device that 
usually relays the effects of cavitation (Apfel, 1984). Stable cavitation created in a constant 
frequency acoustic field (f) has an acoustic signature at the harmonics (2f, 3f etc.), sub-
harmonics (f/2) and ultra-harmonics (3f/2) frequencies. Hence a common way to monitor 
stable cavitation occurrence is by measurement of the sub- or ultra-harmonics. Transient 
cavitation usually results in broadband noise, which can also be recorded by hydrophones 
(Sundaram, 2003). 
 Magnetic Resonance guided Focused Ultrasound Surgery  4.1.2
 MRI Thermometry 4.1.2.1
The principle of MRI thermometry was introduced by Bloembergen, Purcell and Pound 
in 1948 and is known as ‘the BPP relaxation theory’ (Bloembergen et al. 1948). The basics of 
this theory lie in the fundamental movements of atoms: rotating, vibrating, translating, and 
the rapid transfer between them (order of magnitude of time: 10-12 sec). This is also referred to 
as the correlation time (c) and depends on the states of matter of the molecules (c(solid) > 
c(liquid) > c(gas)) and the temperature (thermal increase results in c decrease) (McRobbie et al., 
2003).  
There are several methods to measure temperature via MRI; the majority rely on the 
intrinsic interactions of the spins, although the possibility of using thermosensitive contrast 
agents also exists (Zhang et al., 2005). The spin-based thermometry methods are based on the 
effects of temperature on spin distributions or the spin active nuclei interactions with each 
other or the lattice, and can be measured by the T1 and T2 relaxation times, the PD, the water 
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diffusion constant and the proton resonance frequency (PRF), by either spectroscopic imaging 
(Kuroda et al., 2000) or phase mapping. Since, in the present work, PRF phase mapping was 
implemented, a more detailed description of this method is given below. Further reading on 
other thermometry methods can be found in a review by Rieke and Pauly (2008).  
Water PRF Phase Mapping Thermometry Thermal measurement with the PRF 
method is done by subtraction of an unknown image phase (ϕT)  from a reference one, in ‘RF- 
spoiled’ GE sequences with T1 weighted images. The correlation between ϕT and the 
temperature is described as: 
              
Equation 4.1- Image phase and chemical shift correlation 
where  is the gyromagnetic ratio, as previously mentioned in Section 2.4.5, σT is the chemical 
shift, TE is the echo time and B0 is the strength of the magnetic field (Poorter et al., 1995). The 
chemical shift, σT, is dependent on both the inhomogeneities of B0, σ0, and the thermal 
contribution (σt) as presented in Equation 4.2: 
         
Equation 4.2- Chemical shift relation to temparture 
To eliminate σ0 from the equation, and hence to obtain the temperature change, a 
subtraction of ϕT at a known temperature (Treference) is applied (Ishihara et al., 1995). While TE 
has a linear relation with the difference between ϕT and ϕTreference, it is in inverse correlation 
with signal-to-noise ratio (SNR), so the optimal time for temperature measurement is T2*. 
Because of this, temperature mapping by PRF measurement is not only relatively fast, but also 
has the optimal SNR (Chung et al., 1996). Moreover, PRF is considered to be more precise MRI 
thermometry than the other existing methods such as T1 and D (Wlodarczyk et al., 1998), even 
in relatively small magnetic fields e.g. 0.2 T, as has been shown by Rempp et al. (2008). An 
additional benefit of the PRF method is that it is almost independent of the composition of 
tissue (Peters and Henkelman, 2000).  
Nonetheless, there are several disadvantages to this method, e.g. neglecting the B0 
dependence on temperature is not always possible, and artifacts may occur in the presence of 
lipids. The latter could be partially resolved by suppression of the lipid layer in the appropriate 
sequences, but it is still necessary to take it into account (Li et al., 2009). Although PRF is 
dependent on T2*- which consists of both T2 and the inhomogeneities of B0 - it can either be 
linear relative to B0, if the main contribution comes from the magnetic field, or independent of 
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the magnitude of B0, if the main temperature contribution is from spin-spin interaction. 
Usually, it is considered to be in linear correlation only to B0 (Quesson et al., 2000).  
 One of the main applications of PRF is thermal monitoring in ablation of tissue. PRF 
monitoring is applied in various ablation techniques such as: laser thermotherapy in phantoms 
(Olsrud et al., 1998) as well as in-vivo (Weidensteiner et al., 2003); radiofrequency ablation 
(Vigen et al., 2006); microwave thermocoagulation (Vitkin et al., 1997; Morikawa et al., 2002); 
and in FUS ablation in clinical applications worldwide (Hynynen et al. 2001; Tempany et al., 
2003). 
 ExAblate System Description  4.1.2.2
The main components of the ExAblate 2000 UF system (InSightec, Haifa, Israel) are 
presented in Figure 4.2. 
 
 
 
Figure 4.2- ExAblate main components: (a) cradle, (b) operator console and  
(c) equipment cabinet   
In the UF ExAblate 2000 system, the transducer is located within the water bath in the 
patient table (Figure 4.3). 
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Figure 4.3- Bath components  
The transducer in use in the UF system is a 208-element segmented annular curved 
phased array, Figure 4.4, with radius of curvature 160 mm, aperture 120 mm, and variable 
operating frequencies 0.95 - 1.35 MHz. 
 
Figure 4.4- Drawing of UF transducer dimensions  
The ExAblate 2100 Conformal Bone System (CBS) consists of a planar phased array 
transducer of 550 kHz central frequency, with approximately 1000 transmitting elements in a 
74 mm square aperture. Figure 4.5 depicts the placement of the CBS transducer in the patient 
table as well as the dimensions of the phased array. 
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Figure 4.5- ExAblate 2100 conformal bone system (CBS): (a) connected to a MRI (b) the 
transducer filed with degassed water and (c) the dimensions of the transducer 
 Targeted Drug Delivery with ExAblate 4.1.2.3
Drug delivery with a MRgFUS system was previously introduced in Section 2.4.6. There 
are clear advantages in the utilization of a clinically available MRgFUS system in TDD, including 
beam control to minimise the damage caused by free drugs in other vital organs and the 
enhancement of drug effectiveness in situ (Jolesz, 2009). Currently one of the leading research 
groups investigating the application of TDD with the ExAblate system is located in Fox Chase 
Cancer Centre, Philadelphia, mainly focusing on delivering anticancer agents to solid tumours 
in vivo (Chen et al., 2009; Chen et al., 2010). While this research is carried out in vivo, the 
present study is mainly focused on the in-vitro platform in order to understand the 
fundamentals of USmTDD. Therefore, the arrangements were designed to apply FUS using 
ExAblate in vitro.  
 Challenges in Utilization of a Clinical MRgFUS System In vitro 4.1.2.4
The main challenge in adaptation of the clinical MRgFUS system lies in the overall 
complexity of the system. Because the ExAblate systems were designed and produced for 
clinical use, the high safety levels implemented within the arrangement and the rigidity the 
equipment imposes on operation introduced various difficulties. In general the ExAblate is not 
compatible with biological protocols; hence alterations had to be made from both sides. 
Moreover, MR thermometry is not possible in solid plastic cell culture plates, which required 
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implementation of additional thermal measurement techniques, e.g. thermal camera and 
thermocouples. Specific issues and their solutions are described in the results section. 
 Additional Thermal Evaluation Techniques 4.1.3
 Thermal Camera 4.1.3.1
Thermal infrared (IR) imaging is a non-contact real time technique that is used for 
many purposes such as animal tracking, food quality assessment, and face recognition 
(Hovinen et al., 2008; Gowen et al., 2010; Socolinsky and Selinger, 2002). It is based on the 
assumption that all materials emit IR energy. This occurs because of molecules’ movement on 
the surface of objects, if above absolute zero. Moreover, objects can also reflect and absorb IR 
energy. The IR emission depends on the temperature of the object; hence by measurement of 
the emission, one can determine the temperature of an object with a known emissivity value 
(Speakman and Ward, 1998). The correlation between the IR emission and temperature is 
described by the Stefane-Boltzmann law in the following equation: 
 
         
Equation 4.3- Stefane-Boltzmann law of energy emission as a function of temperature 
where W is the emitted energy from the object (W/cm2); σ is the Stefane-Boltzmann constant 
which is derived from the speed of light, Plank’s constant and Boltzman’s constant and equals 
5.67·10-8 W/m2·K4; T is the temperature; and e is the material’s emissivity, which equals the 
ratio of the material’s emitted energy to that of a perfect black body. Hence, for a perfect 
black body, e equals 1. A perfect black body is a theoretical object that fully emits all the IR 
energy it receives.  
A standard thermal camera consists of: the optical part i.e. a camera with various 
optional sets of lenses, an IR detector and an image processor. The IR detector converts the 
emitted energy into a signal that, after processing, will become a multilayered image in which 
each layer represents a certain temperature. One of the known limitations of IR imaging is its 
inability to measure temperature changes in transparent materials, especially plastic-based 
thin films, as explained by Vollmer and Mullmann (2010, Chapter 3- 3.2.1.2 Plastic Filters, and 
Chapter 9- 9.6.5 Plastic Foils: Selective emitters).  
 Thermocouples 4.1.3.2
The working principle of thermocouples is based on the fact that by introducing a 
temperature gradient to a conductor, a voltage is generated. The voltage can be measured by 
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a connection of a second, dissimilar conductor that, under the same temperature gradient, will 
produce a different voltage. This approach was first taken by Seebeck in 1821; utilising it, 
temperature differences are measured and not the absolute temperature (Morris, 2001). 
Hence, there is great importance in the reference temperature (TR), which by subtraction will 
determine the unknown temperature (TX). Since TR is usually set to 0°C, the conventional 
method was through immersion of the wires in ice-cold water as shown in Figure 4.6. 
 
Figure 4.6- Schematic structure of a copper (Cu)- constantan (C) (T type) thermocouple 
Now, the ice bath is converted to an isothermal block with a thermistor or a resistance 
temperature detector (RTD). The relation between the voltage measured by the voltmeter and 
the temperature is described by: 
             
Equation 4.4- Electro-motive force (EMF) as a function of thermal change 
According to Equation 4.4, EMF equals the difference in voltage which also 
corresponds to the thermal difference multiplied by the Seebeck coefficient (S). From this 
equation, having two materials with different S values and a known reference temperature, TR, 
the unknown temperature, TX, can be easily calculated. 
 Thermocouples are frequently used because they are relatively cheap, easy to operate, 
and can cover a wide variety of temperatures (ASTM Committee E-20, 1981). Nonetheless, one 
of the thermocouple’s limitations is its malfunction in an ultrasonic environment. The effects 
of acoustic field on thermocouple temperature measurements have been investigated since 
1954 (Fry and Fry, 1954). They discovered that, because of the difference in density of the 
thermocouples wires and the medium they are placed in, under application of an ultrasonic 
field, the created motion of the thermocouples generates ‘viscous heating’ which is then 
transmitted into a false temperature reading. In other words, while thermocouples are 
supposed to measure the temperature of their environment, under an acoustic field they 
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absorb the heat generated from the viscous forces between the thermocouples and the media, 
which results in an artefact of a false rapid temperature increase. When the US is turned off, 
they re-measure the temperature of the environment, giving a true signal once again. 
Consequently, Fry and Fry suggested to ignore the initial rapid temperature rise and to 
measure the temperature from time > 0.5 s. According to Hynynen (1983) when working with 
focused beams the thermocouple measurements should be carried out after the ultrasonic 
beam is switched off. Morris et al. have referred to this approach as “wait and measure” in 
their thorough research of the subject (Morris et al., 2008).  
In addition, the location and orientation of the thermocouples in the acoustic field is 
very important, as it can affect the measured temperature. Consequently, great care should be 
taken with the positioning of the thermocouples in acoustic environments, e.g. outside of the 
direct acoustic focus, for better measurements to be achieved (Hynynen, 1983). For more 
information on thermocouples behaviour under acoustic fields the reader is referred to a 
recent paper by Morris et al. (2008). 
 Aims and Objectives  4.1.4
A current challenge in USmTDD is the repeatability and accuracy of the experiments. 
Most biological research is carried out in a sterile environment under constant conditions, such 
as temperature and humidity. In contrast, US is a physical procedure that requires continuous 
physical coupling of the desired target with the transducer by immersion into degassed water 
or application of coupling gel. Therefore the conjunction between the two fields is 
complicated.  
Since there were no easily available commercial tools for biological cell sonication, 
specially designed apparatus was created, in combination with the clinical MRgFUS system. 
The purpose of the bespoke arrangement was to introduce US to cells to investigate their 
behaviour as a result of sonication. Such apparatus could also allow differentiation between 
the thermal and physical effects on cells - a major issue in current cell sonication work. For this 
purpose, three in-vitro ultrasonic arrangements were developed, with two focusing on TDD via 
sonoporation. The MRgFUS UF apparatus allows sonication at frequencies 0.95 - 1.35 MHz in 
an automated manner via a prewritten computer script. The CBS arrangement, f = 550 KHz, 
increased the chance of cavitation and also presented the possibility of multi-focal sonication 
patterns. The third arrangement was set up to investigate the effects of US generated (mild) 
heating on cells. An additional heating arrangement, without FUS, was created to serve as a 
control for the FUS induced heating.   
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 Materials and Methods 4.2
 Materials  4.2.1
Table 4.1- Equipment and consumables  
Material Manufacturer  Place of 
Origin 
Notes 
Equipment    
1.5 Tesla MRI system General Electric USA Model: Signa HDX 
ExAblate 2000 InSightec LTD Israel UF, 0.95-1.35 MHz  
ExAblate 2100  InSightec LTD Israel CBS, 550 kHz 
Thermocouple data logger Omega UK Model TC-08 
Thermocouples  Omega UK Omega T type, 0.25 and 
0.076 mm wire diameters 
Fibro-optical hydrophone Precision Acoustics UK  
Needle hydrophone Precision Acoustics UK 0.5 mm  diameter 
Stuart Heat-Stir  Barloworld Scientific UK Model: CB162 
Techne Dri Block  Techne UK Model: DB-20 
IR thermal camera FLIR UK Model: JADE   
Consumables    
Daily quality assessment 
(DQA) gel phantom 
ATS Laboratories USA  
96-well plates   Greiner Austria Polystyrene cell culture 
microplates with μClear® 
bottom 
Black 96-well plates  Greiner Austria Non cell culture treated 
black base microplates  
 Methods 4.2.2
 Design and Construction of Sonoporation Arrangements  4.2.2.1
 ExAblate UF System Currently most of the studies in USmTDD are carried out in cell 
suspensions (Feril Jr. et al., 2002) or in an Opti-cell environment (Eisenbrey et al., 2009; Feril Jr. 
et al., 2010). The latter, although having excellent visualization possibilities, fundamentally 
lacks an isolated control. In the current study, the effect of FUS was investigated on cell 
monolayers, therefore, a typical arrangement consisting of 96 isolated wells in a uniform plate 
(referred to as a plate henceforth) was chosen to populate the cells. This way various 
treatment groups could be sonicated in one plate, with positive and negative controls in situ 
for each of them. To maintain the sterility of the plate and to ensure isolation of the treatment 
groups, sealing film was applied on top of the plate.  
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The particular plate and the sealing film were chosen such that the plate has a thin 
base, 0.2 mm, and the seal is also thin, 0.01 mm. Moreover, the plates chosen for this work 
had to be opaque, preferably black, for fluorescence studies.  
 
Figure 4.7- Sealed plate (a) before and (b) after sonication 
Figure 4.7 depicts a sealed plate before and after sonication. It can be seen that before 
the sonication, all the treatment groups look approximately the same, and after the 
application of FUS, certain wells contain a white substance; this is MB residue (marked by red 
arrows). The location and order of the optimal sonication pattern (i.e. the sonication pattern 
having the lowest impact on the neighbouring wells) that was developed for the UF 
sonoporation arrangement is presented in Figure 4.8. 
 
Figure 4.8- Diagram of sonication pattern and order in the UF sonoporation arrangement 
According to Figure 4.8, the order of sonication of the plate is as follows: B2-E4-B6-F2-
C4-F6-D2-G4-D6-G2-D4-G6-C2-F4-C6-E2-B4-E6. Since the stability of MBs is time dependent 
(Schneider, 1999), in this pattern all the groups that contained MBs were sonicated first and 
only then the groups without MBs. This specific pattern of sonication was chosen to avoid 
accumulating effects from neighbouring wells in the same plate as was validated by the uptake 
studies presented in 5.3. The plate was placed in water upside down to ensure that the MBs 
are in proximity to the cell monolayer because the MBs float upwards. Initially the sonication 
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via the UF sonoporation arrangement was conducted under MR guidance, as presented in 
Figure 4.9. 
 
Figure 4.9- Initial UF sonoporation arrangement in MR environment 
In Figure 4.9, the plate is located between the FUS source below and the imaging coil 
above. The plate is immersed in 3 litres of degassed water inside a dedicated container which 
consists of a mylar base i.e. US transparent material, plastic rings with special cut outs for 
placement of the plate and holes for insertion of rods to hold the absorbing material, which is 
placed about 5 cm above the location of the plate, Figure 4.10.  
 
Figure 4.10- Plate holder rings (a) separated and (b) stacked 
As presented in Figure 4.10, there are three sizes of rings, with dedicated cutouts for 
the plate positioning in each one. The heights of the rings are 20, 40 and 60 mm. The final 
arrangement consisted of 20 and 40 mm rings placed on top of each other at the final height of 
60 mm. The FUS transducer in the ExAblate UF system is located inside a hermetically sealed 
water tank and is coupled to the experimental container with degassed water. The water in 
the container was degassed and adjusted to 30°C prior to immersion of each plate. 30°C was 
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the optimal temperature since it protected the cell monolayer from hypothermia yet did not 
cause any detachment of the sealing film. To keep the temperature constant throughout the 
experiment a polystyrene box was placed over it, under the imaging coil, as presented in 
Figure 4.11. The polystyrene box thermally isolated the experiment very effectively, with a 
small temperature drop of only 0.5°C - 3°C drop after 2 h in a 20°C room, and hence was 
implemented throughout all the UF arrangements. 
 
Figure 4.11- UF sonoporation arrangement covered by a polystyrene box 
After temperature adjustment and careful polystyrene box positioning, the apparatus 
was moved inside the MRI scanner. The following MRI scans were performed: 3D localizer, 
coronal and sagittal with field of view (FOV) = 48 and 5 mm slice thickness. No axial scans were 
done in order to avoid any table movement that might affect the experiment. In the ExAblate 
software, the spot location was chosen in the coronal slice, as shown in Figure 4.12(a) and 
then adjusted to the specific height using the sagittal images, Figure 4.12(b).  
 
Figure 4.12- Spot planning in (a) coronal and (b) sagittal images of a plate 
Spot accuracy testing in a daily quality assessment (DQA) phantom was performed on 
the day prior to each set of experiments. The DQA phantom is a tissue mimicking phantom 
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that absorbs approximately 10% of the acoustic energy for each centimetre of US propagation. 
During the sonications, temperature mapping scans were conducted via the ExAblate software. 
The thermal imaging consisted of pre-sonication scans for reference; scans during sonication, 
conducted in real-time with the application of FUS; and post-sonication, cooling phase, scans 
to follow the thermal behaviour after sonication. At first, all the experiments were conducted 
with the normal ExAblate software, but as the work advanced more sonication protocols were 
investigated that required access to the control personal computer (CPC) of the ExAblate.  
Each spot location planning took about 60 s and the sonication time was 60 s on 
average per well, with one pre-sonication scan and an additional two post-sonication cooling 
phases. With typically 18 spots per plate, the total sonication time was about 45 min to an 
hour. The adjustment of the plate in the sonication arrangement took around 20 min on 
average and MRI scanning before and after the sonications together with the return of the 
plate to the tissue culture lab took about 20 min, so the total exposure time of each plate was 
approximately 1.5 h to 2 h.  Such long exposure time was problematic from various points of 
view, both biological, e.g. the nonuniformity of cell exposure times, masking of the FUS effects 
(60 s in 2 h), and more basic, e.g. the low replicate number of treatments that could be done 
per experiment. Moreover it introduced physical issues such as the need to add pre-heated 
degassed water to the sonication container and availability issues with booking prolonged time 
of MRI suite.  
An additional problem in the arrangement that has been described concerned the spot 
location chosen as a result of differences between the coronal and sagittal images. As 
previously mentioned and shown in Figure 4.12, the sonication spot was set according to the 
coronal images. When the sagittal images were reviewed to confirm the location of the spot 
and adjust its height, a 2 mm shift in the position of the spot was observed. Further 
investigation showed that the shift is a common phenomenon that exists in many MRI scans of 
purely geometrical shapes as well as human tissue (Sumanaweera et al., 1996).  
Shifts in MRI can occur for various reasons including inhomogeneity of the magnetic 
field and the nonlinearity of the gradients. Image corrections methods are available but they 
often result in loss of quality in the images (Langlois et al., 1999; Wang et al., 2004). As the 
diameter of each well in the plate is 7 mm and the focal spot is about 2.5 mm wide, a shift of 
even 3 mm can result in the focus directly hitting the well wall. This was the case in several 
early experiments, presented in Figure 4.13. The deformation presented in the well happened 
as a result of a shift of the focus from the centre of the well.  
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Figure 4.13- Deformation in a single well due to FUS (marked in red) 
To overcome all the mentioned issues, an automated script was developed that 
sonicated each well in the plate according to pre-established coordinates. The utilization of the 
automated script without the need of MRI resulted in a more accurate and efficient 
arrangement. The improved arrangement not only significantly decreased the experimental 
duration, e.g. 20 min for 60 s sonication at 18 spots, reduced from 2 h, but also eliminated the 
possibility of human error. 
Since the sonications are performed according to specific coordinates, the 
experimental arrangements must be rigid to avoid any movement of the plate or wrong 
placement. In order to ensure repeatability in the location of the placed plate, a metal 
structure was attached to the ExAblate cradle to define a constant plate location, as 
demonstrated in Figure 4.14. 
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Figure 4.14- Final UF sonoporation arrangement: (a) designed model, key: 1- water bath 
containing FUS source; 2- FUS source; 3- degassed water container; 4- the plate; 5- 
ultrasound absorber material, and (b) real imaging  
Ten cm above the plate an absorbing material was placed, as shown in Figure 4.14, to 
absorb any excess of acoustic waves and prevent their reflection from the water-air boundary. 
Prior to each experiment, the arm positioning was calibrated according to the location of the 
focus inside two pre-defined opposite wells in the plate. For this purpose, the water in the 
container was filled such that it reached only half of the height of a special baseless plate, 
following which sonication inside the wells created visually seen fountains. In the automated 
script utilised for sonication of the wells in the plate the following parameters were included: 
spot location (X, Y coordinates), the power applied, the sonication duration and the sonication 
mode (continuous / pulsed- Duty Cycle (DC) and Pulse Repetition Time (PRT)) as well as the 
frequency and the Focal Distance (FD) (Z).  
After thorough acoustic evaluation, the FD was chosen to be 97 mm from the 
transducer, which is located exactly in the middle of the well as shown in Figure 4.15. 
According to the acoustic measurements, focal height of 97 mm had less effect on the 
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neighbouring wells than other FDs, results shown later in Figure 4.54. Full dimensions of the 
plate in use can be found in Appendix iii. 
As previously stated, the UF transducer is a phased array with 208 elements. This type 
of transducer introduced the possibility of having various beam forms by manipulating 
different elements and hence creating different sonication patterns. After examining various 
beam forms, the optimum beam form was found to be when 50% of the transducer rings (Tr) 
are on, and 50% are off. Utilization of 50% Tr resulted in a longer and more concentrated focal 
point that fitted the well geometry better due to lower interference at the entrance to the 
well. The beam diameter and length were calculated to be 2.6 mm and 30.24 mm respectively. 
The calculations were done using technical notes by Olympus NDT (2008); full equations can 
be found in Appendix iii. Figure 4.15 is a schematic representation of the focal point inside a 
single well with 50% Tr at FD = 97 mm i.e. the optimal parameters as were defined by the 
acoustical evaluation.  
 
Figure 4.15- Focus within a single well in an inverted plate 
The frequency of the applied FUS was set to 0.95 MHz to gain a wider focal spot and 
higher probability of cavitation (Maisonhaute et al., 2002).  
 ExAblate CBS The CBS arrangement is shown in Figure 4.16. It comprises the ExAblate 
2100 phased array in its holder, a container full of degassed water, an inverted sealed plate 62 
mm above the planar phased array, and an absorbing material 40 mm above the plate.  
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Figure 4.16- CBS sonoporation arrangement: (a) designed model, key: 1- FUS source; 2- 
degassed water container; 3- the plate; 4- ultrasound absorber material, and (b) real imaging  
The water was pre-heated to 30°C prior to every set of experiments. The plate was 
sealed and placed in water upside down in the same manner as in the UF system. The phases 
for 16 focal points with minimal intensity distribution generation were calculated according to 
the iterative GS algorithm described by Hertzberg and Navon (2011). The points were selected 
such that each point is located inside a single well in the 96 well plates. All the spot locations in 
a single plate are depicted in Figure 4.17.  
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Figure 4.17- Diagram of sonication pattern in the CBS arrangement 
According to Figure 4.17, all the wells in the treatment group were sonicated 
simultaneously with a multi-focal pattern of sonication.  
 Design and Construction of Heating Arrangements  4.2.2.2
As mentioned previously, the carriers in use in this work are temperature dependent 
and the drug release can be triggered by a temperature rise. To obtain a controlled and 
uniform temperature rise in vitro, two arrangements were created. The main one utilizes FUS 
as the heating source; and a control arrangement without FUS. 
Heating Arrangement without Focused Ultrasound The heating arrangement 
without FUS consists of two heating blocks at different temperatures. On the heaters, two 
metal blocks of specific sizes were placed, such that only a certain part of the plate was 
heated, allowing control wells on the same plate. The arrangement is displayed in Figure 4.18. 
As can be seen, the heaters are directly heating the two metal blocks whose temperature is 
constantly monitored by attached thermocouples. 
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Figure 4.18- Heating arrangement without FUS: (a) designed model, key: 1- 75°C heater, 2- 
75°C heating block, 3- plate, 4- top block, 5- 50°C heater, 6- 50°C heating block, and (b) real 
imaging 
In both of the heating arrangements, the plate was placed upside down to avoid direct 
and non-linear heating of the cells through the plastic plate and to ensure that the solution 
within each well heated homogeneously. The optimal heating pattern (i.e. having the highest 
possible amount of treatment groups and isolated control groups) for the heating arrangement 
without FUS is presented in Figure 4.19. As shown in Figure 4.19, all the wells of the treatment 
group were heated simultaneously. 
 
Figure 4.19- Diagram of heating pattern in the heating arrangement without FUS 
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 ExAblate UF System Based on the previously described sonoporation configuration, 
FUS induced heating was tested as a possible mechanism for enhancement of cell 
permeability. This was investigated using a DQA phantom gel. The phantom was placed below 
the plate to deliver the FUS-generated heat to the proximity of the focused wells, and to 
partially absorb the acoustic energy propagation before reaching the well. 
 
Figure 4.20- UF heating arrangement: (a) designed model, key: 1- water bath containing FUS 
source; 2- FUS source; 3- degassed water container; 4- the plate; 5- ultrasound absorber 
material 6 and 7 - lower and upper tissue mimicking phantoms, respectively, and (b) real 
imaging 
As can be seen in Figure 4.20, the DQA phantom was placed underneath and on top of 
the inverted plate. In the cell culture experiments, an absorbing material was placed on top of 
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the upper phantom, not shown in the figure, to sustain a constant temperature in the 
proximity of the cells and to prevent reflection from the air. Because of the long sonication 
periods, about 1 h per plate, and the relativity high acoustic powers in use, the water in the 
container was replaced in between each plate with fresh degassed water to avoid cavitation.  
 
Figure 4.21- Diagram of sonication pattern and order in the UF heating arrangement 
The location and order of the sonication pattern for the UF heating arrangement is 
presented in Figure 4.21 with a sonication order as follows: C2-C6-E2-E6-G2-G6-B4-B8-D4-D8-
F4-F8. This sonication order was chosen to avoid heat accumulation by thermal isolation of 
each well by surrounding air filled wells. The frequency was set to 1.35 MHz to decrease the 
possibility of cavitation and to increase the absorption in the phantom and hence to shorten 
the propagation distance. Due to the CBS’s low frequency, 550 kHz, it was not considered 
suitable for heating purposes in the current arrangements.   
 Thermal Evaluation of the Apparatus  4.2.2.3
MRI The MRI thermometry in use in the present work was achieved via the software 
supplied with the ExAblate system. As part of the tracking of temperature rise in tissues, a 
graph (e.g. Figure 4.22, where green line shows average temperature in the nine pixels 
surrounding / including the selected pixel, red line is the temperature at the selected pixel) is 
recorded which represents real time temperature in situ based on PRF MRI thermometry. 
 
Figure 4.22- PRF temperature measurement via the ExAblate software 
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Thermal Camera The thermal evaluation of the UF sonoporation arrangement was 
performed by IR thermal camera measurements outside the MRI suite. The camera was placed 
above a partially submerged plate, focusing downwards on the part of the plate which is above 
the water level, Figure 4.23. 
 
Figure 4.23- Positioning of thermal camera on the UF table 
After careful positioning of the thermal camera on a tripod on the UF table, the 
camera was connected to a PC with Altair software (FLIR, UK) to record the thermal changes. 
Via the Altair software both videos and graph of temperature time dependence were created 
as shown in Figure 4.24. 
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Figure 4.24- Altair software for thermal evaluation via FLIR IR thermal camera 
Thermocouples The thermocouples in use in all the experiments were of type T. 
Type T thermocouples consist of copper, Cu, and constantan, Ni-Cu, wires. This type was 
chosen for its wide range of temperature measurement, -250°C - 400°C, and relatively low 
error, 1°C / 0.75% above 0°C; 1°C / 1.5% below 0°C, whichever is higher in both cases (Omega, 
n.d.). The thermocouples were connected through a data logger to the computer. The data 
were recorded using Picolog software (Omega, UK). Each thermocouple was attached to the 
surface of the plate using a medical plaster, to keep it in a constant place yet not to interfere 
with the temperature measurement. 
Heating without FUS The heating arrangement was based on monitoring 
temperature changes throughout the plate and subsequently moving it between two different 
heaters (Figure 4.18). To measure and record the temperature changes in the plate in real 
time, thermocouples were attached to the base and sealing film on the plate, as presented in 
Figure 4.25. 
 
Figure 4.25- Thermocouples attached to the (a) base and (b) sealing film on a plate 
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UF Heating Arrangement To validate the temperature rise measured by MR 
thermometry, a second thermal evaluation of the heating arrangement was conducted using 
thermocouples. The thermocouples were attached to the plate inside and outside several 
wells, and the plate was placed inverted and the right way up between two DQA phantoms 
(Figure 4.26) in the arrangement presented in Figure 4.20. 
 
Figure 4.26- (a) thermocouples attached to a plate and (b) placed over a phantom  
UF Sonoporation arrangement To ensure that no temperature rise occured in the 
sonoporation arrangement, it was evaluated by thermocouples attached to the base of 
sonicated wells. After attachment of the thermocouples to the various wells in the plate, it was 
placed upside down inside the water container, as shown in Figure 4.27. 
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Figure 4.27- Thermocouples attached to a plate in the UF Sonoporation arrangement 
As can be seen in Figure 4.27, the plate with the thermocouples attached to it was fully 
immersed in water. A Hg thermometer was placed in the container to validate the functioning 
of the thermocouples by comparison with the initial temperature in the container.  
 US Evaluation of the Apparatus by Hydrophone Measurements  4.2.2.4
A 0.5 mm needle hydrophone or a fibre-optic hydrophone was placed inside a bespoke 
positioning device with two automated degrees of freedom and a manual Z-axis. The 
hydrophone positioner was fixed on top of the arrangement and the acoustic properties of the 
plate were observed. The peak voltage from the hydrophone was recorded for each location. 
US properties of the plate base and seal To evaluate the acoustic properties of the 
plate base and sealing, special arrangements were made with plates consisting of the plate 
frame and only a sealing or a base film, without any wells (Figure 4.28).  
 
Figure 4.28- Special plates with (a) only a sealing film or (b) base attached to the plate frame 
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These plates were placed in the sonication arrangement, between the US source and 
the hydrophone, as presented in Figure 4.29. 
 
Figure 4.29- (a) the hydrophone positioner (b) scanning base part of a plate (c) hydrophone 
position over the plate  
Figure 4.29 shows a fibre-optic hydrophone inside the hydrophone positioner, 
scanning the base part of a plate; similar scans were performed for the sealing film.  
US Field Measurements To establish the behaviour of a focused US beam 
penetrating through a plate, US field measurements were done. A 0.5 mm diameter 
hydrophone was positioned in the same way as presented in Figure 4.29, and the US field with 
and without the plate was mapped as shown in Figure 4.30. 
 
Figure 4.30- (a) US field measurements (b) positioning of the hydrophone above the plate (c) 
interpretation of the data using dedicated software  
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Figure 4.30 depicts the scan over an inverted plate. As mentioned previously all the 
data was interpreted via dedicated software to obtain the results shown in this manuscript.   
 Results 4.3
 Thermal Evaluation  4.3.1
 Magnetic Resonance Imaging Thermometry 4.3.1.1
The main use of MRI thermometry was in thermal evaluation of the heating 
arrangements with the UF system. As previously mentioned it is impossible to retrieve 
temperature mapping of a solid plastic material by PRF measurements, hence the temperature 
mapping took place in the tissue mimicking DQA phantom below and above the plate.  
Prior to the sonication, positioning images were collected, with coronal, sagittal and 
axial scans presented in Figure 4.31 - Figure 4.32. 
 
Figure 4.31- Coronal images of a plate between two DQA phantoms 
 Figure 4.31 represents the coronal scan of the plate placed between two phantoms at 
different slice heights. In the slice presented in ‘a’ the bottom phantom is visible, slice ‘b’ is in 
the middle of the plate, and slice ‘c’ shows the plate with the upper phantom. As can been 
seen in the figure several wells appear bright coloured whereas others remain dark. The bright 
wells are filled with the testing solutions and the dark wells contain air for isolation.    
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Figure 4.32- (a) sagittal and (b) axial images of a plate between two DQA phantoms 
Figure 4.32 depicts the sagittal and axial scans of the plate in the UF heating 
arrangement. According to these scans the thicknesses of the bottom phantom, the plate and 
the upper phantom are 34.6 mm, 10.2 mm and 93.7 mm respectively. The sagittal scan shows 
the expected area of the US beam passage called the passzone.  
The sonication pattern in the heating arrangement consists of two sonication modes: 
initial continuous sonication to achieve a fast temperature rise and a second pulsed sonication 
to maintain a constant elevated temperature, as presented in Figure 4.33. 
 
Figure 4.33- Schematic representation of the combined sonication mode 
To evaluate the heating process in each well, MRI temperature mapping of the upper 
and lower phantoms was performed. The figure presented below correlate to real sonications 
on a cell monolayer inside an inverted plate with an acoustic power of 30 Watts (Wa) (i.e. the 
output power as defined by the ExAblate system) for 30 s continuous sonication and 30 Wa for 
180 s, with 0.5 s on, 3 s off pulsed sonication. 
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Figure 4.34- Thermal Monitoring by MRI: (a) axial MR image showing FUS induced heating 
arrangement, with a white and orange crosses marking the chosen pixel for temperature 
measurement in the lower and upper phantoms, respectively, (b) temperature graph 
measurement during sonication in the (i) lower and (ii) upper phantoms and (c)  a thermal 
map, with a white and orange crosses marking the chosen pixel for temperature 
measurement in the lower and upper phantoms, respectively 
In Figure 4.34 the thermometry of the lower and upper phantoms during a combined 
sonication is presented. In the temperature graph, the green line represents the average 
heating over the nine pixels surrounding and including the selected pixel, marked by a white/ 
orange cross, and the red line is the temperature at the selected pixel. As can be seen in the 
temperature graph of the lower phantom (i), the temperature reaches an average of 65°C ±2°C 
standard deviation (Sd), which would have caused necrosis of the cell monolayer if the plate 
were placed the right way up and not inverted. Yet, in the upper phantom, in the proximity of 
the cells in the inverted position, according to temperature graph (ii), there is an average of 
about 43°C ±2°C, which is the desired temperature. The fact that the lines overlay, indicates a 
real thermal measurement, rather than a single spot artefact.  
 Thermal Camera 4.3.1.2
To ensure that there is no significant heat generated in the sonoporation arrangement, 
temperature measurements were made with a thermal camera and thermocouples. The 
thermal camera was utilized to measure the heat generated on the perimeter of the well.  
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Figure 4.35- Thermal camera measurement of the well perimeter temperature of a plate 
Figure 4.35 depicts measurement of temperature during sonication at the perimeter of 
a single well with powers 1, 2, 5 and 10 Wa, by a thermal camera. Each applied power is 
represented by a colour line with two black points surrounding the each line representing the 
sd. Consequently, lines without visible black marks in the graph have very low Sd. All the 
sonications were performed in an inverted plate with 50% Tr for 90 s, FD = 97 mm, f = 0.95 
MHz. The time line is as follows: point 1- start sonication; point 2- end sonication and start 
cooling time; point 3- end measurements.   
 
Figure 4.36- Thermal camera imaging of the well perimeter temperature of a plate at the 
powers (a) 1, (b) 2, (c) 5, and (d) 10 Wa  
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Figure 4.36 presents images of the thermal changes in the perimeter of the well as a 
result of 90 s sonication which correspond to the lines presented in Figure 4.35. As can be seen 
in Figure 4.36 heating appears only on the perimeter of the well while the inner, transparent 
part remains dark.  
As a control for the data presented for the thin transparent base additional 
measurements were made in a different type of plate, the latter with a relatively thick, 
1.27 mm, black base, Figure 4.37. 
 
Figure 4.37- Black thick base plate 
 
Figure 4.38- Thermal camera measurement of the well base temperature of a black thick 
base plate 
 Figure 4.38 depicts the temperature during sonication of the base part of a plate with 
a black thick base with the powers 1, 2, 5 and 10 Wa, by a thermal camera. The black marks 
surrounding the lines represent the Sd. Consequently, lines without visible black marks in the 
graph have very low Sd. All the sonications were performed in an inverted plate with 50% Tr 
for 90 s, FD = 97 mm, f = 0.95 MHz. The time line is as follows: point 1- start sonication; point 
2- end sonication and start cooling time; point 3- end measurements.   
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Figure 4.39- Thermal camera imaging of the well base temperature of a black thick base 
plate at powers of (a) 1, (b) 2, (c) 5, and (d) 10 Wa  
Figure 4.39 presents images of the temperature of the base of a plate with a black 
thick base as a result of 90 s sonication which correspond to the lines presented in Figure 4.38. 
As can be seen in Figure 4.39 the heating appears on the perimeter of the well as well as in the 
inner part.  
 Thermocouples 4.3.1.3
 Heating Arrangements without FUS As described in Section 4.2.2.2, the evaluation 
of heating without FUS is based on measurements with thermocouples. The treatment plan 
progressed according to the real time measurements of the temperature at the base and in 
the sealing film on the plate. To determine the temperature rise inside a well in the plate 
during the heating process, thermocouple measurements without cells were performed. 
Moreover, in this set of experiments, the optimal positioning of the plate, i.e. inverted and 
right way up, was investigated. 
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Figure 4.40-Thermocouple measurements of (a) regular and (b) inverted positioning of the 
plate 
Figure 4.40 depicts the measurements conducted in a plate the right way up and an 
inverted plate where two thermocouples were placed outside the plate, on the base, green 
line, and seal, blue line, and another two thermocouples were placed inside a single well in the 
plate. The red line is the temperature of the medium inside the well and the pink line is the 
measurement by a thermocouple attached to the base of the well from inside of the well, 
measuring the temperature at the location of the cell monolayer. After establishment of 
optimal parameters i.e. inverted plate with 3 min exposure at 42 - 46°C, cell work was 
implemented.  
 
Figure 4.41- Thermocouple measurements in a heating process of an inverted plate 
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Figure 4.41 represents typical thermocouple measurements during heating of an 
inverted plate without FUS. The timeline is as follows:  
 Point 1- plate placed on the hot plate at 75°C until the base, green line, reaches 42°C. 
 Point 2- after the cells have reached 42°C, the plate is moved to the 50°C heater. 
 Point 3- after continuous heating for 3 min on the 50°C heater, the plate was removed 
to cool down.  
 Point 4- end of measurement.  
UF Heating Arrangement The MRI thermometry of the UF heating arrangement was 
verified by thermocouple measurements. As mentioned in Section 4.3.1.1, the sonication 
pattern in the heating arrangement is a combined sonication pattern with high power 
continuous sonication followed by pulsed sonication to achieve a fast temperature rise and 
then to maintain a constant elevated temperature. To evaluate the optimal positioning of the 
plate, thermal measurements were performed with both regular and inverted positioning of 
the plate. Additional measurements were made to define the optimal sonication mode. Both 
types of measurements were conducted as part of the apparatus evaluation without any cells.  
 
Figure 4.42- Thermocouple measurements of FUS induced heating in (a) regular and (b) 
inverted plates 
The measurements presented in Figure 4.42 correspond to the evaluation of the 
positioning of the plate and compare regular and inverted positions. The timeline is as follows:  
 Point 1- start of continuous, high power sonication.  
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 Point 2- end of continuous sonication and immediate start of pulsed sonication. 
 Point 3- after a period at 42 - 46°C, the sonication is finished and the well cools down.  
 Point 4- end of measurement.  
The initial sonication was at a power of 20 Wa for 10 s in continuous mode followed by a 
second sonication of 20 Wa for 120 s in pulsed mode, 0.5 s on, 2.5 s off. 
 
Figure 4.43- Thermocouple measurements of FUS induced heating at (i) 0.5 s on, 2.5 s off 
mode and (ii) 0.5 s on, 3 s off in a Plate 
Figure 4.43 depicts the temperature rise as a result of two different sonication modes. 
The first mode is 0.5 s on, 2.5 s off, and the second is 0.5 s on, 3 s off. Both temperature rise 
slopes are represented in red on top of each graph. The timeline as follows:  
 Point 1- start of the continuous, high power sonication. 
 Point 2- end of continuous sonication and immediate start of pulsed sonication.  
 Point 3- after a period at 42 - 46°C, the sonication is finished and the well cools down.  
 Point 4- end of cooling period.  
 Point 5- start of the continuous, high power sonication.  
 Point 6- end of continuous sonication and immediate start of pulsed sonication.  
 Point 7- after a period at 42 - 46°C, the sonication is finished and the well cools down;   
 Point 8- end of measurement.  
In the first mode the initial sonication is at a power of 60 Wa for 15 s in continuous mode 
followed by a second sonication of 60 Wa for 120 s in pulsed mode, 0.5 s on, 2.5 s off. In the 
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second mode, the initial sonication is at a power of 60 Wa for 15 s in continuous mode 
followed by a second sonication of 60 Wa for 120 s in pulsed mode, 0.5 s on, 3 s off. 
UF Sonoporation Arrangement Following discussion in Section 4.1.3.1 regarding 
the accuracy of thermal camera measurements through transparent materials and for 
validation, additional thermal measurements were made with thermocouples in the 
sonoporation arrangement. The thermocouples were attached to Row 2 of wells on the base 
of the inverted plate (Figure 4.27) to evaluate the temperature not only in the sonicated well 
at the time of sonication but also in its neighbours. To establish a safety margin, the following 
measurements were done at a factor 15 times higher energy, 2.5 Wa for 60 s = 150 J, than the 
final cell sonication parameters, 1 Wa for 10 s = 10 J.  
 
Figure 4.44- Thermocouple measurements in the UF sonoporation arrangement 
The thermal measurements in Figure 4.44 were taken during a whole plate sonication 
using the automated script. The time line is as follows:  
 Point 1- start of first sonication (well B2).  
 Point 2- end of first sonication. 
 Point 3- start of the fourth sonication (well C2).  
 Point 4- end of fourth sonication.  
 Point 5- start of the seventh sonication (well D2). 
 Point 6- end of seventh sonication.  
 Point 7- start of the 10th sonication (well E2).  
 Point 8- end of 10th sonication.  
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 Point 9- start of the fourth 13th sonication (well F2).  
 Point 10- end of 13th sonication.  
 Point 11- end of measurement.  
 US Evaluation  4.3.2
 US Properties of the Plate Base 4.3.2.1
The acoustic properties of the base of a plate were measured using the arrangement 
described in Section 4.2.2.4. All the results presented in the figures below correspond to 
sonication of 1 Wa at 0.95 MHz for 3 min, with the sealing film / base part located 92 mm over 
the transducer (z = -5). 
 
Figure 4.45- XY Slice of acoustic measurements (a) without and (b) with the base of a plate 
 
Figure 4.46- Acoustic measurements in XZ plane (a) without and (b) with base and in YZ 
plane (c) without and (d) with base of a plate 
Figure 4.45 -Figure 4.46 show a comparison between the US field propagation in an XY 
slice as well as axial XZ and YZ slices, through the base of a plate and in pure degassed water 
without the plate.  
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Figure 4.47- Focus cross-sections in main axes and schematic representation of the focal 
point without (a and b respectively) and with (c and d respectively) base of a plate 
In Figure 4.47, cross-sections in the main axes at the focal point as well as a schematic 
representation of the focal point are presented both for the base of a plate and in pure 
degassed water without the plate.  
 Acoustic Properties of the Plate Seal 4.3.2.2
The acoustic properties of the sealing film were measured using the same 
arrangement as for the base, described in Section 4.2.2.4. All the results presented in the 
figures below correspond to 1 Wa at 0.95 MHz for 3 min. 
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Figure 4.48- XY slice of acoustic measurements (a) without and (b) with sealing film 
 
Figure 4.49- Acoustic measurements in XZ plane (a) without and (b) with sealing film and in 
YZ plane (c) with and (d) without sealing film 
Figure 4.48 -Figure 4.49 show a comparison between the acoustic field propagation in 
an XY slice as well as in axial XZ and YZ slices, in degassed water and through the sealing film 
used to seal the plate. In Figure 4.50, cross-sections in the main axes at the focal point as well 
as a schematic representation of the focal point are presented both for the sealing film of the 
plate and in pure degassed water without the seal. 
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Figure 4.50- Focus cross-sections in main axes and schematic representation of the focal 
point with (a and b respectively) and without (c and d respectively) sealing film 
 Acoustic Field Measurements 4.3.2.3
 UF Sonoporation Arrangement To identify the optimal sonication pattern, i.e. FD 
and the form of the beam, propagation of the applied acoustic field through a plate, at various 
parameters, was measured. As mentioned in Section 4.1.2.2, the UF transducer is a phased 
array consisting of 208 elements organised in 26 transducer rings (Tr), each of which can be 
individually adjusted for amplitude and phase and turned off and on. To define an optimal 
beam, various measurements were done: 100% of the Tr are on (mode 0), 50% of the Tr are 
on, 20% of the Tr are on, 50% of the transducer elements are in random phases, 100% of the 
transducer elements are in random phases, with an annular ‘doughnut’ shaped focus that was 
tested as a possibility to achieve a bigger radius of exposure. In order to observe the generated 
focus and to evaluate the characteristics of each beam, all the above measurements were 
done in the absence of the plate.  
In Figure 4.51-Figure 4.54, FD = 82 mm, with a power of 1 Wa at 1.15 MHz. 
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Figure 4.51- XY slice of acoustic measurements of (a) 100% Tr (b) annulus (c) 50% Tr (d) 20% 
Tr (e) 50% Tr random phases and (f) 100% Tr random phases 
 
Figure 4.52- Acoustic measurements in sagittal plane at (a) 100% Tr (b) donut (c) 50% Tr (d) 
20% (e) Tr 50% Tr random phases and (f) 100% Tr random phases 
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Figure 4.53- Pressure graphs with X and Y axes represented by the green and blue lines, 
respectively, at (a) 100% Tr (b) annulus (c) 50% Tr (d) 20% Tr 50% Tr (e) random phases and 
(f) 100% Tr random phases 
Figure 4.51 and Figure 4.52 show the XY slice and the sagittal slice of the various 
acoustic beam patterns, respectively, and Figure 4.53 shows the focal pressure as a function of 
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distance in the XY plane. It is important to note that although the intensity scale varies 
between the graphs, the XY coordinates remain constant. The variation in the intensity scales 
is not significant in this observation, since the desired information is in the pattern of the 
beam.  
Table 4.2- Summary of measured beam forms 
Beam Form Max Amplitude 
[mV] 
Area 
[mm
2
] 
Diameter 
[mm] 
20% Tr 1.73 6.42 3.09 
50% Tr 2.56 3.51 2.17 
50% Tr with random phases 2.15 1.95 1.6 
100% Tr with random phases 2.14 2.01 1.63 
100% Tr 3.44 1.9 1.59 
 
In Table 4.2 the dimensions and maximum amplitude of the focal point for the various 
beam forms at FD = 82 mm, are presented. The annular beam is not presented in the table 
because of its split focal point.   
An additional issue that may influence the focal behaviour is the FD inside a well. 
Because of the plate geometry, as stated above, various disruptions can occur during the 
passage of the beam through the well. To establish the optimal height for sonication inside a 
single well within a plate, acoustic field measurements were performed over an inverted plate 
at different focal points. The hydrophone in these measurements was less than one mm from 
the surface of the inverted plate, meaning that the presented measurements are in close 
proximity to the theoretical cell location. 
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Figure 4.54- XY slice of acoustic measurements at FD of (a) 92, (b) 97, (c) 102, and (d) 106 mm 
Figure 4.54 represents the acoustic measurements at different focal points performed 
at 50% TR with a power of 1 Wa at 0.95 MHz. The red arrows in Figure 4.54 highlight the 
locations of acoustic field propagation through the neighbouring wells in the plate.  
 UF Heating Arrangement To evaluate the effectiveness of the DQA phantom as an 
acoustic absorber, acoustic field measurements were conducted over the plate with the 
phantom present. All measurements were performed at FD = 82 mm, f = 1.35 MHz. Although, 
in cell work, the applied acoustic power was 30 W, the acoustic power chosen for the field 
mapping was 2 W to avoid damaging the hydrophone.  
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Figure 4.55- Acoustic field measurements over a plate in XY plane (a) without and (b) with a 
DQA phantom, in XZ plane (c) without and (d) with DQA phantom and focus cross-sections in 
main axes (e) without and (f) with DQA phantom below the plate 
As can be seen in Figure 4.55, the acoustic field measurements over a plate on top of 
the phantom are approximately half the amplitude of those without any phantom.  
 CBS Sonoporation Arrangement To assess the uniformity of the power distribution 
between the 16 allocated spots in the CBS sonoporation arrangement, measurements were 
performed without the plate in single spot and multi-focal configurations. Measurements were 
also made at several heights to create 3D images of the focal points. The FD was chosen to be 
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62 mm- the height of the inverted plate sealing film from the transducer. This FD was chosen 
after careful observation of the occurrence of the US-created water fountains (described in 
4.2.2.1). FD at 62 mm produced a fountain with the highest amplitude, yet with a focused 
structure.  
The single focus acoustic measurements were performed at 0.78 Wa and for the multi-
focal measurements 7.8 Wa was used to avoid cavitation at the focus. To evaluate the 
efficiency and uniformity (Appendix v) of the multi-focal pattern, the single spot 
measurements were scaled up to match the multi-focal ones. The scan value of the single well 
was multiplied by the square root of the applied ultrasonic load of the multi-focal sonication, 
i.e. √10. All measurements were done at 0.55 MHz. Figure 4.56 depicts the single spot 
measurement in the XY, XZ and YZ planes as well as the pressure graph of the measurement. 
 
Figure 4.56- Single point acoustic measurement in (a) XY plane, (b) the focus cross-sections in 
main axes X and Y, green and blue, respectively, and the (c) XZ plane and (d) YZ plane  
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Figure 4.57- Acoustic measurement of 16- well multi-focal pattern in (a) XY and (b) XZ plane 
Figure 4.57 shows the acoustic measurement in the XY plane at a height of 72 mm, 
marked by a black line in (b), and the acoustic measurement parallel to the beam path. The 
black line in (a) corresponds to the measurement plane in (b). Spot sizes measured at half the 
maximal pressure and locations were calculated from the acoustic field measurements. The 
average area over the 16 spots was 8.79 ±0.92 mm2 and the average distance between each 
two spots was 9.06 ±0.25 mm in the X direction and 9.02 ±0.2 mm in the Y direction.  
Since the frequency of the transducer is below the calibration range of the 
hydrophone, the hydrophone calibration constants H(V
2cm2/W) and H(V/Pa) were 
calculated according to Appendix v, to be 8.45 ±1.12·10−5 V2cm2/W and 7.53 ±0.44·10−8 V/Pa. 
The adjusted acoustic pressure (MPa) for each spot in the multi focal pattern is presented in 
Table 4.3. 
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Table 4.3- Acoustic pressure measurements of the 16 points focal pattern per well inside the 
plate 
Row/Line 5 6 7 8 
C 0.279 0.253 0.279 0.279 
D 0.307 0.322 0.265 0.28 
E 0.244 0.293 0.33 0.323 
F 0.244 0.32 0.285 0.277 
 
The efficiency (Eff) and uniformity (Uni) were calculated according to Appendix v to be 
89% and 86%, respectively. 
 Discussion 4.4
As presented in the previous section, three innovative arrangements for investigation 
of the mechanical and thermal effects of US on cells were created and evaluated by both 
thermal and acoustic means. The thermal evaluation of the different arrangements was done 
by MRI thermometry, thermal camera observation and thermocouples and the acoustic 
evaluation was conducted using hydrophones and multiaxis scanning systems.   
Thermal camera measurements were performed to assess occurrence of unwanted 
heating in the sonoporation arrangement. From Figure 4.35, the average temperature rises 
(±Sd) on the perimeter of a single well from a 10 s sonication at powers of 1, 2, 5 and 10 Wa 
were 0.44°C (±0.2°C), 1.25°C (±0.35°C), 3°C (±0.5°C) and 6.4°C (±0.9°C), respectively. After 90 s 
sonication at the same powers of 1, 2, 5 and 10 Wa, temperature rises were 2.7°C (±0.2°C), 
5.6°C (±0.3°C), 10.7°C (±0.25°C) and 19.8°C (±0.9°C), respectively. Figure 4.36 presents the 
visualization of the temperature rise in the plate due to 90 s of continuous sonication. It can be 
seen that the thermal distribution in the plate as a result of sonication develops from the 
inside of a well towards the surrounding wells. This important fact was taken into account in 
the order of cell sonications in each arrangement.  
As mentioned in Section 4.1.3.1, there are some limitations in measurement of heating 
of transparent thin films. Although there is no visualization of the heating process in the base 
of the plate, some heating may have occurred in the transparent parts of the plate, e.g. the 
base and/ or the sealing film. As a control for the transparent thin base (0.2 mm) plate, a black 
thick (1.27 mm) base plate was sonicated and the average temperature over the well base 
area was recorded, with the results presented in Figure 4.38. From Figure 4.38 the 
temperature rises (±Sd) in a black thick-base plate from 10 s sonication at powers of 1, 2, 5 and 
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10 Wa are 1.8°C (±0.2°C), 3.7°C (±0.5°C), 8.2°C (±1.4°C), and 15.9°C (±3°C), respectively. After 
90 s sonication at the same powers of 1, 2, 5 and 10 Wa, the temperature rises were 3.4°C 
(±0.2°C), 7.3°C (±0.5°C), 15.9°C (±1.6°C) and 30.9°C (±4.2°C), respectively. 
The temperature changes in the black thick-base plate are visualized in Figure 4.39. 
The difference in the temperature rises (±Sd) between the transparent thin base and the black 
thick-base plates from 10 s sonication at powers of 1, 2, 5 and 10 Wa equal 1.4°C (±0.3°C), 
2.5°C (±0.6°C), 5.2°C (±1.5°C) and 9.5°C (±3.1°C), respectively. After 90 s sonication at the same 
powers of 1, 2, 5 and 10 Wa, the differences were 0.63°C (±0.25°C), 1.72°C (±0.6°C), 5.18°C 
(±1.7°C) and 11.09°C (±4.3°C), respectively.  
From these results, suggesting a difference of 1°C to 10°C difference between the two 
tested plates, it seems clear that the thin base plate is preferable to use in order to decrease 
unwanted heating. Nonetheless, for additional validation, thermocouples measurements were 
also made. 
In the present work, thermocouple utilization for temperature measurements 
provided a good insight into the thermal behaviour of the created arrangements without and 
with FUS. In the heating arrangement without FUS, utilization of thermocouples allowed real 
time monitoring of the temperature rise and, by that, deciding when to move the plate to the 
lower temperature heater. The initial thermal evaluation of the heating arrangement without 
FUS generated parameters for the cell work. In the thermal measurements of the inverted and 
regular plates in Figure 4.40 it can be seen that there is a greater difference between the 
temperature of the inner well base, cell monolayer location, and the outer well base, marked 
by the green and pink lines, respectively, in the regular positioning of the plate compared to 
the inverted plate, 4 - 8°C difference and 0.5 - 2°C difference, respectively. Additionally, in the 
case of the inverted plate, the cells receive heat from the surrounding media rather than 
through the plastic base. In the latter, because of the proximity of the plastic to the cells the 
transmitted heat can cause a sudden, spatially nonuniform temperature rise in the cell 
monolayer which can result in inconsistent results and even cell death. As can be seen in the 
results, the heating arrangement without FUS proved to be a successful control for the FUS 
induced heating, simulating the same thermal behaviour. In both arrangements similar 
temperature profiles, consisting of a fast rise of several degrees followed by a thermally 
constant state, were achieved. This special pattern of local heating can be useful in local drug 
delivery and hyperthermia treatments (Chen et al., 2010).  
The rationale behind the design of the UF heating arrangement was to utilize a 
commercially available US absorber material with good heat conductivity as a heat conductor 
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to the cell monolayer. A good candidate for such a purpose was the DQA tissue mimicking 
phantom. In theory, according to Appendix vi, at a height of 36 mm, the DQA phantom should 
absorb 41% of the transmitted intensity. In practice, according to the measurements 
presented in Figure 4.55, the DQA phantom absorbed slightly more, about 48%, of the acoustic 
intensity when placed below the plate.  
The thermal evaluation of the UF heating arrangement with thermocouples provided 
some insights regarding the sonication modes in regular and inverted positions. At the same 
power, in the regular position, the temperature rise at the base of the plate, i.e. the cell 
monolayer location, was larger and had relatively more impact on the neighbouring wells 
(Figure 4.42). In the inverted position, the cells were heated through the medium in the well 
and hence the heat distribution was much more uniform with less potentially damaging 
influence on the cell monolayer. However, as can be seen in Figure 4.42, the temperature rise 
in the inverted plate, ∆ ≈ 10°C, is lower compared to the regular position, ∆ ≈ 20°C.  
To gain a higher temperature rise in the inverted plate, greater power was applied 
(Figure 4.43). In the initial sonication, which provides the initial temperature rise in the plate, 
the power was increased from 20 Wa for 10 s with total energy of 200 J, to 60 Wa for 15 s with 
total energy of 900 J. Because of this increase, the mode of 0.5 s on, 2.5 s off was no longer 
found suitable since a constant rise in temperature appeared throughout the pulsed sonication 
i.e. the slope of the increase marked with the first red line in Figure 4.43. A sonication mode 
with longer cooling time, 0.5 s on, 3 s off, provided a more constant temperature i.e. the 
reduced slope of the increase marked with the second red line in Figure 4.43.  
Because of concerns about cell viability the power was decreased by a factor of two in 
the final experiments, and the time was increased by the same factor, hence maintaining the 
same energy (900 J), yet with a more gradual delivery. 
From Figure 4.55, it can be seen that there is some US influence on the neighbouring 
wells in the plate. It is important to notice that the influence on the neighbouring wells occurs 
at FD = 82 mm, regardless of the presence of a phantom. The intensity of the field in the 
neighbouring wells is 66% of the intensity transmitted into the target well. Consequently, to 
reduce the mentioned US influence and lower the level of heat transfer between wells and 
accumulation in neighbouring wells, the treatment group wells were separated by air-filled 
neighbours, Figure 4.21.   
Thermocouple monitoring of heat propagation throughout the plate during heating 
without FUS resulted in accurate real time measurements. However, in the FUS induced 
heating arrangement, the use of thermocouples is rather doubtful. Although thermocouples 
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are in use in measuring temperature rises due to US (Dasgupta et al., 2011), the results should 
be carefully considered for their accuracy in an US field. As explained in Section 4.1.3.2, when 
the thermocouples are placed in US fields, they can produce artefacts such as a false rapid 
temperature rise. Nonetheless, if the initial temperature rise is ignored, according to the “wait 
then measure” approach (Morris et al., 2008), and with proper positioning of the 
thermocouples, i.e. away from the focal point, accurate data can be achieved.   
In the sonoporation arrangement, the thermocouple measurements of possible 
heating occurrence because of sonication at 2.5 Wa for 60 s, i.e. 150 J, have shown that the 
maximum possible temperature rise at the base of the sonicated well is about 4°C, and 1°C in 
the neighbouring well (Figure 4.27). According to the thermal camera measurements, the 
same energy level of 150 J due to sonication of 2 Wa for 75 s, the temperature rise at the 
perimeter of the well was 5.2°C ±0.25°C. 
 These measurements were done at an energy a factor of 3 to 15 higher than the ones 
used in the final protocols for sonoporation cell experiments. This suggests that during the 
sonoporation experiments at 10 J and 50 J the temperature rise was approximately 0.26°C - 
0.72°C and 1.3°C - 1.73°C, respectively. The overall thermal evaluation of the sonoporation 
arrangement by both thermal camera and thermocouples suggests that there is no significant 
temperature rise as a result of sonication at 10 J, e.g. 1 Wa for 10 s, and even at 50 J, e.g. 2 Wa 
for 25 s. 
According to the evaluation of the US properties of the base and seal of the plate in 
Figure 4.45 - Figure 4.50, there is minimal absorption of US in the tested parts and hence they 
are suitable for sonication of cell monolayers.    
Following the assessment for the optimal sonication beam, it can be seen in Figure 
4.51, that the 50% Tr has a wider focal zone than 100% Tr, yet it retains the same focal shape, 
while at a lower excitation percentage of the transducer, e.g. 20%, the focal beam is distorted. 
From the sagittal slice in Figure 4.52, it can be seen that the focal point of 50% Tr is 
significantly longer than for 100% Tr and has higher focal intensity than for 20% Tr. According 
to Table 4.2, which presents the measurement at FD = 82 mm, 50% Tr has the optimal power 
to diameter ratio. The diameter of the focal point generated by 50% Tr is 2.17 mm, which is 
40% higher than for 100% Tr and lower by 40% than for 20% TR, yet the intensity of 50% Tr is 
25.6 W / cm2 which is 47% higher than the 20% Tr focal intensity, 17.3 W / cm2. Therefore, 50% 
Tr has a wider focal diameter than the nominal 100% Tr, yet it retains a relatively high intensity 
at the focal point compared to lower percentage of Tr. From these results, 50% Tr was chosen 
to be the optimal sonication pattern.  
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The measured values of the focal sizes at FD = 82 mm as presented in Table 4.2, are 
consisted with the calculation preformed according to equations in Appendix iii, e.g. the focal 
diameter of 50% Tr at FD = 82 mm is 2.17 mm and 2.2 mm according to the measurement and 
the calculation, respectively. This has proven that the theoretical calculations can be used to 
define the focal sizes at various beam forms and parameters. According to the calculations, the 
focal diameter of 50% Tr at FD = 97 mm, is 2.6 mm. 
To define the optimal FD, acoustic measurements at different FDs were performed, as 
shown in Figure 4.54. All the measurements were conducted with the optimal sonication 
pattern, 50% Tr. From Figure 4.54, it can be seen that at FD = 97 mm the ultrasonic pressure is 
the most uniform in the well. Moreover, at FD = 97 mm there is minimal effect on the 
neighbouring wells due to sonication, marked by red arrows in Figure 4.54. 
The establishment of the CBS arrangement for cell sonication, Figure 4.16, provided 
the opportunity for multi-focal sonication patterns. According to the US evaluation of the 
multi-focal patterns it provides efficient delivery of the beam at 16 foci simultaneously. 
Moreover, the focal area remains the same as in the single focus case, which is still smaller 
than the single well area, Ø = 7 mm. The distance between every two points in the grid of the 
96-well plate is 9 mm (Appendix ii), suggesting that the planned pattern hit its targets exactly. 
The intensity deviation of the spots was up to 7% from the average, allowing similar acoustic 
properties for each well. The multi-focal patterns have shown good Eff and Uni levels, both 
over 85%, meaning that most of the power reaches the targets in a relatively uniform pattern.  
 Conclusions 4.5
In this chapter the design and evaluation of the different arrangements for in-vitro 
USmTDD application, were presented. The thermal evaluation of the sonoporation 
arrangement confirmed that no significant heating occurred during sonication at the tested 
powers and energy levels that correspond to the ones used in vitro. The meaning of this is that 
during FUS application in the sonoporation arrangement any observed in-vitro effects will 
correlate solely to the US related physical effects on cells. MRI thermometry measurements of 
the heating generated during the application of FUS induced heating, confirmed that the 
designed sonication mode can be used to achieve temperature rise in a hyperthermia mode. In 
the heating without FUS arrangement thermocouple measurements validated that the heating 
mode applied without FUS is similar to the one observed in the FUS induced heating 
arrangement. This confirmed that the heating without FUS arrangement can be utilised as a 
control model for evaluation of hyperthermia related mechanisms occurring in-vitro. The 
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conducted acoustic measurements confirmed that the sealing film and base part of the plate 
are suitable for in vitro USmTDD research. Furthermore, by the acoustic evaluation of the 
beam propagation a specific beam pattern and focal point height were chosen for the in-vitro 
studies. The acoustic measurements in the CBS arrangement for multifocal cell sonication 
confirmed the uniformity and efficiency in the beam distribution within 16 focal spots.     
 The overall evaluation of each arrangement with several methodologies has resulted 
in sets of parameters for cell application in each arrangement. The results of the in-vitro cell 
work are presented in Chapter 5. 
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 FOCUSED ULTRASOUND APPLICATION CHAPTER 5
ON CELLS – AN IN-VITRO STUDY 
 Introduction  5.1
USmTDD was first realized in 1974, and has been widely investigated since then 
(Tachibana and Tachibana, 2001). The implementation of non-invasive surgery techniques such 
as FUS in conjunction with a targeting moiety can produce new platforms for safe, site specific 
drug delivery. In this chapter a brief introduction is given on the interaction of US with living 
cells and current studies in this area followed by the in-vitro results achieved via the dedicated 
arrangements described in Chapter 4. 
 Therapeutic Ultrasound and Cells 5.1.1
US waves can propagate through soft tissues resulting in thermal and mechanical 
effects on the cells. Although these biophysical effects are commonly divided into two 
separate trends, with application of US in vivo, the mechanical and thermal effects occur 
simultaneously, and are thus inseparable (Baker et al., 2001). Nonetheless, when investigating 
the fundamental acoustic impacts on cells, the two effects should be isolated as much as 
possible from one another to accurately assess the overall bioeffects of US on cells. 
 Thermal Effects of Ultrasound 5.1.1.1
US generation of heating in tissues is probably the best understood mechanism of US 
behaviour in vivo (Frenkel, 2008). The thermal effects of US currently used in tissue ablation in 
FUS surgery are described in Section 02.4.5. Stable, controlled heating can be achieved in 
tissue via the application of a focused ultrasonic beam (ter Haar, 1995). Utilization of this 
temperature rise can allow in situ heating to achieve moderate hyperthermia. This is known 
for its ability to increase cellular uptake of anticancer drugs (Chen et al. 2010). Moreover, 
hyperthermia modes were investigated recently, in conjunction with MBs, to enhance cellular 
uptake of anticancer agents in vivo (Yudina et al., 2012). 
 Mechanical Effects of Ultrasound 5.1.1.2
Ultrasonic enhancement of cell membrane permeability using MBs is a widely 
investigated field of research. Enhancement of cell membrane permeability is often considered 
to occur via the formation of holes in the cell membrane (Ferrara, 2008). The diameters of the 
holes that are created determine whether the effect is reversible, for drug delivery into living 
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cells, or necrotic, resulting in cell death (Böhmer et al., 2009). There are two different 
mechanical ultrasound effects that cause cell membrane distortion - inertial and stable 
cavitation. During stable cavitation, bubbles oscillating in proximity to the cells produce 
“cellular massage” (Wu and Nyborg, 2008). Inertial cavitation is the process where bubbles 
imploding near the cell membrane cause “sonoporation” effects (Pitt at al., 2004). 
MBs as Ultrasonic Contrast Agents Initially MBs were developed as a tool in 
diagnostic US. Hence, they must be small enough to go through the capillary vessels (<8 m) 
(Duck et al., 1998). As research advanced, the use of MBs for therapeutic purposes became of 
interest (Mayer et al., 2008; Wu and Nyborg, 2008). MB consist of a gas core entrapped in a 
polymeric/ lipid shell of 2 – 500 nm thickness, Figure 5.1, and sizes usually vary between 1 - 8 
m with an average of about 2.5 m. 
 
Figure 5.1- Sonovue MBs 
First generation MBs had an air filled core but because of stability issues, second and 
third generation MBs progressed to sulphur hexafluoride (SF6)- such as the Sonovue MB, 
Figure 5.1, or perfluorocarbon core fillings (Hernot and Klibanov, 2008). A general estimate of 
the correlation between MI and MB behaviour in an US field is presented in Table 5.1. 
Table 5.1- MBs deformation dependance on the MI 
Mechanical Index (MI) MB Physical Condition 
Higher than 0.6 
 
0.6 
 
0.3 
 
0.1 
 
0.05 
Bubble Destruction 
Stable Cavitation State: Non-linear 
Oscillation, Backscattering at Various 
Frequencies (sub-harmonics, ultra-
harmonics etc.) 
Linear Oscillations: Inversely 
Proportional to Pressure, Linear 
Backscattering 
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There is an inverse correlation between the MB diameter and the resonance frequency 
(Greis, 2004). At the average Sonovue MB size of 2.5 m, the measured resonance frequency is 
about 3 MHz, while for slightly larger bubbles, of 4 μm diameter, it is around 1.6 MHz (Meer et 
al., 2004). Formulations of MBs are constantly under development and testing for their 
potential contribution to site specific drug delivery (Tinkov et al., 2010). Recent studies have 
shown that the use of Sonovue MBs can increase cell permeability in vitro in the presence of 
US (Yudina et al., 2010). The advantages of using such commercially available MBs are both 
safety, as the MBs are approved for clinical use with rare adverse side effects (Bokor et al., 
2001; Stewart and Sidhu, 2006), and to provide already investigated background (Greis, 2004). 
 Current Trends in USmTDD Research in vitro 5.1.1.3
In today’s research, US is being explored for various drug delivery methodologies such 
as gene therapy, drug release from vehicles such as liposomes (Schroeder et al., 2009), 
nanocarriers, micelles (Husseini and Pitt, 2008) etc., protein delivery, and small structured 
chemical drug delivery (Pitt, 2004), with nominal frequencies being 1 MHz and 500 KHz for 
drug and gene delivery (Mitragotri, 2005). There are several mechanisms by which US can aid 
TDD. Some of the approaches are based on ultrasonic modification of the cell layers, whereas 
others utilize US as a drug release stimulus from vehicles by thermal or mechanical effects. 
When discussing sonoporation as a TDD method, numerous data were collected in the past 
two decades and have been summarised in many reviews indicating the on-going interest in 
this field (Byl, 1995; Tachibana and Tachibana, 2001; Bekeredjian et al., 2005; Polat et al., 
2011).  
Referring to the experimental data described in the literature for cell poration, several 
setup related principles become apparent: 
I. US exposure is mostly done in cell suspensions (Ashush et al., 2000; Sundaram et 
al., 2003; Karshafian et al, 2009). 
II. Sonications are carried out in a dedicated chamber (Guzman et al., 2001; Feril Jr. 
et al., 2002), in an Opti-cell environment (Eisenbrey et al., 2009; Feril Jr. et al., 
2010) or in wide petri-dishes (Conti et al., 2004; Hundt et al., 2009). 
III. Most of the acoustic sources in use are bespoke transducers (Yudina et al., 2010; 
Wang et al., 2010). 
The decision to work in cell suspension is very attractive. While it may seem the 
straightforward way to introduce US into cells due to the relative simplicity of handling cells in 
suspension, this model is significantly far from cellular structures in vivo. Although cell 
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monolayers can rarely mimic accurately the in-vivo system, they are much closer to real cell 
behaviour in existing tissue.  
When applying US to cells, especially into a cell monolayer, the sonication chamber is 
highly important. From an acoustical point of view it must be transparent to US propagation, 
without attenuation, with good coupling to the transducer, preferably by degassed water. 
Moreover, the excess acoustic energy propagating outside the chamber is also important 
since, without a proper acoustic absorber, e.g. absorbing material or excess water, the energy 
can be reflected back into the chamber. Any reflection from the chamber walls or other 
components should be taken into consideration in the construction and evaluation stages of 
the arrangement. From a biological point of view, the chamber should be sterile to allow 
healthy cell growth, sealed for the time of exposure, yet accessible for cell handling and, most 
important, with isolated control groups.  
When working in a single chamber environment, it is practically impossible to achieve 
isolated control groups undergoing the same conditions. Although the Opti-cell chamber is 
designed for cell work, and is also US transparent, it lacks this isolated control, which positions 
it in this work as a purely optical observation tool with outcomes presented below. Figure 5.2 
depicts the effects of sonication by the ExAblate 2000 UF system on A375m cells observed in 
an Opti-cell chamber at different powers. As can be seen, at the lower power of 5 Wa there is 
no visual difference due to sonication, whereas at the higher power of 20 Wa there is a 
detached cell agglomerate.  
 
Figure 5.2- 5 Wa continuous sonication for 20 s (a) prior to sonication, (b) after sonication (c) 
after 20 Wa continuous sonication  
Although it is clear from Figure 5.2(c) that there is significant destruction of the cell 
monolayer, since the Opti-cell is a unitary chamber there is no possibility to assess the scale of 
damage to the cells due to FUS application.   
In addition to the importance of the cell environment, the type of US source also has 
an impact on the final results achieved in sonoporation. Furthermore, the lack of proper 
monitoring of the applied US may result in inaccurate conclusions.  
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As a part of the search for the optimal cell sonication arrangement in the presented 
work, a dedicated cell sonicator was tested, as shown in Figure 5.3.  
 
Figure 5.3- Bespoke cell sonicator (a) without and (b) with a plate  
Although the in-vitro cell sonicator has the potential to become a useful instrument for 
investigation of USmTDD, in practice proper monitoring tools such as input and output data of 
all the sonication parameters, cavitation detection and thermal isolation are still under 
development.  
 
Figure 5.4- (a) uptake of Dox and (b) viability of MCF7 cells without and with FUS 
Early Dox uptake results from this system looked promising, such as an increase by a 
factor of 2.3 compared with non-sonicated cells, in a single point measurement, as shown in 
Figure 5.4, but unfortunately this data had poor repeatability. As previously mentioned, 
because of the cylindrical shape of the wells, a secondary focus is created. In the bespoke cell 
sonicator an absorbing material was placed on top of the plate to absorb any excess of 
acoustic waves. In practice, air bubbles created on the surface of the absorbing material 
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reflected the acoustic energy back into the well, creating possible standing waves, acoustic 
streaming and additional foci. All of these phenomena are hard to monitor in a relatively 
simple cell sonicator; therefore, it caused an inconsistency in the achieved results and no 
possibility to draw reliable conclusions on the mechanism of cell behaviour due to FUS.  
An additional example of the lack of consistency in results from such a system can be 
seen in the viability studies presented in Figure 5.54b. This represents the viability summary 
for two plates sonicated with the same FUS parameters and under the same experimental 
conditions. As can be seen from the values in Figure 5.4, although in each plate the results 
seem consistent, Sd = ±4%, there is a factor of 5.6 difference between the two tested plates.  
 
Figure 5.5- MCF7 cells (a) control without FUS (b) FUS plate #1 and (c) FUS plate #2 
Figure 5.5 presents the cell images corresponding to the treatment groups in Figure 
5.4. As can be seen for the cell images, there is indeed a major variation between the cells 
after sonication in the two different plates, where in Figure 5.5(b) except for a single cell 
agglomeration, the well is empty of cells, and in Figure 5.5(c) there is a relatively intact cell 
monolayer. The cell images correspond to the viability values presented in Figure 5.4b, where 
the wells in plate #1 are mostly empty of viable cells, 14% ±4%, and the wells in plate #2 
contain up to 79% ±4% viable cells. These variations are attributed to the random occurrence 
of cavitation. To overcome this problem and achieve more uniform results, MBs were used as 
cavitation nuclei in later work.  
FUS Induced Heating for TDD An additional means of US facilitated TDD is via a 
local temperature rise. Hyperthermia can assist in the process of drug delivery both as a 
release mechanism from drug carriers (Kost et al., 1989; Schroeder et al., 2009) as well as to 
increase the cellular permeability (Feril Jr. et al., 2002).  All the qualifications regarding the 
design of the sonoporation arrangement mentioned above apply for thermal application of US 
as well. Furthermore, the utilization of US induced hyperthermia requires accurate 
temperature monitoring (Moonen, 2010).   
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 Aims and Objectives 5.1.2
The aim of this chapter is to demonstrate the feasibility and efficiency of the 
arrangements created with the ExAblate clinical MRgFUS system for in vitro applications. 
Despite the fact that application of US behavioural studies to clinical environments is generally 
conjectural (Baker et al., 2001), the results achieved in vitro may serve as a fundamental 
baseline for studies in vivo. 
 Materials and Methods 5.2
 Materials  5.2.1
Table 5.2- Materials for in-vitro work 
Material Manufacturer  Place of 
Origin 
Notes 
Equipment    
1.5 Tesla MRI system General Electric USA Model: Signa HDX 
ExAblate 2000 InSightec LTD Israel UF, 0.95-1.35 MHz  
ExAblate 2100  InSightec LTD Israel CBS, 550 kHz 
Tecan infinite  Tecan  UK Model M200 
Stuart Heat-Stir  Barloworld 
Scientific 
UK Model: CB162 
Techne Dri Block  Techne UK Model: DB-20 
Thermocouple data logger  Omega UK Model TC-08 
Thermocouples  Omega UK Omega T type, 0.25 and 
0.076 mm wire diameters 
Cell Culture    
MCF7 cell line ATCC USA  
A375m cell line ATCC USA  
Consumables    
Daily quality assessment (DQA) gel 
phantom 
ATS Laboratories USA  
96-well plates  Greiner Austria Polystyrene cell culture 
microplates with μClear® 
bottom 
Black 96-well plates  Greiner Austria Non cell culture treated 
black base microplates  
Cell culture flasks TPP UK 75 cm
2
 
Titer Top ™  ealing film ESM USA  
Opti- cell NUNC Denmark  
Syringe filters  Thermoscentific UK Pores diameter of 0.2 mm 
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Sonovue®  Bracco Italy  
Chemicals    
Roswell Park Memorial Institute 
(RPMI) 1640 medium  
Gibco Invitrogen UK  
Dulbecco's Modified Eagle Medium 
(DMEM) 
Gibco Invitrogen UK  
Fetal Bovine Serum (FBS) Gibco Invitrogen UK  
Penicillin Streptomycin (P/S)  Gibco Invitrogen UK (5000 I.U./ml, 5000 lg/ml) 
Dimethyl Sulfoxide (DMSO)  Gibco Invitrogen UK  
Trypsin- Ethylenediaminetetraacetic 
acid (EDTA)  
Gibco Invitrogen UK 0.05% 
Membrane Integrity Kit Invitrogen UK  
Phosphate Buffered Saline (PBS)  Oxoid UK  
Sodium Dodecyl Sulfate (SDS) Sigma Aldrich  UK  
Bovine Serum Albumin (BSA) Sigma Aldrich  UK  
Bicinchoninic acid (BCA) and Cu(II) Sigma Aldrich  UK  
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 
Sigma Aldrich  UK  
Doxorubicin (Dox) Discovery UK  
 Methods 5.2.2
 Cell Growth and Maintenance 5.2.2.1
The two cancer cell lines used in this study were MCF-7, human breast cancer cells, 
ATCC HTB-22, and A375m, human melanoma cells, ATCC CRL 1619. The cells were cultured in 
complete medium (CM), as monolayers in 75 cm2 cell culture flasks in humidified air with 5% 
CO2 at 37°C. Twice each week, the cell cultures were subcultured. Each flask was washed with 
10 ml of Phosphate Buffered Saline (PBS) to remove any dead cell and remains of old media.  
Straight after washing, the cells were detached using 1.5 ml of trypsin- 
ethylenediaminetetraacetic acid (EDTA) 0.05% and heated for 5 min at 37°C. Ten ml of 37°C 
pre-heated CM was added and the cells were transferred into 15 ml Eppendorf tubes and 
centrifuged for 5 min at 750 rpm. The CM was removed and the cells were re-suspended in 10 
ml fresh CM. 1.5 ml of the solution was re-seeded in a new flask with an additional 15 ml CM. 
For US exposure experiments, 15,000 cells per well in 100 µL CM were seeded in 96-well plates 
three days in advance to reach confluence on the day of the experiment. 
 Evaluation of Drug Uptake into Cells  5.2.2.2
The uptake of Dox into both cell lines was investigated using fluorescence intensity 
measurements. Prior to the FUS / heating application, the medium in each well was replaced 
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with 420 µL of various solutions, as described in the appropriate plate descriptions for each 
arrangement in Figure 4.8, Figure 4.17, Figure 4.19 and Figure 4.21, and the plates were sealed 
using Titer-Tops® sealing film. Following sonication, the cells were washed twice with 100 µL of 
PBS. The PBS was removed and the cells were lysed using 0.5% SDS. The total fluorescence 
intensity of each well in the plate was measured under the conditions in Table 5.3:  
Table 5.3- Fluorescence measurement parameters 
Parameter Value 
Excitation wavelength 485 nm 
Emission wavelength 592 nm 
Excitation bandwidth 20 nm 
Gain 100 
Number of flashes 25 
Integration time 20 s 
Temperature Room temperature (RT) 
 
The fluorescence readings were normalized by total protein amount using the BCA method 
(Smith et al., 1985). The uptake of Dox was calculated as: 
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Equation 5.1- Uptake calculation 
 Cell Viability Evaluation   5.2.2.3
The viability of cells after US exposure was measured using MTT 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide- a colorimetric assay that determines 
the cell enzymatic activity (Gerlier and Thomasset, 1986). Prior to the FUS / heating 
application, the medium in each well was replaced with 420 µL of various solutions, as 
described in the appropriate plate descriptions for each arrangement in Figure 4.8, Figure 4.17, 
Figure 4.19 and Figure 4.21, and the plates were sealed using Titer-Tops® sealing film. 
Following sonication, the cells were washed twice with 100 µL of PBS. 100 µL of fresh CM was 
added and the cell viability was determined immediately for cell loss studies or incubated at 
37°C in 5% CO2 for 24 h for cell recovery studies.  
185 
 
 
At the end of the incubation period, 20 µL of MTT was added, and the cells were 
incubated at 37°C in 5% CO2 for an additional 3 h, after which all the liquid was removed and 
100 µL of DMSO was added to dissolve the Formazan- an artificial chromogenic product 
created by the reduction of the tetrazolium salt (MTT) (Cole, 1986; Twentyman and Luscombe, 
1987). The plate was shaken linearly in the Elisa plate reader at 1 mm for 50 s and the 
Formazan absorbance was measured at 550 nm. The cell viability was calculated with 
                (
                               
                                
)      
Equation 5.2- Cell viability calculation 
 Membrane Integrity 5.2.2.4
A membrane integrity test was conducted to quantify the levels of membrane 
permeability due to US application (Cho et al., 2002). In the presence of MBs, US is known to 
increase cell membrane permeability. Therefore, measurement of lactate dehydrogenase 
(LDH) levels released from leaking membrane into the media can indicate the levels of 
membrane permeability achieved by US. A membrane integrity assay was conducted using the 
CytoTox-ONE kit according to its nominal protocol. The level of resofurin, which is proportional 
to the amount of LDH, was measured by fluorescence intensity. Prior to US application, the 
medium in each well was replaced with 420 µL of various solutions, as described in the 
appropriate plate descriptions in Figure 4.8, and the plates were sealed using Titer-Tops® 
sealing film.  
Following sonication, the plate was centrifuged at 2000 rpm for 10 min to spin down 
any cells present in the media. 50 µL of the medium in each well were transferred into a new 
black 96-well plate and an equivalent amount of resazurin reagent was added. After an 
incubation period of 10 min at RT, the stop solution was added and the fluorescent signal was 
measured with an excitation wavelength of 560 nm and emission wavelength of 590 nm. The 
fluorescence readings were normalized by the total protein amount using the BCA method 
(Smith et al., 1985). The membrane permeability was calculated with 
                       
(
    [   ]                 
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Equation 5.3- Membrane permeability calculation 
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 Cell Total Protein Estimation: The Bicinchoninic Acid Assay 5.2.2.5
The estimation of the total protein located in each well after treatment, was quantified 
as noted using a BCA assay. BCA (Bicinchoninic Acid) forms a complex with Cu(I) that results in 
a purple solution with maximum absorbance at 562 nm. Cu(I) appears in the solution as a 
result of reduction from Cu(II) after reaction with proteins. This is a highly sensitive protein 
concentration-dependent reaction (Smith et al., 1985). 
Following the fluorescence measurement of the plate, 150 µL of the cell solution in 
each well were transferred into a new plate and 50 µL of BCA Working Reagent (WR) were 
added to the individual wells. Additionally, each plate contained a duplicate of a standard 
curve and triplicate of background, i.e. 150 µL of 0.5% SDS with 50 µL of the BCA WR. After 
addition of the BCA WR the plates were shaken linearly at 1 mm for 30 s and incubated at 37°C 
in 5% CO2 for 1 h. At the end of the incubation time the absorbance of the plate was measured 
at 562 nm.  
The final protein quantity in the samples after deduction of the background was 
derived from the average standard curve for each plate. Since the BCA assay does not have an 
end point, it is important to have a standard curve for each plate to accurately assess the 
amount of protein in each sample. Unfortunately, the BCA assay standard curve supplied in the 
kit was not compatible with the tested samples. It consisted of Bovine Serum Albumin (BSA) at 
significantly higher concentration than the samples in a plate and hence the measurements 
were at the noise level of the standard curve. Moreover, the supplied BSA was dissolved in a 
different solvent than the samples resulting in a need for different background and was thus 
generally incomparable. Consequently, the BSA standard curve was adjusted to the specific 
needs of the experiments. The final standard curve solutions consisted of BSA in 0.5% SDS, the 
same as the cell sample, with linearly increasing concentration from 6.25gml to 400 gml.  
 Solution Preparation 5.2.2.6
PBS (Phosphate Buffered Saline) Five tablets of PBS were dissolved in 500 ml of 
purified water in RT and the solution was autoclaved. The solution was kept at RT before 
opening, and after opening was stored in a fridge. 
Complete Media (CM) CM consists of Roswell Park Memorial Institute (RPMI) 1640 
medium  for A375m and Dulbecco's Modified Eagle Medium (DMEM) for MCF-7 supplemented 
with 10% Fetal Bovine Serum (FBS) and 1% Penicillin Streptomycin (5000 I.U./ml, 5000 lg/ml). 
The solution was stored in a fridge. 
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MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 250 mg 
of the MTT salt was added to 50 ml PBS, final concentration 5 mg/ml. The solution was stirred 
using a magnetic stirrer until all solid was dissolved. The solution was filtered using a 0.2 mm 
filter, then aliquoted into Eppendorf tubes in 5 ml/tube ratio and kept frozen until use. 
Sodium Dodecyl Sulphate (SDS) Solution For the final concentration of 0.5% SDS 
in H2O, 500 mg of SDS was dissolved in 1 L purified water. The solution was kept at RT. 
Bovine Serum Albumin (BSA) To achieve a concentration of 400 µg/ml (mother 
solution), 400 mg BSA was dissolved in 1 L of SDS 0.5%, as described in Section  5.2.2.5. 
Solutions of 200, 100, 50, 25, 12.5, and 6.25 µg/ml, were created by dilution of the mother 
solution with 1:1 volume of 0.5% SDS.  All solutions were kept in a fridge. 
Preparation of the BCA Assay Reagent The BCA WR consisted of Cu(II) sulphate 
pentahydrate 4% solution and BCA solution of 1:8 ratio, freshly prepared on the day of the 
experiment. 
Dox Solution Dox was kept in stock solution consisting of DMSO at a concentration of 
100 mM, referred to as ‘stock solution’. The amount of Dox was weighted according to the 
following calculation:  
         
Equation 5.4- Weight dependence on concentration and volume 
where G is the mass, Mw is the molecular mass, C is the concentration, and V is the volume of 
the final solution. Therefore to prepare a 100 mM solution in 1 ml of DMSO, 58 mg of Dox was 
weighed. On the day of the experiment, the Dox concentration in CM was adjusted according 
to 
            
Equation 5.5- Correlation between volumes and concentrations 
where C stands for concentration, and V for volume. According to Equation 5.5, to convert 
100 mM of Dox in DMSO into a volume of 50 ml with a final concentration of 25 µM of Dox in 
CM (referred to as ‘final solution’), one must take 12.5 µl of the stock solution. Each stock 
solution was kept refrigerated for no longer than 3 months and the final solutions were always 
prepared freshly on the day of experiment. 
Carrier (Ca-1709) Solutions Solutions of Ca-1709 were prepared in media with and 
without Dox depending on the experiment. The ratio between the Ca-1709 and Dox was 20:1. 
Hence when a concentration of 25 µM of Dox was used, the Ca-1709 concentration was 
500 µM. The Ca-1709 was added to the final Dox solution . The weight of Ca-1709 was 
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calculated according to Equation 5.3. For the desired concentration of 500 µM at a volume of 
50ml, 37.35 mg of Ca-1709 was added to the Dox solution/CM at RT. The final solutions were 
vortexed for 1 min and used immediately. For viability studies, all the solutions were filtered 
using 0.2 mm filters. 
Dox with Sonovue MB Solution The Sonovue MBs were prepared on the day of the 
experiment according to the manufacturer’s instructions and kept in an ice bath during the 
experiment. 0.5 ml of the Sonovue solution was added to 10 ml of Dox or CM solutions, to 
reach the final concentration of 4.7%, i.e. 4·106 bubbles/well.  
 Sonication and Heating Protocols  5.2.2.7
UF Sonoporation Arrangement The plate layout for cell sonication in the UF 
sonoporation arrangement is presented in Figure 4.8. From there it can be seen that wells 
B - G in rows 2, 4 and 6 were sonicated and wells B - G in rows 9 and 11 were control wells with 
no sonication. Line H1 - 6 was a negative control, meaning it did not undergo any treatment 
and was not subjected to FUS. For cellular drug uptake experiments, Section 5.2.2.2, the 
following solutions were used: Dox with Sonovue MBs, Dox only, and negative control, line 
H1 - 6, that consists of 100 µl of the existing CM filled with an additional 320 µl of fresh CM. 
For the viability and membrane integrity studies, CM with and without Sonovue MBs was used. 
Following the sealing of the plate, it was placed in its dedicated location in the water 
container, Figure 4.14. The temperature of the water in the container was preset to 30°C. After 
positioning the plate, the polystyrene thermal isolation box was placed over the apparatus and 
the sonications were performed according to the prepared protocol. All the sonications were 
performed at the optimal sonication configuration for the UF sonoporation arrangement i.e. 
50% Tr at FD = 97 mm. Immediately after sonication, the plate was returned to the culture 
hood and treated according to the protocols in Section 5.2.2. 
CBS Sonoporation Arrangement The plate layout for cell sonication in the CBS 
sonoporation arrangement is presented in Figure 4.17. From there it can be seen that wells 
C - G in rows 5 - 8 were sonicated and wells B - G in rows 2 and 11 were control wells with no 
sonication. Line H1 - 6 was a negative control, meaning it did not undergo any treatment and 
was not subjected to FUS. For cellular drug uptake experiments, Section  5.2.2.2, the following 
solutions were used: Dox with Sonovue MBs, Dox only, and negative control, line H1 - 6, that 
consists of 100 µl of the existing CM filled with an additional 320 µl of fresh CM. For the 
viability studies, CM with and without Sonovue MBs was used. Following the sealing of the 
plate, it was placed in its dedicated location in the water container, Figure 4.16. The 
temperature of the water was preset to 30°C. After positioning the plate, the cells were 
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subjected to FUS using the multi-focal sonication pattern. All the sonications were performed 
at the optimal FD = 62 mm. Immediately after sonication, the plate was returned to the culture 
hood and treated according to the protocols in Section 5.2.2. 
UF Heating Arrangement The plate description for cell sonication in the UF heating 
arrangement is presented in Figure 4.21. From there it can be seen that wells C, E and G in 
rows 2, 4, 6 and 8 were sonicated, while wells B - G in rows 9 - 11 were control wells with no 
sonication. Line H1 - 6 was a negative control, meaning it did not undergo any treatment and 
was not subjected to FUS. For cellular drug uptake experiments, Section 5.2.2.2, the following 
solutions were used: Dox with Ca-1709, Dox only, and negative control, line H1 - 6, that 
consists of 100 µl of the existing CM filled with an additional 320 µl of fresh CM. For the 
viability studies, CM with and without Ca-1709 was used. Following the sealing of the plate, it 
was placed in its dedicated location in the water container, Figure 4.20, with DQA phantom 
above and below. The temperature of the water in the container was preset to 30°C. After 
positioning the plate, the polystyrene thermal isolation box was placed over the apparatus and 
the sonications were performed according to the prepared protocol. All the sonications were 
performed at the optimal sonication configuration for the UF heating arrangement i.e. 50% Tr 
at FD = 82 mm. Immediately after sonication, the plate was returned to the culture hood and 
treated according to the protocols in Section 5.2.2. 
Heating without FUS The plate description for cell sonication for heating without 
FUS is presented in Figure 4.17. From there it can be seen that wells C, E and G in rows 2 - 6 
were subjected to heat, while wells B - G in rows 9 - 12 were control wells without heating. 
Line H1 - 6 was a negative control meaning it did not undergo any treatment and was not 
heated. For cellular drug uptake experiments, Section 5.2.2.2, the following solutions were 
used: Dox with Ca-1709, Dox only, and negative control, line H1 - 6, that consists of 100 µl of 
the existing CM filled with an additional 320 µl of fresh CM. For the viability studies, CM with 
and without Ca-1709 was used. Following the sealing of the plate, it was placed on top of the 
heating blocks as shown in Figure 4.18. Immediately after heating, the plate was returned to 
the culture hood and treated according to the protocols in Section 5.2.2. 
 Results 5.3
 Sonoporation with UF System  5.3.1
To evaluate the efficiency of the UF sonoporation arrangement for cell sonication, 
uptake, viability and membrane integrity studies were conducted. 
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 The Influence of FUS on Dox Uptake  5.3.1.1
Following the construction and evaluation of the apparatus, fine tuning of the 
sonication parameters was performed to establish the optimal sonication powers and 
patterns.  
 Investigation of Various Sonication Powers To find the optimal power for 
enhancement of Dox cellular uptake, sets of sonications were performed. The power levels of 
the various sonications conducted were chosen such that there could be comparison between 
various sonication times with the same power, e.g. 1 Wa for 50, 25 and 10 sec; the same 
sonication times with different powers, e.g. 25 s with 1 and 2 W; and the same applied energy 
in different modes, e.g. 50 J by 2.5 Wa for 20 s and 1 Wa for 50 sec.     
 
Figure 5.6- Uptake of Dox into MCF7 Cells at Various Sonication Parameters 
Figure 5.6 depicts the Dox uptake, as a % of control ±standard error (Se), into MCF7 
cells, with and without Sonovue MBs, at the various sonication powers and energy levels 
presented in Table 5.4. 
Table 5.4- Applied US powers in Dox uptake studies 
 
Total Energy [J] Pressure [MPa] Mechanical Index (MI) 
2 W, 25 sec 50 0.75 0.77 
2,5 W, 20 sec 50 0.84 0.86 
1 W, 50 sec 50 0.53 0.54 
1 W, 25 sec 25 0.53 0.54 
1 W, 10 sec 10 0.53 0.54 
0.5 W, 10 sec 5 0.37 0.38 
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Table 5.4 summarises the power levels tested for their potential in enhancement of 
drug uptake, together with their pressure and MI (as calculated according to Equation 2.10). To 
avoid destructive implosion of the MBs, all the power levels were chosen such that MI < 0.9. 
Figure 5.7 represents the Dox uptake, as % of control ±Se, into A375m cells with and without 
Sonovue MBs at the optimal sonication power of 1 Wa for 10 sec. 
 
Figure 5.7- Uptake of Dox into A375m cells at 1 Wa for 10 s 
 Establishment of Optimal Sonication Pattern To define the best sonication 
pattern (i.e. the sonication pattern having the lowest impact on the neighbouring wells) as 
presented in Figure 4.8, the uptake of Dox was examined as a function of the sonication 
pattern. 
 
Figure 5.8- Location dependence of Dox uptake into MCF7 cells at 2 Wa for 25 sec 
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Figure 5.8 presents the Dox uptake, as a % of control, into MCF7 cells at 2 Wa for 25 s 
in correspondence with the sonication number, as appears in the plate description.  
 The Influence of Focused Ultrasound on Cell Viability  5.3.1.2
Viability assays were conducted to evaluate the level of irreversible membrane 
damage which results in cell death due to the application of FUS. The viability assays were 
done at two time points, immediately after the sonication and at 24 h follow up. The 
immediate viability studies were conducted to evaluate the amount of cell loss due to FUS, 
while the 24 h studies indicated the recovery level of the remaining cells. Additionally, viability 
studies were done at higher power to serve as a safety margin. 
 
Figure 5.9- High power viability assessment in MCF7 cells 24 h after sonication 
Figure 5.9 represents the viability, as % of control ±Se, for studies conducted 24 h after 
sonication to assess the impact of US on cells at the relatively high power of 2.5 Wa for 20 s for 
safety purposes. The viability, as % of control ±Se, immediately and 24h after 1 Wa for 10 s 
sonication, of MCF7 and A375m cells, is presented in Figure 5.10. 
 
Figure 5.10- Viability of (a) MCF7 and (b) A375m cells immediately and 24 h after sonication 
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 Membrane Integrity Studies  5.3.1.3
To help establish the mechanism of uptake enhancement by MBs, the membrane 
integrity of the cells was assessed.  
 
Figure 5.11- Membrane integrity due to FUS in (a) MCF7 and (b) A375m cells 
Figure 5.11 shows the membrane permeability, as % of control ±Se, of MCF7 and 
A375m cells as defined in Equation 5.3, at a power level of 1 Wa for 10 s exposure.  
 Sonoporation with Conformal Bone System  5.3.2
To examine the accuracy in vitro of the CBS arrangement, multi-focal sonication 
pattern, uptake and viability studies were conducted. 
 Dox Uptake in a Multi-Focal Sonication Pattern 5.3.2.1
To find the optimal power for enhancement of Dox cellular uptake, set of sonications 
at different powers were performed.  
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Figure 5.12- Uptake of Dox into (a) MCF7 and (b) A375m cells with a multi-focal sonication 
Figure 5.12 shows the Dox uptake, as % of control ±Se, into MCF7 and A375m cells 
with sonication of 16, 18 and 20 Wa for 10 s using a multi-focal sonication pattern.  
Table 5.5- Average acoustic pressure and MI for different powers 
 
Pressure [MPa] Mechanical Index (MI) 
16 W 0.43 ±0.03 0.58 ±0.04 
18 W 0.46 ±0.03 0.62 ±0.04 
20 W 0.48 ±0.02 0.65 ±0.04 
 
Table 5.5 summarizes the average acoustic pressure and MI of the 16 points on the cell 
level for different acoustic power levels. 
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Figure 5.13- Average within each well of Dox uptake into (a) MCF7, (b) A375m cells and (c) 
the MI, with 20 Wa multi-focal sonication 
Figure 5.13 depicts the Dox uptake averages, as % of control ±Se, into MCF7 and 
A375m within each well of the 16 wells simultaneously sonicated at an applied power of 
20 Wa. The MI is presented at the same power in the equivalent locations.  
 Cell Viability Studies in a Multi-Focal Sonication Pattern 5.3.2.2
Viability studies were conducted to establish the impact of the multi-focal pattern on 
the cell monolayer. Figure 5.14 depicts the viability as % of control ±Se, immediately and after 
24h, due to sonication of 20 Wa for 10 s in MCF7 and various power levels in A375m cells, 
respectively. 
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Figure 5.14- Viability of (a) MCF7 cells after 20 Wa multi-focal sonication and A375m cells (b) 
immediately and (c) 24 h after multi-focal sonication at various powers  
 Sonoporation and Heating Influence on Encapsulated Drug 5.3.3
Uptake and Cell Viability  
The novel nanocarrier, Ca-1709, presented in this work was tested for its ability to 
release the encapsulated drug upon an US trigger. The application of FUS in the presence of 
Ca-1709 was examined in the sonoporation arrangement and in the heating arrangements 
which are more realistically linked to possible applications in vivo. 
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 Sonoporation Influence on Encapsulated Drug Uptake 5.3.3.1
Drug release from Ca-1709 due to MB-mediated cavitation was studied in the UF 
sonoporation arrangement. The same conditions as in the free drug sonoporation studies were 
applied, i.e. 50% Tr at FD = 97 mm. Figure 5.15 and Figure 5.16 depict the Dox uptake, as % of 
control ±Se, into MCF7 and A375m, at various power levels, in the presence of Ca-1709 with 
and without Sonovue MBs. 
 
Figure 5.15- Dox uptake into (a) MCF7 and (b) A375m cells in the presence of Ca-1709 
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Figure 5.16- Dox uptake into MCF7 cells in the presence of Ca-1709 at (a) 1 Wa for 33 s, (b) 1 
Wa for 50 s and (c) 2 Wa for 25 s 
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 Heating without Focused Ultrasound Influence on Encapsulated Drug 5.3.3.2
Uptake and Cell Viability 
To establish the influence of heating on the mechanisms of drug penetration within 
cancer cells, uptake and viability studies were conducted.  
 Dox Uptake in the Presence of Ca-1709 According to the protocol described in 
Section 5.2, each plate was placed on a 70°C heater until the base of the plate reached 42°C; 
immediately, the plate was moved to the 50°C heater for what was referred to as ‘the heating 
time’. The fluorescence of the plate was measured and the uptake as a percentage of the Dox-
only control ±Se, is presented in Figure 5.17 -Figure 5.18.  
 
Figure 5.17- Uptake of Dox into MCF7 cells in different rows after 3 min heating of a non-
inverted plate 
Figure 5.17 depicts the Dox uptake into MCF7 cells as a result of 3 min heating in each 
row of a non-inverted plate. Line (i) represents the average of Dox only, whereas line (ii) 
represents the average of Dox + carrier. Figure 5.18 depicts the Dox uptake into MCF7 and 
A375m cells in an inverted plate, as result of 3 and 6 min heating.  
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Figure 5.18- Uptake of Dox into MCF7 cells after (a) 3 and (b) 6 min and (c) into A375m cells 
after 3 min heating 
 Cell Viability in the Presence of Ca-1709 To establish the effect of heating on the 
cells, viability measurements were conducted. The viability of both cell lines is presented in 
Figure 5.19 and Figure 5.20. 
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Figure 5.19- Viability of MCF7 cells after 24 h as a result of (a) 3 and (b) 6 min heating  
 
Figure 5.20- Viability of A375m cells after 24 h as a result of 3 min heating  in 5 plates 
Figure 5.19 presents the viability, in % of control ±Se, of MCF7 after 3 and 6 min of 
heating, whereas Figure 5.20 depicts the viability, in % of control ±Se, of A375m cells after 
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3 min heating of five different plates. Line (i) represents the average viability without Ca-1709 
between plates 2 - 5, whereas line (ii) represents the average viability with Ca-1709 between 
plates 1 - 5. 
 Focused Ultrasound induced Heating Influence on Encapsulated Drug 5.3.3.3
Uptake and Cell Viability 
To evaluate the efficiency of FUS induced heating in cellular uptake of free and 
encapsulated drug within cancer cells and to define the cellular damage, uptake and viability 
studies were conducted. All the sonications were performed at the optimal sonication 
configuration for the heating arrangement of 50% Tr, FD = 85 mm.  
 Dox Uptake in the Presence of Ca-1709 The uptake as a percentage of the Dox-
only control ±Se, of free and encapsulated Dox at various sonication parameters are presented 
in Figure 5.21 and Figure 5.22.  
 
Figure 5.21- Uptake of Dox into MCF7 cells after FUS induced heating with (a) 30 Wa for 30 s 
and (b) 30 Wa for 20 s 
Figure 5.21 presents the Dox uptake into MCF7 cells due to continuous sonication of 
(a) 30 Wa for 30 s and (b) 30 Wa for 20 s. In each case it was followed by a pulsed sonication of 
30 Wa for 180 s, 0.5 s on and 3 s off. 
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Figure 5.22- Uptake of Dox into A375m cells after FUS induced heating (see text for Mode 
details) 
Figure 5.22 presents the Dox uptake into A375m cells due to continuous sonication as 
follows: 
 Mode 1- 30 Wa for 30 s followed by a pulsed sonication of 30 Wa 
 Mode 2- 30 Wa for 20 s followed by a pulsed sonication of 30 Wa 
 Mode 3- 20 Wa for 45 s followed by a pulsed sonication of 20 Wa 
 Mode 4- 15 Wa for 60 s followed by a pulsed sonication of 15 Wa 
In each case, the pulsed sonication was 180 s, 0.5 s on and 3 s off. 
Cell viability in the Presence of Ca-1709 Figure 5.23 depicts the viability, in % of control 
±Se, of MCF7 cells due to continuous sonication of 30 Wa for 30 s followed by a pulsed 
sonication of 30 Wa for 180 s, 0.5 s on and 3 s off. 
Figure 5.24 depicts the viability, in % of control ±Se, of A375m cells due to continuous 
sonication under different conditions. In each case, the pulsed sonication was 180 s, 0.5 s on 
and 3 s off. 
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Figure 5.23- Viability of MCF7 cells 24 h after FUS induced heating 
 
Figure 5.24- Viability of A375m cells 24 h after FUS induced heating (a) 30 Wa for 30 s 
followed by a pulsed sonication of 30 Wa, (b) 20 Wa for 45 s followed by a pulsed sonication 
of 20 Wa, and (c) 15 Wa for 60 s followed by a pulsed sonication of 15 Wa 
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Figure 5.25- A375m cells viability plate following FUS induced heating 
Figure 5.25 depicts the A375m cells plate after FUS induced heating at 30 Wa for 30 s, 
with representative images of the cells from the treatment, control and background groups. 
 Discussion 5.4
As the UF sonoporation arrangement was the first to be established for in-vitro 
application, a major baseline study was carried out with it, including tuning of the parameters 
and definition of the optimal sonication patterns.  
The initial fundamental research was designed to discover the optimal sonication 
parameters by scanning possible sonication powers, times and energy levels. Since the half-life 
of Sonovue during sonication at 1 MHz was shown to be as low as 41 s (Tinkov et al., 2009), 
sonication times longer than 50 s were considered irrelevant and hence were not tested.  
As can be seen in Figure 5.6, all the applied powers except the lowest one, of 0.5 Wa, 
caused a factor of 2 increase in Dox uptake with no major difference between them. This 
indicates that the MB activity is a threshold dependent phenomenon. Consequently the 
chosen power was the lowest, yet beneficial, sonication power level of 1W at the shortest 
sonication time of 10 sec.  
In addition to the definition of the optimal sonication parameters, the sonication order 
was investigated. The sonication order in the plate is very important due to the fragility of the 
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MBs. In both the sonication patterns, the treatment groups containing MBs were sonicated 
first. In Figure 5.8 the top sonication pattern, (a), was planned to have the most of treatment 
groups with MBs. In this pattern it was established that there is an influence on the bubbles in 
the neighbouring wells. From Figure 5.8(a) it can be seen that after the fourth sonication, the 
uptake is significantly lower than the first three sonications, e.g. in sonication number three, 
the uptake value is 230% of the control whereas in sonication five it is only 139%. This could 
suggest that the bubbles imploded prior to the sonication as a result of the acoustic power 
impinging on the neighbouring wells. 
At the same power, in a pattern that isolates the MB treatment groups by Dox only 
groups, Figure 5.8(b), the uptake of Dox in the presence of MBs is more uniform, e.g. in 
sonication number three, the uptake value is 261% of the control and in sonication five it is 
207%, averaging 233% ±12%. Although three replicates of the MB treatment group were 
swapped by the Dox only group, the latter sonication pattern proved to be the most uniform, 
with the highest repeatability. 
To assess the impact of FUS application on cells in the presence of MBs, viability 
studies were conducted. The safety margin was chosen to be the highest applied power, i.e. 
2.5 Wa for 20 sec. As can be seen in Figure 5.9, sonication at this power causes significant cell 
damage, 31% ±2%, even after a 24 h recovery period. When applying 1 Wa for 10 s the viability 
increases. As seen in Figure 5.10, immediately after application of FUS there is a significant cell 
loss, 27% ±2% in MCF7 and 40% ±1% in A375m, yet after recovery period of 24 h there is a 
smaller percentage of cell death, 13% ±1% in MCF7 and 7% ±1% in A375m. This indicates that 
the remaining cells after sonication are fully functioning and dividing normally.  
Membrane integrity tests were conducted to gain better understanding of the 
mechanism of uptake enhancement by MBs in acoustic environment. The membrane integrity 
assay quantified the level of LDH present in the media due to leaking cell membranes. 
Accordingly it was possible to evaluate the membrane permeability achieved by FUS 
application. As can be seen in Figure 5.11, in both cell lines there is doubling of the 
permeability of the membrane due to FUS in the presence of MBs and no significant change 
without MBs. These data correspond to the uptake values at 1W for 10 s, shown in Figure 5.6 
and Figure 5.7, being double the control for the MB group and without a major difference in 
the Dox only treatment group. From the membrane integrity results it can be concluded that 
the mechanism of enhanced cellular uptake via sonoporation is achieved specifically by the 
Sonovue. 
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Development of the CBS sonoporation arrangement introduced the possibility of 
multi-focal sonication. Utilization of multi-focal patterns can significantly lower the treatment 
period and may thus contribute towards repeatability of results. To define optimal sonication 
parameters, several power levels were tested and the uptake and viability were recorded.  
MCF7 cells show strong power dependence both from the uptake and the viability 
evaluation. The uptake 376% ±23%, of Dox within the MCF7 cells after sonication of 20 Wa was 
higher than at powers of 18 Wa, 176% ±5%, and 16 Wa, 143% ±5%, Figure 5.12. Figure 5.13 
presents the uptake as an average in each well location, rather than over the whole treatment 
group, at the applied power of 20 Wa. As can be seen from Figure 5.13, there is a variation 
within MB treatment groups between the different wells of up to a factor of 2.19 in MCF7 cells 
and 1.38 in A375m cells. The same figure presents the MI at the same locations as the average 
uptake in Figure 5.13. The sudden increase in uptake at a power of 20 Wa, together with the 
large variation in the uptake values between the individual wells, may indicate the occurrence 
of a threshold-related phenomenon influencing the cell monolayer. 
A possible existing threshold is reported to be between stable and transient cavitation 
(Leighton, 1997; Brennen, 1995). As explained previously, stable cavitation is a process in 
which a MB, or a cloud of MBs, undergoes steady state oscillation during the application of 
ultrasound, expanding during negative pressure peaks and shrinking during positive pressure 
peaks. The oscillations can be either linear i.e. the bubble changes its size equally in every 
direction or non-linear, i.e. the bubble is no longer spherical and may take different oscillation 
shapes. The presence of stable cavitation in proximity to cells also causes micro-streaming. 
This produces large shear forces on the cells, contributing to increased membrane 
permeability. Stable cavitation generates an acoustical signature that depends on the type of 
oscillation and appears as harmonic and sub-harmonic peaks of the transmitted frequency. 
Transient cavitation, in contrast, is a process in which, during the expansion stage 
under negative pressure, a bubble can no longer sustain itself and violently implodes. During 
such an event, a jet may be formed towards a nearby surface. This jet can be considered as a 
micro-needle, rupturing the cell membrane. Transient cavitation has a broadband acoustical 
signature in the frequency domain.  
Stable cavitation in the presence of MBs is reported to occur for 0.3 < MI < 0.6 (Wu 
and Nyborg, 2008; Hernot and Klibanov, 2008). Moreover, it was reported by Hung et al. 
(2011) that application of US with MI = 0.6 causes Sonovue MB destruction in vivo. In the 
present experiments, the cavitation activity was not directly measured. Therefore, because of 
the uptake behaviour, it was assumed that stable cavitation occurred during application of 16 
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Wa and 18 Wa of acoustic power and a mixture of the two phenomena during the application 
of 20 Wa of acoustic power, resulting in higher values and variability in the drug uptake results. 
According to the viability studies there was a minor impact on the immediate viability 
of the MCF7 cells with, 12% ±1%, and without, 15% ±4%, MBs as a result of sonication at 
20 Wa for 10 s in the multi-focal pattern. The recovery studies 24 h after sonication indicate a 
full recovery of the MCF7 cells with, 112% ±3%, and without, 97% ±2%, MBs at the same 
power. Consequently, 20 Wa for 10 s was taken as the optimal protocol for MCF7 cell 
sonication.  
When a power of 20 Wa was applied to the A375m cell line, the viability results 
indicated significant cell damage in the presence of MBs, 75% ±2% immediately after 
sonication and 30% ±2% following 24h recovery. Lower power showed no significant 
improvement in the viability, demonstrating that there is no major difference in the impact on 
uptake and viability in the range of the applied powers, Figure 5.12 and Figure 5.14.   
When comparing the uptake achieved in the CBS arrangement to that of the UF 
system, the CBS multi-focal sonications appear to have a stronger effect on the uptake of Dox 
into MCF7 cells, even at lower MI. An explanation for this can be found in the significantly 
lower total exposure time to Dox. In the CBS arrangement, the exposure time equals the 
sonication duration, e.g. 10 s, whereas in the UF sonoporation arrangement with the same 
sonication duration, the total sonication time equals at least 10 min, which includes 10 s 
sonication in 18 wells and additional transducer movement time. The additional time following 
the sonication in a specific well creates a masking effect of the FUS impact on the cells. 
To evaluate the efficiency of FUS as a drug release stimulus from the Ca-1709 
nanocarrier, both sonoporation and heating experiments were conducted. During 
sonoporation, the cells were exposed to FUS in the presence of encapsulated drug with and 
without MBs. According to the uptake studies, Figure 5.15, at a power of 1 Wa for 10 s in the 
presence of MBs, the uptake of Dox into A375m was increased by a factor of 3.83, resulting in 
almost equivalent amounts of Dox penetrating the cells as in the free Dox control. 
Nonetheless, in MCF7 at the same power, no significant increase in uptake was recorded. An 
increase in the applied power realised a significant increase in uptake, up to a factor of 5.5 at a 
power of 2 Wa for 25 s, Figure 5.16. A suggested mechanism for the cell uptake increase is via 
penetration of the encapsulated drug into the cells due to increased cell membrane 
permeability achieved by the MBs.  
To establish the effect of heat with and without FUS on the cellular drug uptake of the 
free and encapsulated Dox, a set of experiments was conducted in two dedicated 
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arrangements. While it is clear that the plate should be placed inverted in the sonoporation 
arrangements in order to retain the buoyant MBs in proximity to the cells, the rationale behind 
the inverted plate in the heating arrangement is to achieve a uniform heating effect 
throughout the plate. As can be seen in Figure 5.17, placing a non-inverted plate on the 
heaters results in a different uptake in each row in the plate. This can be explained simply by 
the fact that the cells receive the heat straight from the hot plate in a nonuniform pattern 
which results in various levels of uptake increase. Moreover, during heating in a non-inverted 
plate, the cells are heated while the solution of the free or encapsulated drug inside each well 
remains at RT. This is also indicated by the relatively low average increase in uptake of the 
heated encapsulated Dox treatment group, 29% ±6%, compared to an inverted plate, 71% 
±10%, Figure 5.18(a).  
At the same exposure time of 3 min to heating without FUS in an inverted plate, the 
uptake values of encapsulated Dox and free Dox into MCF7 were 96% ±10% and 379% ±18%, 
respectively. The viability values following 3 min heating without FUS of an inverted plate were 
85% ±5% with carrier and 78% ±7% without carrier, Figure 5.19(a). Doubling of the heating 
exposure time to 6 min without FUS resulted in a factor of 1.83 increase in the uptake of the 
encapsulated Dox, 176% ±19%, and 1.54 in the uptake of the free Dox, 585% ±20%, according 
to Figure 5.18(b). Neverthless, the viability of MCF7 cells following the longer exposure time of 
6 min significantly decreased by a factor of 1.63 with carrier and 1.81 without carrier to values 
of 52% ±3% with carrier and 43% ±4% without the carrier, Figure 5.19(b).  
The uptake of encapsulated and free Dox into A375m cells as a result of 3 min heating 
without FUS was 142% ±12% and 396% ±9%, respectively, Figure 5.18(c). As presented in 
Figure 5.20 the average viability, excluding plate 1, of A375m at the same exposure time is 80% 
±5% with carrier and 68% ±8% without carrier.  
According to the overall results of uptake and viability studies, the optimal duration for 
heating cells to achieve significant uptake increase yet maintain low viability damage, is 3 min. 
Moreover, heating for 2 min at exactly 43°C (or if the temperature is 42.5 - 43°C, for up to 
4 min) is described in the literature as ‘the optimal thermal dose’ for cancer therapy (Saparfto 
and Dewey, 1984). In view of that, the FUS induced heating exposure time was set to 3 min, 
and consequently in the validation setup without FUS as well. In both arrangements the cells 
were subjected to a rapid temperature rise followed by sustained moderate heat treatment. 
Whereas the duration of the initial temperature rise in the heating without FUS was decided in 
real-time due to thermocouple monitoring, in the FUS induced heating, a predefined power 
and duration must be applied.  
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In the search for the optimal FUS induced heating parameters, several power levels 
were applied for various durations. The following initial powers were tested in A375m cells for 
their potential of drug uptake increase: 30 Wa for 30 s (900 J); 30 Wa for 20 s (600 J); 20 Wa 
for 45 s (900 J); and 15 Wa for 60 s (900 J). From the uptake values presented in Figure 5.22, 
while there were some effects on the free Dox uptake at all the power levels, only at the 
highest power of 30 Wa for 30 s (900 J) was there an increase in the uptake of the 
encapsulated Dox. Moreover, the length of the initial continuous sonication has a major 
impact on the uptake of the free and especially the encapsulated Dox in MCF7 cells, as can be 
seen from Figure 5.21. A 10 s reduction in the initial sonication duration resulted in insufficient 
heating to produce an increase of the Dox uptake into MCF7 cells.  
According to Figure 5.23 there is no major impact on the viability of MCF7 cells, 
101% ±7% with and 96% ±7% without carrier, due to FUS induced heating at the maximum 
applied power level of continuous 30 Wa for 30 s followed by pulsed 30 Wa sonication for 
180 s, 0.5 s on 3 s off. After sonication at the same power, A375m cells had shown no 
substantial viable signals, 3% ±0.42% with and 3% ±0.4% without carrier, Figure 5.24(a). 
Furthermore, even at lower power levels there was no significant improvement in the viability 
of A375m cells, Figure 5.24(b,c). In general, lack of viable signals indicates complete cell death 
in the measured area. As a result of cell death in a monolayer of cells, the cells detach from the 
base surface and float in the surrounding media. Yet, in the case discussed above, where the 
cells have not shown any viable signal due to FUS induced heating, there was no cell 
detachment, Figure 5.25.  
As can be seen in the viability studies without FUS, Figure 5.20, there is a great 
variation between the different plates that undergo the same 3 min heating process. It can be 
seen that in plate 1 the amount of damage to the cells is significantly higher, 78%, than in the 
average of all the other plates, 32%. The fact that this phenomenon occurred occasionally in 
the heating without FUS, as well as in the FUS induced heating, suggests that it is related to the 
heating process, with some threshold dependence, rather than to any excess US that might 
propagate during the FUS induced heating process. Consequently, a suggested explanation of 
this phenomenon might be heat-induced arrest in the metaphase of the cell cycle or disability 
to satisfy the spindle assembly checkpoint (Rieder and Maiato, 2004) which will not necessary 
lead to cell death (Erenpreisa et al. 2000; Erenpreisa and Cragg, 2001).  
Since the 1960s wide research has been carried out on the topic of thermal effects on 
cancer cells in vitro (Levine and Robbins, 1976). These studies indicate that a temperature rise 
in cultured cells results in manipulation of their mitotic cycle (Abu-absi and Srienc, 2002). Most 
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of the phases in the mitotic cycle respond to thermal changes similarly to other biochemical 
reactions, in which there is an increase in the chemical reactivity until a certain optimal 
temperature is reached, which is then followed by a decrease due to denaturation of the 
proteins involved in the process (Sisken et al., 1965). Although MCF7 cells are known to be 
relatively more resistant to hyperthermia (Lee et al., 1994) than other cell lines, the large 
variance between the viability of MCF7 and A375m cells emphasizes once more the diverse 
impact of heating on different cell lines (Cavaliere et al., 1967; Michalakis et al., 2005).  
As can be seen throughout all the viability studies, the presence of Ca-1709 does not 
influence the viability of cells, Figure 5.19 and Figure 5.23, and at times even appearts to 
contribute to the total cell viability, Figure 5.20. The slight increase of viability in the presence 
of Ca-1709 may be due to the CDs ability to stimulate the dehydrogenase cell activity (Al-Omar 
et al., 1999). These results indicate that the nanocarrier Ca-1709 has no cytotoxicity at applied 
concentrations of 500 M. 
In both of the heating arrangements, with and without FUS, a significant increase in 
the uptake of encapsulated drugs was observed. This rise in the amount of Dox present within 
the cells because of heating indicates two possible mechanisms. The first is release from the 
encapsulation due to the heat sensitivity of the carriers, and the second is that the 
encapsulated drug penetrates as it is into the cells due to heat-enhanced membrane 
permeability. The latter explains the rise in the uptake of the free Dox. In heating without FUS 
the rise in uptake of free Dox is significantly higher than in the FUS induced heating, e.g. a 
factor of 2.5 in MCF7 cells, Figure 5.18a and Figure 5.21a. Opposing this, the rise in uptake of 
encapsulated drug is similar, i.e. A375m cells, Figure 5.22, or higher  i.e. 1.8x in MCF7 cells, 
Figure 5.18a and Figure 5.21a, with FUS induced heating rather than heating without FUS. 
These results suggest that the possible mechanisms of uptake increase in heating without FUS 
are heat-induced membrane permeability, as indicated by the free Dox uptake values, with 
potential drug release, whereas in the FUS induced heating, it is mainly attributed to the first 
mechanism where the drug is released from the encapsulation due to the temperature 
increase, indicated by the higher encapsulated Dox uptake results.  
 Conclusions 5.5
In this chapter the in-vitro applications of all the ExAblate arrangements were 
presented. The potential of Sonovue as a membrane permeability enhancing tool was 
confirmed in both UF and CBS sonoporation arrangements. The significant increase in uptake 
in both cell lines alongside relatively high viability results has confirmed that the membrane 
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rupture is a reversible and non-permanent process (Böhmer, M.R. et al. 2009), which does not 
lead directly to cell necrosis. In addition, moderate heating was shown to be highly beneficial 
in drug release and cellular uptake increase of free and encapsulated drug. Possible in-vivo 
implementation of the achieved results is outlined in Chapter 6. 
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 CONCLUSIONS AND CHAPTER 6
IMPLEMENTATION OF RESEARCH: TOWARDS 
CLINICAL TRIALS  
 Introduction 6.1
This is the concluding chapter of the thesis and includes a summary of the key results 
achieved in the three main research areas presented in Chapters 3, 4 and 5, respectively. 
Chapter 3 focused on the creation through chemistry and the chemical investigation of a CD-
based carrier and its complexation with Dox, Chapter 4 presented  the design and evaluation 
of in-vitro research environments based on a clinical MRgFUS system for investigation of the 
mechanical and thermal effects associated with US application, and Chapter 5 discussed the 
outcomes of the in-vitro application of the investigated drug, Dox, both in free and 
encapsulated forms, in the various FUS application arrangements. Here the final outcomes of 
each chapter as well as the overall conclusions will be discussed.  
In addition, this chapter describes the early stages in translatation of the achieved 
knowledge of USmTDD mechanisms from the in-vitro studies in the in-vivo platform. 
Consequently, the second part of this chapter will discuss the current trends in research of 
USmTDD in vivo and present some preliminary ex-vivo results as part of the preparation for the 
in-vivo stage. 
 Conclusions of Research 6.2
This thesis has described the synthesis and evaluation of a novel TDD drug carrier and 
its implementation in vitro in specially designed and constructed in-vitro arrangements for 
investigation of mechanical and thermal effects of USmTDD, as well as in an additional heating 
arrangement, as validation of FUS induced heating.  
The novel drug carrier employed in this work is based on the CD technology. It consists 
of a truncated-cone-shaped sugar molecule, CD, which is covalently bonded to an amino acid 
derivative with a naphthalene moiety. The synthesis of the carrier as described in Chapter 3, 
was done by a two step reaction where the first step was coupling of CD with a Boc-
naphthalic-amino acid, and the second step was the removal of the N-protecting Boc group 
from the wanted yield- a monosubstituted CD. The reaction was monitored by TLC and HPLC 
to confirm the generation of the desired compound. The final yield, in the form of small white 
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crystals, was 51%. The created CD-based carrier was spectroscopically evaluated by 1H- and 
13C-NMR, which provided evidence supporting the intended structure.  
 The designed carrier was aimed to be a potentially successful drug vehicle for delivery 
of Dox via a complexation reaction. The behaviour of the cytotoxic agent, Dox, in different 
solutions and concentration was studied by 1H-NMR and DOSY measurements. Under the 
applied conditions, Dox has exhibited the well-studied phenomenon of self-aggregation, also 
referred to as “stacking”, with dependence on the concentrations tested.       
The examination of Dox in the complexation reaction with the carrier was investigated 
via fluorescence and NMR. According to the fluorescence studies, where a significant decrease 
in the Dox signal was recorded with dependence on the carrier concentration, Kbinding of the 
created complex was approximately 62,000 M-1. This value is significantly higher than Kbinding of 
Dox to the unmodified CD (Anand et al., 2012). This could be attributed to the formation of -
* interactions between the Dox and the naphthalene moiety of the carrier. This was also 
evident in 3D NMR studies conducted, where a correlation was suggested between the 
protons of the Dox’s aromatic rings and those of the naphthalene.  
This data, together with the other 3D and 2D NMR studies, have suggested a possible 
encapsulation conformation presented in Figure 3.29. The overall chemical analysis of the 
carrier and Dox, on their own as well as in a complex, aid in understanding of their behaviour 
in various media, as well as validating their chemical structures and, most importantly, their 
roles in complex formation.  
To examine the potential of the CD-based drug carrier in delivering Dox into cancer 
cells via USmTDD, several in-vitro arrangements were constructed. As the main goal in the in-
vitro studies was to evaluate individually the mechanical and thermal effects of FUS during 
USmTDD, two different types of FUS application arrangements were designed.  
The first, dealing with mechanical effect on the cells, utilised low power FUS in the 
presence of MBs to generate controlled stable cavitation. This was done in two arrangements 
allowing different frequencies and sonication patterns, including multi-focal ones.  
The second US mediated effect, i.e. in-situ temperature rise, was studied in an 
arrangement including tissue mimicking phantoms in specially crafted shapes, to provide mild 
heating in order to produce hyperthermia in proximity to the cells. To validate the impact of 
FUS induced heating on the cell monolayer; an additional arrangement was designed, 
generating heating without FUS. All the USmTDD arrangements were constructed on clinical 
MRgFUS systems. The main arrangements for investigation of USmTDD for both its mechanical 
and thermal effect were constructed on the ExAblate 2000 system (InSightec, Haifa, Israel), 
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referred to as the UF system. An additional arrangement was created using the ExAblate 2100 
system (InSightec, Haifa, Israel), for application of multi-focal sonication patterns to the cells 
and is referred to as the CBS arrangement.   
To validate the accuracy and proper functioning of all the discussed arrangements, 
thorough thermal and acoustical evaluation were conducted and reported in Chapter 4. 
According to the thermal evaluation of the sonoporation experiment by both thermal camera 
and thermocouples, it was confirmed that there is no significant temperature rise as a result of 
sonication at the in-vitro applied energies of 10 and 50 J. This confirms that during sonication 
to achieve sonoporation, the mechanical effects of US were observed rather than thermal 
effects. 
The performed acoustic measurements verified that the base and seal parts of the 
tested 96-well plate produce minimal absorption of acoustic power and are thus suitable for 
USmTDD research. Moreover, the acoustic evaluation also defined the optimal shape, size and 
height of the focal spot for in-vitro application. This resulted in the following parameters as the 
optimum sonication pattern: single focus with an average size of about 2 mm with Tr = 50% at 
FD = 97 mm at applied frequency f = 0.95 MHz. The sonications were performed in an 
automated manner via a prewritten computer script. 
In addition to the single spot sonication, a multi-focal pattern was examined for 
simultaneous sonication at several locations. Using the ExAblate 2100 CBS transducer, it was 
possible to sonicate simultaneously 16 different wells in the same plate. According to the 
acoustic evaluation, the multi-focal sonication pattern was highly efficient and accurate, with 
both values over 85% (Gourevich et al., 2012).  
Alongside the sonoporation arrangements, a FUS induced heating arrangement was 
constructed, together with a control experiment without FUS. Both were evaluated for 
application of temperature-induced TDD. MRI thermometry as well as thermocouples, was 
used to define the optimal sonication pattern for application of FUS induced heating in-vitro.  
The established heating protocol for FUS induced heating in vitro consists of a continuous 
sonication to produce a rapid temperature rise, followed by 3 min stable heating in a pulsed 
mode of 0.5 s on, 3 s off. In the experiment on heating without FUS, a similar heating pattern 
was applied where initially the plate was placed on a higher temperature heater (75°C) to 
achieve the rapid temperature rise, and then moved to stable heating for 3 min on a 50°C 
heater.  
 All of the above arrangements were utilised in in-vitro studies with the outcomes 
presented in Chapter 5. The mechanical effects of FUS application were evaluated in both the 
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UF and the CBS arrangements. According to the in-vitro studies performed on the UF 
sonoporation arrangement, in the presence of Sonovue MBs, the uptake of Dox into human 
cancer cells is increased by a factor up to 2.4, while the viability of the cells remained high, i.e. 
viability values were above 85% after 24 h recovery. Moreover, the membrane integrity test 
results were in line with the uptake values suggesting that the increased uptake of Dox is due 
to increased cell membrane permeability caused by the MBs.  
In the CBS arrangement, the uptake of Dox was increased by a factor of up to 4 
compared to the non-sonicated control. Yet greater cell damage, resulting in lower viability 
values, was observed in both cell lines. Comparing these results with those achieved in the UF 
sonoporation arrangement, it appears that the multi-focal sonication pattern has a greater 
impact on the uptake of Dox. This could be explained by the significantly lower total exposure 
time to Dox, i.e. 10 min in the UF and 10 s in the CBS experiments. This additional time 
following the sonication might mask the effect of the FUS on the cells. 
The thermal effect of FUS was investigated using the UF system, and also validated 
with an experiment involving heating without FUS. Heating at what is described in the 
literature as ‘the optimal thermal dose’ for cancer therapy (Saparfto and Dewey, 1984), i.e. 2 - 
4 min  at about 43°C, resulted in an increase in the cellular uptake of Dox by a factor of 4 in 
both cell lines. Whereas previously, the viability studies were only slightly different between 
the two cancer cell lines, A375m and MCF7, in the FUS induced heating the viability values 
varied greatly between the two tested cell lines, where in the MCF7 cells they were over 85%, 
yet only about 33% in the A375m cells. A suggested explanation for this low viability signal 
might be heat-induced arrest in the metaphase of the cell cycle or inability to satisfy the 
spindle assembly checkpoint (Rieder and Maiato, 2004) which will not necessary lead to cell 
death (Erenpreisa et al. 2000; Erenpreisa and Cragg, 2001).  
In addition to the described in-vitro investigation of increased Dox uptake by the 
mechanical and thermal effects of FUS, the ability of the designed carrier to encapsulate and 
release the Dox, in vitro, via the same mechanisms, was established.    
According to the in-vitro evaluation of the complex, the carrier successfully 
encapsulated the Dox resulting in inhabitation of 80% of Dox penetration within the cancer 
cells. The tested release mechanisms using mechanical and thermal triggers, was found to be 
successful in achieving close to 100% release of Dox as compared to the control.  
Via the sonoporation mechanism the uptake of encapsulated Dox in the presence of 
MBs was increased by a factor of 5.5, resulting in almost equivalent amounts of Dox 
penetrating the cells as in the free Dox control. A suggested mechanism for the cell uptake 
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increase is via penetration of the whole complex into the cells due to increased cell membrane 
permeability achieved by the MBs, followed by dissociation within the cell itself.  
Thermal effects of FUS have resulted in increased factors of up to 9.6 in the uptake of 
the encapsulated Dox into the cells. This was validated using the heating without FUS 
arrangement, where an increase by a factor of 5.7 was recorded. These increases in the Dox 
uptake due to heating suggest two possible mechanisms. The first is the release from the 
encapsulation due to the heat sensitive feature of the carriers, while the second possible 
mechanism is that the encapsulated drug translocates across the cell membrane due to heat 
enhanced membrane permeability. Although the probability is that both of the described 
mechanisms act simultaneously, it can be postulated from the achieved results that the 
possible mechanisms of uptake increase in the heating treatment without FUS is due to the 
heat induced membrane permeability, as indicated by the free Dox uptake values, with 
potential drug release, whereas in FUS induced heating it is mainly attributed to the first 
mechanism where the drug is released from encapsulation, as indicated by the higher 
encapsulated Dox uptake results. 
The carrier was verified to be non-toxic at the tested concentrations of 500 M, as 
confirmed by all the performed viability studies.  
In conclusion, the presented arrangements for in-vitro investigation of USmTDD were 
proved to be successful in achieving the desired goals of a well monitored, reliable research 
environment with high repeatability, able to differentiate between the thermal and 
mechanical effects of FUS. In addition, the in-vitro results confirmed the designed nanocarrier 
as a promising drug delivery vehicle for USmTDD for controlled release by both temperature 
and cavitation. 
While the fundamental objective behind this work was the establishment of a properly 
monitored sonication arrangement for in-vitro studies, the obvious development to the in-vivo 
stage and clinical trials was kept in mind. As previously explained, all of the arrangements were 
constructed on the ExAblate system - a commercially available, clinically approved device for 
MRgFUS. Although the translation from in-vitro work into in-vivo research is not 
straightforward, a good in-vitro background can contribute greatly to the success of in-vivo 
outcomes. Consequently, the work reported here provides a baseline for potential in-vivo TDD 
research using the ExAblate system, which can then lead to clinical applications.  
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 USmTDD In vivo 6.3
Many research groups worldwide are currently examining the potential of USmTDD in 
vivo. As previously mentioned, two bioeffects can occur due to sonication of tissues: cavitation 
and increased temperature, which are related to the mechanical and thermal effects of US, 
respectively. Although generally these effects can happen simultaneously, and neither of them 
can be entirely eliminated in the application of FUS, proper tuning of the parameters can 
provide relatively well isolated effects. Even though, in the current in-vivo USmTDD research, 
both the mechanical (Rosenthal et al., 2004) and thermal (Grüll and Langereis, 2012) effects of 
US are under investigation, the latter are considered safer and more clinically applicable. 
Although the application of cavitation-enhanced drug delivery in vivo is rather 
problematic due to rapid fluid conduction through the vascular system (Pitt et al., 2004), 
researchers have shown some promising results in tumour regression with a combination of 
drug delivery vehicles with MBs in the presence of US (Rapoport et al., 2009). Additional in-
vivo research suggests that, via the mechanical effects of USmTDD in vivo, a reduction in 
neointima formation with significantly lower drug doses can be obtained (Phillips et al., 2012) 
or an increase in drug delivery via the BBB (Lewis et al., 2011). A possible combination of the 
mechanical effects of US and an in-situ temperature increase showed promising results in vivo 
in the intracellular delivery of cell-impermeable molecules (Yudina et al., 2012).     
The possibility to achieve in-situ hyperthermia via application of FUS presents an 
improved mechanism over the conventional methods of heat generation in tissues. These 
include utilization of water baths- which provide only superficial heating; microwaves emitting 
electromagnetic radiation; and invasive catheters. Application of FUS induced heating is a non-
invasive method, with deep tissue penetration and a good safety profile (Staruch et al., 2011). 
Currently, the main research platform for US induced thermal effects is thermally triggered 
drug release from liposomes, especially under MRI guidance (Grüll and Langereis, 2012). US 
induced temperature increases have produced a significant increase in the drug delivery of 
anticancer agents into tumour sites in various in-vivo models such as mice (Chilkoti et al., 2002; 
Chen et al., 2010) and rabbits (Ranjan et al., 2012).  
All types of in-vivo USmTDD require an imaging modality (Vaezy and Zderic et al., 
2009). A variety of possible imaging techniques is available to monitor the application of US in 
vivo. At times, the delivery mechanism suggests a certain imaging method, e.g. the use of 
ultrasonic contrast agents as membrane permeability enhancers (Rapoport et al., 2009) or 
conjugation of MRI contrast agents in the drug delivery vehicle (Deckers et al., 2008) can lead 
to the choice of US or MRI as the preferred imaging modality. There are several advantages for 
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using MRI as the imaging techniques in USmTDD in vivo: not only does it offer high resolution 
image guidance in TDD, but also real time thermal mapping (Moonen et al., 2010).  
 Aim and Objectives 6.3.1
As a part of the final goal to reach clinical trials, this section outlines a possible in-vivo 
study protocol as an outcome of the work achieved and presented in this thesis. 
 As a first stage towards in-vivo experiments, several ex-vivo experiments were 
conducted towards the end of the work reported here. The phrase ‘ex-vivo’ in this context 
refers to deceased animals of the same species as planned to be used in vivo. The first stage in 
the proposed in-vivo studies will focus on the feasibility of FUS as a drug release stimulus in 
situ. In terms of protocol, the in-vivo studies, and hence the preliminary ex-vivo studies will be 
based on healthy mice injected with encapsulated or free drugs intravenously, that will 
undergo a set of sonications under MRI guidance. The target sonication location is the 
quadriceps muscle. This is an external tissue which makes accessibility easier. An additional 
benefit is that the quadriceps muscles on the second leg can be used as an intrinsic control in 
the same animal, which significantly reduces the number of sacrificed animals.  
In in-vivo work, following the experimental protocol as described above, the aim will 
be to show the in-situ absorption of drugs released from the carriers. This could be achieved 
by a measurement of fluorescence intensity, similarly to the in-vitro work, from the sonicated 
muscle, in comparison with the non-sonicated control. 
 Materials and Methods 6.3.2
Table 6.1- Materials for ex-vivo work 
Material Manufacturer  Place of Origin Notes 
1.5 Tesla MRI system General Electric USA Model: Signa HDX 
ExAblate One InSightec  Ltd. Israel 0.95-1.35 MHz 
Single Channel Surface Coil  InSightec  Ltd. Israel 5 GP- Breast Coil 
Ex-Vivo Tissue  Science in Action Ltd. Israel Deceased  Mice 
DQA Phantom ATS Laboratories USA  
Gel Pad InSightec  Ltd. Israel  
Veet® Hair Removal Cream Reckitt Benckiser France  
 
All the ex-vivo studies were performed in Sheba Medical Centre, Israel. For the ex-vivo 
experiments, deceased mice were brought to Sheba after being sacrificed in Science in Action 
Ltd. (Building 3, Weizmann Science Park, Israel). Transportation took 1 h from the time of 
death. Upon arrival, Veet® hair removal cream was placed on the lower part of each mouse, 
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with a focus on the quadriceps muscles, as shown in Figure 6.1. Each mouse was covered with 
the hair removal cream twice, for 10 min at a time, to achieve maximal depilation. 
 
Figure 6.1- Deceased mice (a) on their arrival, (b) covered with Veet shaving cream, and (c) 
after the second fur removal 
The experimental arrangement consisted of a gel pad, 5 GP breast coil and a plastic 
ring, all placed on top of the FUS source in the ExAblate UF table. The coil was wrapped in cling 
film to keep it dry and sterile, and placed on top of the gel pad. Inside the coil, a round plastic 
circle was placed to contain the water needed for sonication. The arrangement is shown in 
Figure 6.2. 
 
Figure 6.2- Arrangement for FUS application ex-vivo and in-vivo 
 
Figure 6.3- Positioning of mice (a) inside breast coil (b) covered with a glove full of warm 
water 
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The shaved mice were wiped of any excess fur and placed inside the ring. Figure 6.3 
presents the placement of the mice in the experiment, such that their upper body parts are on 
top of the coil, for breathing in vivo, and the lower part on the gel pad soaked with water for 
US exposure. The heads and front feet of the mice were held by medical tape to the coil. A 
glove filled with warm water was placed on top of the mice to secure their location and, in 
future when dealing with live mice, to prevent hypothermia.    
To create and evaluate a combined sonication mode which includes both continuous 
and pulsed sonications, additional experiments in a DQA phantom were performed. 
 
Figure 6.4- DQA phantom arrangement 
Figure 6.4 presents the DQA phantom arrangement for sonication mode validation, 
consisting of a DQA phantom placed inside the 5GP breast coil, on top of the gel pad in the 
same manner as the ex-vivo tissues.    
 Results 6.3.3
 Magnetic Resonance Imaging 6.3.3.1
The first set of MRI parameters was based on those of Chen et al. (2010) with 
adjustment to local experimental arrangements. A GE 3D localizer sequence was used for quick 
localization. The coronal images were obtained (T2-weighted, FSE) with the following 
parameters: TR/TE = 3180/96.3 ms; bandwidth: 10.4 kHz; FOV = 20 × 20 cm; matrix: 384 × 384; 
Number of Excitations (NEX): 4; slice thickness: 2.0 mm/1.0 sp; number of slices: 8; frequency 
direction: SI; and spatial resolution: 0.52 mm. The total duration of the scan was 5 min 37 s. 
The sagittal and axial images were taken with similar parameters, except the following: FOV = 
14 × 14 cm; number of slices: 24, which prolonged the scanning time to 17 min 13 s for sagittal, 
and 20 min 6 s for axial.  
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Since the sonication planning was done solely on the coronal images, and due to the 
long axial and sagittal scanning times, in further ex-vivo and in-vivo experiments it was decided 
to perform only the MRI coronal imaging and ExAblate calibration scans. Additional 
optimization of the imaging parameters was performed to achieve minimal scanning time yet 
without major impact on the image quality. Therefore, NEX was reduced to two instead of 
four, which shortened the coronal scanning time to 2 min 52 s.   
 Sonication 6.3.3.2
The first sonications were done to define the spot accuracy, feasibility of hitting the 
targeted area and to have the maximal optional temperature increase for a given applied 
power. Figure 6.5 depicts the sonication location of continuous and pulsed sonications. The 
temperature rise following these sonications is presented in Figure 6.6. 
 
Figure 6.5- Spot location of the (a) continuous and (b) pulsed sonication 
 
Figure 6.6- Sonication at 4 Wa in (a) continuous and (b) pulsed sonication 
Figure 6.6 presents the PRF thermal measurements at the sonication locations 
presented in Figure 6.5. The sonication parameters were 4 Wa for 60 s continuous sonication, 
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and 4 Wa for 60 s, 0.5 s on, 2.5 s off in a pulsed mode. It is important to notice that all the red 
areas outside the yellow rectangle in Figure 6.6 are artefacts and should be ignored. 
The creation and evaluation of a combined sonication pattern, similar to the one 
explained in Section 4.3.1.1, was initially performed in a DQA phantom, in the arrangement 
described in Figure 6.4. The final combined sonication mode for hyperthermia in vivo consists 
of 10 s continuous sonication and 45 s pulsed (0.5 s on, 2.5 s off) as schematically presented in 
Figure 4.33.  
As part of the sonication investigation, an additional heating pattern was tested: the 
annular focus. Using beam manipulation, the same power was applied in an annular focus, 
presented in Chapter 4, and the temperature was recorded via PRF measurement. Figure 6.7 
and Figure 6.8 depict the PRF thermometry of the normal and annular foci in a DQA phantom 
due to sonication in the described hyperthermia mode with powers of 4 and 16 Wa, 
respectively.    
 
Figure 6.7- PRF thermometry measurement at the (a) normal and (b) annular foci in DQA 
phantom at a power of 4 Wa 
 
Figure 6.8- PRF thermometry measurement at the (a) normal and (b) annular foci in DQA 
phantom at a power of 16 Wa 
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The testing of the previously described hyperthermia sonication mode was performed 
in ex-vivo mice tissues to examine its ability to cause temperature increase in situ.   
 
Figure 6.9- Spot location of the (a) normal and (b) annular foci 
 
Figure 6.10- PRF thermometry measurement at the (a) nominal and (b) annular shaped spots 
in ex-vivo tissue 
Figure 6.10 depicts the PRF thermometry at the sonication location presented in Figure 
6.9, for the normal and annular foci. The sonication parameters were 4 Wa for 10 s continuous 
sonication immediately followed by 4 Wa pulsed sonication for 45 s, 2.5 s off, 0.5 s on. As 
before, all the red areas outside the yellow rectangle are artefacts and should be ignored.  
 Discussion and Conclusions 6.3.4
The ex-vivo model provided many important insights such as creation of a tailor-made 
arrangement to the species in use, the handling of the animals, and proper positioning in the 
experimental arrangements, definition of optimal imaging parameters, establishment of 
optimized sonication modes and patterns, and examination of the feasibility of conducting 
work in vivo according to the anaesthesia time window that will apply.  
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The quality of the MR imaging is crucial in MRgFUS, especially when dealing with small 
animals. Moreover, in this work it is extremely important, since the focus location is in the 
quadriceps muscle, which is almost impossible to detect on the MRI. The width of the entire 
leg is between 7 to 9 mm. Due to the time frame dictated by the anaesthesia, the scans need 
to be a short as possible, yet their resolution should remain high in order to accurately locate 
the sonication spot. Optimization of scanning parameters is presented in Section 6.3.3.1. From 
these results, the optimized imaging parameters total time frame is adjusted to as little as 34 s. 
As an initial step for testing the protocols for both continuous and pulsed sonications, 
Figure 6.6, were examined for their ability to create a temperature increase in the quadriceps 
muscle. As can be seen in Figure 6.6(a) the increase due to the 4 Wa continuous sonication is 
about 24°C. Since the aim is an increase of 4°C to 7°C, there is a need to lower the power by a 
factor of four to six. This can be achieved via a pulsed mode similar to the one utilized in the in-
vitro studies. In the application of FUS in vitro, the accumulating heat in the plastic was greater 
than in the ex-vivo tissue, hence a longer cooling interval between the sonications was applied 
(0.5 s on, 2.5 s off instead of 0.5 s on, 3 s off). Sonication at the same power of 4 Wa, in pulsed 
mode is presented in Figure 6.6(b).  
Although the temperature increase was significantly lower, the long heating time prior 
to the stable state needed to be shortened. This could be achieved via the combination of two 
sonication modes, the same as in vitro. A first continuous sonication for a short time period 
achieves an initial rapid temperature increase that can then be followed by a pulsed sonication 
in order to sustain the temperature at a specific level. Consequently, a dedicated sonication 
mode was created that consists of 10 s continuous sonication and 45 s with 2.5 s off and 0.5 s 
on, pulsed sonication. This mode was examined initially in a DQA phantom to evaluate its 
efficiency.  
As can be seen in Figure 6.7, at a power of 4 Wa, there is no significant temperature 
rise in either sonication pattern, i.e. single spot or annular. Therefore the same mode was 
tested at a power of 16 Wa, where a different thermal rise can be seen in both sonication 
patterns, Figure 6.8. In the normal single spot sonication, following sonication of 16 Wa with 
the combined mode, a maximal thermal increase of 10°C was recorded. The area of 7°C 
temperature increase is 9 mm2, as defined by the yellow line in Figure 6.8a. In the annular 
sonication patterns, the same applied power resulted in a 3°C lower maximum temperature 
increase, i.e. 7°C. The area of 7°C temperature increase is 4 mm2 as defined by the inner yellow 
line in Figure 6.8(a), whilst the area of 4°C increase is 13 mm2 as defined by the outer yellow 
line in Figure 6.8(b).  
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From these results it is clear that an annular focus lowers the maximal temperature 
rise at the focal point, while creating a broader focal zone. This was further confirmed in the 
ex-vivo studies. Figure 6.10 depicts the application of 4 Wa in the combined sonication mode 
in deceased mice at the locations indicated in Figure 6.9, in two sonication patterns: single 
spot, i.e. normal and annular. From Figure 6.10, it can be seen that the combined sonication 
pattern was successful in both its targets: a fast temperature rise followed by a stable heating 
mode. The application of the annular focus results in a wider focal zone with lower 
temperature rise, 45 - 7°C ±0.9°C in the normal focus compared to 42°C ±0.9°C in the annular 
case, Figure 6.10.   
The specific sonication shape of the focal point as indicated by the temperature rise in 
situ is somewhat similar to an annulus, whereas the central point of the annulus remains 
relatively cool. This introduces a possibility of a wider, more uniform pattern of sonication 
which may be applied in order to cover larger areas with fewer sonications. The difference 
between the temperature rises in the DQA phantom and those in the ex-vivo tissues with 
application of the same acoustic power of 4 Wa, may be attributed to several physical 
differences between the tissue mimicking phantom and the deceased mice.  
The sonication location in the ex-vivo studies in this work was chosen to be the 
quadriceps muscles as it would be the primary study subject in the first stage of in-vivo trials. A 
mouse leg is about 8 mm wide in the region of the quadriceps muscles and includes the 
muscles, bones and various blood vessels. Therefore it is not a perfect tissue the DQA phantom 
is mimicking but rather a complicated combination of tissues. Consequently, in the ex-vivo 
tissues there may be greater absorbance, e.g. in the bone, and different heat distribution due 
to air or stiffness variation in the subject area.   
As can be seen from Figure 6.10, with both spot shapes there is a relatively slow 
temperature decrease after the end of sonication. This can be attributed to the fact that there 
is no blood flow in the ex-vivo mice for rapid in situ-cooling. The significant temperature 
decrease that can be seen in Figure 6.6, i.e. from 60 - 61°C ±0.9°C to about 44 - 42°C ±0.9°C, is 
due the difference from room temperature (RT).  
When working in an in-vivo arrangement, especially dealing with small species such as 
mice, the duration of the experiment is highly important. The anaesthesia period dictates a 
working window of a maximum of 45 min. While in the ex-vivo experiments the possibility of 
sonication of three mice under the same imaging procedure was suggested, in-vivo it may be 
necessary to scan and sonicate each mouse individually. Part of the ex-vivo goal was to provide 
a timed procedure for MRI-guided mouse sonication and to optimize the timeline to fit in the 
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anaesthesia window. The final minimum exposure time for a single mouse was achieved to be 
as low as 21 min, comprising: 10 min for temperature adjustment and positioning of the 
mouse within the experiment, 2 min 52 s coronal scan, 70 s per sonication i.e. 10 s continuous 
sonication + 45 s pulsed sonication + 5 cooling phases = 3 s x 5, x number of sonications per 
leg, 4 in average = 4 min, and 3.5 min for retrieval of the mouse from the MRI environment to 
the laboratory.  
To conclude the initial preparation for in-vivo studies reported in this chapter, the 
results have proved the feasibility to apply the achieved in-vitro knowledge in an in-vivo 
research platform. Although practical application for in-vitro research is sometimes difficult, in 
this work it was shown that emerging in-vitro sonication protocols may be used in in-vivo 
models to achieve local hyperthermia. Following the proof of concept in healthy mice, the 
same platform could be used for treating tumour-bearing mice and larger species, with the 
ultimate goal of reaching clinical trials.  
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Appendices 
i. Diffusion Coefficient (D) Calculations 
  
   
     
 
KB= Boltzmann constant (J/K)  
T= Temperature (°K) 
= Dynamic Viscosity (N s/m2) 
RS= Stokes Radius (m) 
√
   
   
 
 
  
  
 √
   
   
 
 
Mw= Molecular Weight (g/mol) 
                                       
Dobs= Measured Diffusion Coefficient of the Complex (m
2/s) 
Dfree= Diffusion Coefficient of the free guest (m
2/s) 
Pfree= Population fraction of the free guest (m
2/s) 
Dfree= Diffusion Coefficient of the complexed guest (m
2/s) 
Pfree= Population fraction of the complexed guest (m
2/s) 
                   
Pfree= Population fraction of the free guest (m
2/s) 
Pfree= Population fraction of the complexed guest (m
2/s) 
           
          
                
 
Dobs= Measured Diffusion Coefficient of the Complex (m
2/s) 
Dfree= Diffusion Coefficient of the free guest (m
2/s) 
Pfree= Population fraction of the free guest (m
2/s) 
Dfree= Diffusion Coefficient of the complexed guest (m
2/s) 
Pfree= Population fraction of the complexed guest (m
2/s) 
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ii. Dimensions of 96-well plate (Greiner Bio-One, UK) 
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iii. Beam dimensions calculations 
  
     
       
 
N = Near Field Distance (mm)  
Ap = Aperture (mm) 
f = Frequency (Hz) 
c = Speed of Sound (m/sec) 
   
  
 
 
Sf = Normalized Focal Length 
FD = Focal Distance (mm) 
N = Near Field Distance (mm) 
        (
 
  
  
 
) 
Bl = Beam Length (mm) 
Sf = Normalized Focal Length 
FD = Focal Distance (mm) 
N = Near Field Distance (mm) 
                
Bd = Beam Diameter (mm) 
Ap = Aperture (mm) 
Sf = Normalized Focal Length 
 
iv. The Efficiency (Eff) and the Uniformity (Uni) calculations 
    
 
       
∑  
 
 
Isingle= The intensity at a single spot measurement (W/cm
2
) 
Im= The intensity at a single spot in a multi focal measurement (W/cm
2
)  
       
         
         
 
Imax= The maximal intensity at a single spot in a multi focal measurement (W/cm
2
) 
Imin= The minimal intensity at a single spot in a multi focal measurement (W/cm
2
)  
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v. Hydrophone Calibration constants HV2cm2/W) and  HV/Pa) and 
calculations 
  
∑           
   
 
Aij= the measured peak voltage (mv) 
dx·dy= the acoustic field measurements steps (mm) 
Wac= the applied acoustic load (W) 
 H was derived from  Haccording to: 
   √
  
 
 
Z= acoustical impedance of water 
 
vi. Attenuation of Ultrasound Waves in Tissues  
      
        
I= intensity in the point of interest (W/cm2) 
I0= applied intensity i.e. power on the transducer (W/cm
2) 
= absorption coefficient (Np/mm)  
dz= the propagation distance (mm) 
f= acoustic field frequency (MHz) 
 
